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ABSTRACT OF DISSERTATION 
INCREASING DENGUE VIRUS VACCINE SAFETY AND IMMUNOGENICITY BY 
MANIPULATING ANTIGENIC DETERMINANTS OF THE FLAVIVIRUS 
ENVELOPE PROTEIN 
Dengue virus (DENV), which exists as four closely related srotypes, is a 
mosquito-borne pathogen causing significant global disease burden, either as classic 
dengue fever (DF) or in its most severe manifestation, dengue hemorrhagic fever 
(DHF)/dengue shock syndrome (DSS).  Severe dengue disease is often associated with 
secondary DENV infection and hypothesized to frequently be induced by cross-reactive, 
weakly neutralizing antibodies, a process referred to as antibody-dependent enhancement 
of infection (ADE).  Due to the complex humoral immune response to DENV infection 
and the complexity of severe DENV disease, currently no licensed DENV vaccine is 
available. 
The goal of this dissertation is to increase the safety and immunogenicity of 
DENV vaccination through a better understanding of the antigenic properties of the 
envelope protein.  To these ends the objectives of this research were to: 1) use site-
directed mutagenesis and monoclonal antibody mapping to identify possible cross-
reactive epitopes of the DENV-2 E protein which could contribute to ADE (Chapter 2), 
2) use B cell epitope modification to construct a serotype-specific DENV-2 vaccine with
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reduced potential of vaccine-induced ADE (Chapter 3), and 3) identify potential 
dominant T cell epitopes in West Nile virus E which could act as immunological 
adjuvants for DENV-2 vaccines (Chapter 4). 
Humoral immune responses to DENV infection are complex and can exacerbate 
pathogenicity, yet are essential for immune protection.  DENV-2 E protein epitope-
specific antigens were created and used to measure immunoglobulin responses to three 
distinct epitopes in serum samples from DENV-2 infected humans. Immunoglobulin 
responses to DENV-2 infection exhibited significant levels of individual variation.  
Antibody populations targeting broadly cross-reactive epitopes centered on the fusion 
peptide in structural domain II were large, highly variable, and greater in primary than in 
secondary sera from DENV-2 infected patients, confirming previous st die  and 
identifying the fusion peptide as an immunodominant epitope.  E protein domain III 
cross-reactive immunoglobulin populations were similarly variable and much larger in 
IgM than in IgG.  DENV-2 specific domain III IgG formed a very small proportion of the 
antibody response, yet was significantly correlated with DENV-2 neutralization, 
suggesting that the highly protective IgG recognizing this epitope n murine studies plays 
a role in humans as well. These results begin to tease apart complex humoral immune 
responses to DENV infection and thus are important for improving our understanding of 
dengue disease and immunological correlates of protection relevant to DENV vaccine 
development and testing. 
 DENV vaccines must induce a balanced protective immunity to all f ur serotypes 
to reduce the possibility of cross-reactive antibody induced severe disease upon 
subsequent infection.  By modification of immunodominant B cell epitopes of E, cross-
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reactivity reduced (CRR) DENV-2 DNA vaccine candidates were developed and tested 
in mice for immunogenicity and potential reductions in developing vaccine induced ADE 
in mice.  Unlike wild-type vaccine, CRR vaccine immunized mouse sera neutralized 
virus and did not enhance viral infection in vitro.  Thus, reducing cross-reactivity in the 
envelope glycoprotein of DENV may provide a solution to increase vaccine safety and 
resolve the long-standing obstacle of immune enhancement in dengue vaccine 
development. 
DNA vaccination is a highly pursued vaccine platform for its safety, stability, and 
ease of development, use and manufacturing.  However, DNA vaccination is hindered by 
lower immunogenicity.  Methods investigated to increase the immunogenicity of DNA 
vaccines have included the use of immunological adjuvants; however, few are approved 
for human use.  A dominant, naturally occurring CD4 T cell epitope located in the 
transmembrane domain of West Nile virus was identified and its ab lity to increase the 
immunogenicity of heterologous flavivirus vaccines was investigated.  The incorporation 
of the West Nile virus CD4 epitope into a DENV-2 DNA or protein vaccine significantly 
increased neutralizing antibody titers compared to parental vaccines without the CD4 
epitope.  Identifying differential antigenic properties of vaccines may alleviate concerns 
of imbalanced immunity associated with multivalent vaccinations. 
Holly Ruth Hughes 
Department of Microbiology, Immunology and Pathology 
Colorado State University 
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 Recent history has seen a global resurgence of viral diseases once thought to be 
under control such as dengue, Japanese encephalitis, and yellow fever, or viruses that 
have expanded their geographic distribution such as West Nile virus (Gubler, 2002b) and 
dengue.  With the recent autochthonous transmission of dengue virus in Key West, 
Florida (CDC, 2010), a region that has not seen local dengue transmission in the past60 
years, the need for appropriate control measures for such viruses is evident. 
Flaviviridae 
The viruses composing the family Flaviviridae are single stranded RNA viruses 
with positive polarity divided into three genera: Hepacivirus, Pestivirus and Flavivirus.  
The Hepacivirus genus includes the blood borne hepatitis C virus causing persistent 
hepatotrophic infections in humans, as well as GB virus B, in which the natural 
distribution and disease is not fully understood.  The Pestivirus genus includes viruses 
causing disease in livestock such as bovine viral diarrhea virus, classical swine fever 
virus and border disease virus.  The Flavivirus genus is composed of close to 70 viral 
species most, but not all, of which require a hematophagous arthropod vector to maintain 
the natural transmission cycle, including the prototype yellow fever virus (YFV).  
Historically flaviviruses, known as Group B arboviruses, were separated from G up A 
arboviruses, alphaviruses, based upon hemagglutination inhibition tests, which define the 
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broadest spectrum of antigenic differences (Casals and Brown, 1954).  The group A and 
B arboviruses were placed in the family Togaviridae based on their mode of transmission 
and biochemical properties.  Not until 1984, when the morphological, biochemical, and 
replicative differences of the flaviviruses were understood, was a new Flaviviridae family 
created (Westaway et al., 1985).  Flaviviruses are widely distributed throug out the world 
with the exception of Antarctica.  More than half of the known flaviviruses are associ ted 
with human disease, including the important human pathogens YFV, dengue virus 
(DENV), Japanese encephalitis virus (JEV), West Nile virus (WNV), and the Tick-borne 
encephalitis viruses (TBEV) (Vasilakis and Weaver, 2008).  The most common outcome 
of human flavivirus infection is subclinical; however, clinical infections present as a flu-
like disease with fever, arthralgia, myalgia, retro-orbital headache, maculopapular rash, 
leucopenia, vascular leakage, hepatitis and/or encephalitis.  
 Viruses are taxonomically grouped within the Flavivirus genus by their antigenic 
relationships, which correlate with their vector: tick-borne, mosquito-borne, and no 
known vector.  There are eight antigenic complexes within flaviviruses that approximate 
the ecological characteristics of these viruses based on geographic distribution, vertebrate 
host, and arthropod vector (Calisher et al., 1989).  Phylogeny of the flavivirus genus, 
based on a 1kb 3’ terminal segment of the non-structural protein 5 (NS5) gene, also 
reveals taxonomic clustering predominantly coincident with their vector associ tions and 
antigenic relationships among them (Kuno et al., 1998).  From the putative ancestor, two 
major branches are composed of the cluster of non-vector and vector-borne viruses.  The 
vector-borne group then further divides into the tick-borne and mosquito-borne clusters.  




(POWV) and Omsk hemorrhagic fever virus create a distinct clade from the seabird 
viruses.  The mosquito-borne cluster divides into clades generally based on the principal 
vector, either Aedes or Culex mosquitoes (Kuno et al., 1998).  Viruses vectored by Culex 
mosquitoes are generally encephalitic and include the JEV serogroup, where birds are the 
natural reservoir, while viruses vectored by Aedes mosquitoes are viscerotropic and 
include the DENV serogroup as well as YFV, where humans or primates serve as the 
natural reservoir (Gaunt et al., 2001; Sabin, 1959). The NS5 phylogenic analysis supports 
the possibility of the non-vector viruses evolving first, followed by the tick-borne and 
finally the mosquito-borne clusters.  This is further supported by the observation that 
some mosquito-borne viruses such as SLEV, WNV, and YFV have been isolated from 
ticks, while the only tick-borne virus to be isolated from mosquitoes is POWV (Kuno et 
al., 1998).  The non-vector group is mainly isolated from bats or rodents and some cause 
a persistent infection in the vertebrate host (Baer and Woodall, 1966; Constantine and 
Woodall, 1964).  Few of the non-vector viruses have been isolated from humans, but they 
commonly induce a febrile disease (Shope, 2003).   
 Flavivirus genome:  The flavivirus RNA genome is single-stranded and 
approximately 11 kilobases in length (Rice et al., 1985).  The genomic RNA is infectious 
and therefore of positive polarity.  Genomic length RNA are the only viral mRNAs 
present in flavivirus infected cells (Boulton and Westaway, 1977).  The genomic RNA 
has a type I cap at the 5’ end (m7GpppAmp) and lacks a poly(A) tail on the 3’ end 
(Wengler, Wengler, and Gross, 1978).  A striking feature of the flavivirus genome is the 
presence of a single long open reading frame (ORF) that spans nearly the whole genome, 




coding regions (NCR), respectively (Rice et al., 1985).  The 5’ NCR is not well 
conserved among the flaviviruses; however, a common stem-loop secondary structure is 
often shared (Brinton and Dispoto, 1988).  This stem-loop structure influences 
translation, as antisense oligos to this structure inhibit translation and viral replication 
(Deas et al., 2005; Holden et al., 2006).  Similarly, the 3’ NCR is also highly variable 
among flaviviruses but a common stem-loop structure is present (Markoff, 2003).  The 3’ 
stem-loop is important in translation and replication, as several viral replicase proteins 
interact with the stem-loop (Chen et al., 1997).  Upstream of the 3’ stem-loop is a region 
that is complementary to the beginning of the capsid gene (Hahn et al., 1987), referred to 
as a cyclization sequence.  These long-distance RNA-RNA interactions are vital for viral 
replication, but do not play a role in viral translation (Holden et al., 2006; Khromykh et 
al., 2001).    
The structural proteins capsid (C), membrane (M; expressed in the precursor form 
prM), and envelope (E) are encoded on the 5’ quarter of the genome while the non-
structural (NS) proteins compose the remainder (Rice et al., 1985).  The ORF generates a 
single polyprotein in the order 5’-C-prM/M-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-
NS5-3’.  The polyprotein is post- and/or co-translationally cleaved into the individual 
proteins.  Processing of the structural region requires membranes and an intact sig al 
sequence, as it has been shown that proteolytic processing of TBEV polyprotein in Krebs 
ascites cells is not active when treated with detergent (Svitkin et al., 1984; Svitkin et al., 
1981).  Presumably, following translation of the C 3’-hydrophobic sequence, the 
flavivirus polysome becomes associated with the rough endoplasmic reticulum (ER) and 




(Chambers et al., 1990a).  Host signal peptidase is responsible for the cleavage of the N 
termini of prM, E, NS1 and NS4B (von Heijne, 1984).  A viral encoded serine protease 
cleaves intracellular C to create virion C, NS2B, NS3, NS4A and NS5 (Rice et al., 1985).  
The prM protein is cleaved into the pr peptide and mature M in the Golgi network by 
resident furin-like protease (Stadler et al., 1997).  Processing of the flavivirus polyprotein 
results in the formation of 10 direct or indirect membrane-associated viral proteins: three 
structural proteins, seven non-structural proteins, and two polypeptide cleavage 
fragments. 
Flavivirus proteins:  The capsid (C) protein is a small protein, approximately 
120 amino acids long, which constitutes the protein component of the nucleocapsid.  The 
C protein is quite basic, probably acting to neutralize the negatively charged vi al RNA in 
such a compact structure (Rice et al., 1985).  C protein folds into a compact dimer, with 
each monomer containing four alpha-helices (Jones et al., 2003).  A C-terminal 
hydrophobic region of the C protein (intracellular C), which functions as a signal peptide 
for ER translocation of prM, is cleaved from the mature C protein (virion C) by the 
NS3/NS2B viral serine protease (Lobigs, 1993). 
The prM protein is the precursor glycoprotein to the structural protein M.  The N 
terminal region of prM contains one to three N-linked glycosylation sites, one at Asn69 
in DENV, (Chambers et al., 1990a) and six conserved cysteine residues, all of which 
contribute to disulfide bridging (Nowak and Wengler, 1987).  The transmembrane 
domains of prM and E act as ER retention signals and may assist in heterodimer 
formation (Lin and Wu, 2005).  prM undergoes a delayed cleavage to form the M protein, 




fusing with host cell membranes (Li et al., 2008).  Proteolytic cleavage of prM in prM/E 
heterodimers, results in dissociation, release of pr, and formation of E homodimers 
(Stiasny et al., 1996; Wengler and Wengler, 1989). 
The E protein is the major surface glycoprotein and is glycosylated in some, but 
not all flaviviruses.  E has 12 completely conserved cysteine residues, and all have been 
demonstrated to contribute to intramolecular disulfide bridges in WNV (Nowak and 
Wengler, 1987).  The native form of E folds into an elongated structure rich in beta-
sheets, forming head-to-tail homodimers.  E homodimers lie parallel with regards to the 
virion surface and form a relatively smooth viral surface.  The surface is composed of 
three sets of nearly parallel E dimers forming a herringbone pattern (Kuhn et al., 2002). 
  Through crystallographic analysis, each flavivirus E protein has been shown to 
be composed of three structural domains (Rey et al., 1995) labeled E domain I (EDI) to 
EDIII.  EDI is the central beta-barrel domain, composed of 120 residues in three 
segments (1-51, 137-189, and 285-302).  EDI acts as a flexible hinge region that is 
important in fusion.  This domain is stabilized by two disulfide bridges, and has a 
conserved glycosylation site at Asn153, with an additional site at Asn 67 in EDII of 
DENV.  These glycosylation sites do not have an effect on the antigenic recognition of 
the E protein by monoclonal antibodies (Adams et al., 1995; Winkler, Heinz, and Kunz, 
1987).  EDII is the dimerization domain composed of two segments (52-136, 190-284), 
and containing three disulfide bridges.  EDII also contains an internal type II fusion loop 
at the distal end, which is packed against EDIII of the adjacent E protein, and undergoes a 
dramatic acid-mediated conformational change (Guirakhoo, Heinz, and Kunz, 1989).  




the E protein (303-395).  EDIII is joined to EDI through 15 residues and anchored by one 
intra-monomer disulfide bridge.  This interface is partly hydrophobic and partly olar.  
The Ig beta-barrel lies perpendicular to the virion surface and projects the furthest (Rey et 
al., 1995).  
Flavivirus E is involved in several important biological functions.  Flaviviruses 
mediate host cell entry through receptor mediated endocytosis (Barth, 1992; Krishnan et 
al., 2007), utilizing EDIII for interaction with cellular receptors (Chen, Maguire, and 
Marks, 1996; Huerta et al., 2008).  Murine derived monoclonal antibodies (MAb) 
targeting EDIII, efficiently neutralize virus by blocking viral attachment (Crill and 
Roehrig, 2001).  In addition, recombinant EDIII is able to bind vertebrate target cells 
through interactions with heparan sulfates (Hung et al., 2004; Thullier et al., 2001) and 
inhibit viral infection (Bhardwaj et al., 2001; Chu et al., 2005; Hung et al., 2004). 
  In addition to receptor binding, E is a type II fusion protein responsible for 
fusion of the viral envelope with the cellular endosome membrane (Lescar et al., 2001).  
After exposure to acidic pH, virions are no longer fusion-competent and therefore non-
infectious (Corver et al., 2000; Heinz et al., 1994).  Of particular importance regardin  
fusion is the presences of a highly conserved, hydrophobic region in EDII (Rey et al., 
1995), which mutational analysis has shown to be an internal fusion peptide (FP) (Allison 
et al., 2001).  In the native dimer, this fusion loop is buried by a hydrophobic pocket 
provided by EDI and EDIII of the adjacent monomer, shielding the fusion loop from 
interactions with membranes in its neutral-pH conformation (Modis et al., 2003).  Upon 
exposure to acidic pH, E under goes a complete oligomeric rearrangement formi g 




(Stiasny et al., 2001).  The conversion of dimers to trimers requires the disintegration of 
the structure of the viral envelope, including the dissociation of E dimers into monomers.  
This leads to the exposure of the FP loop, allowing for its interaction with target
membranes (Stiasny et al., 2002).  The conformational rearrangement involves 
reorganization of E from a horizontally oriented anti-parallel dimer, into a 
perpendicularly oriented trimeric spike, where each monomer is arranged in parallel.  
Importantly, these dramatic transitions do not require refolding of the E polypeptide 
chain and the structural integrity of the three domains remains intact.  Instead, th  major 
conformational changes involve the reorientation of the domains with respect to each 
other, made possible by the flexible hinge regions between EDI and EDII and between 
EDI and EDIII (Stiasny and Heinz, 2006).             
 The NS1 protein contains two or three N-linked glycosylation sites and 12 
conserved cysteines, all of which form disulfide bonds (Mason, 1989; Smith et al., 1970).  
Rapidly after synthesis, NS1 forms highly stable homodimers with a high affinity or 
membranes (Winkler et al., 1989; Winkler et al., 1988); however, due to the largely 
hydrophilic amino acid content and lack of a transmembrane domain, the nature of this 
membrane association is unclear.  NS1 is largely retained within infected cells 
(Lindenbach and Rice, 2003) and plays an important, yet unclear role in RNA replication.  
Immunofluorecense analysis has shown that NS1 localizes to sites of RNA replication 
(Mackenzie, Jones, and Young, 1996) and mutation of the N-linked glycosylation sites 
has a dramatic effect on RNA replication and virus production (Muylaert et al., 1996).  
NS1 associates with the plasma membrane (Cardiff and Lund, 1976) and is expressed on 




cytolysis (Schlesinger et al., 1990).  NS1 antigen is also secreted from infected c lls 
simultaneously with E protein, suggesting a role in virion transport or release (Lee, 
Crooks, and Stephenson, 1989).  Additionally, anti-NS1 antibodies confer partial 
protection from virus challenge (Gould et al., 1986; Schlesinger et al., 1986).   
 NS2A is a relatively small, hydrophobic, multifunctional, membrane-associated 
protein involved in RNA replication (Chambers, McCourt, and Rice, 1989; Mackenzie et 
al., 1998).  NS2A binds to replication proteins NS3 and NS5, as well as the 3’ NCR of 
the genome RNA with high affinity (Mackenzie et al., 1998).  This interaction allows for 
NS2A to be involved in virus assembly.  Studies with YFV have shown mutation at 
amino acid position 190 efficiently blocks the production of infectious virus particles, 
although the secretion of empty, non-infectious prM/E virus-like particles (VLP) is 
unaffected (Kummerer and Rice, 2002).  Additionally, substitutions at amino acid 
position 59 impaired production of infectious virus particles and the formation of virus-
induced membrane formation (Leung et al., 2008).  NS2A has also been shown to inhibit 
signaling of the host anti-viral interferon response by blocking phosphorylation of STAT-
1 and inhibiting the subsequent nuclear translocation (Liu et al., 2005).  In addition, 
mutation of a single amino acid at position 30 disables IFN antagonism and attenuates 
WNV virulence in mice (Liu et al., 2006).  
 NS2B is also a small membrane-associated protein (Clum, Ebner, and 
Padmanabhan, 1997).  NS2B forms a stable complex with NS3 and acts as a cofactor for 
catalytic activity of the viral serine protease (Falgout et al., 1991).  The NS2B increases 
the rigidity of NS3 leading to a remodeling of the protease that facilitates cleavage 




 NS3 is a large, multifunctional protein required for polyprotein processing and 
RNA replication.  The N-terminal third of the NS3 protein is the catalytic domain of the 
NS2B-NS3 serine protease complex (Bazan and Fletterick, 1989; Chambers et al., 1990b; 
Gorbalenya et al., 1989), preferentially cleaving after dibasic residues (Chambers et al., 
1990a).  The NS2B-NS3 complex cleaves NS2B, NS3, NS4A and NS5 of the polypeptide 
(Rice et al., 1985) as well as generating the C-termini of mature C proteins (Amberg et 
al., 1994; Yamshchikov and Compans, 1994).  The C-terminal region of the NS3 protein 
displays RNA-stimulated nucleoside triphosphatase (Wengler and Wengler, 1991) and 
RNA unwinding activities (Warrener, Tamura, and Collett, 1993).  In addition to a role in 
replication, NS3 has been shown to induce apoptosis of mammalian cells in infection by 
Langat virus, DENV, WNV and JEV (Prikhod'ko et al., 2002; Ramanathan et al., 2006; 
Shafee and AbuBakar, 2003; Yang et al., 2009) through activation of caspases 3 and 8 
(Prikhod'ko et al., 2002; Yang et al., 2009).   
 NS4A/2K is a small hydrophobic protein that localizes to sites of RNA replication 
(Mackenzie et al., 1998) and interacts with NS1, which is essential for RNA replication 
(Lindenbach and Rice, 1999), suggesting a role in viral replication.  NS4A has been 
implicated in the rearrangement of cytoplasmic membranes involved in replication 
(Roosendaal et al., 2006).  NS4A associates with membranes through four internal 
hydrophobic regions, where the N-terminal third localizes to the cytoplasm while the C-
terminus localizes in the ER lumen (Miller et al., 2007).  This topology suggests a 
mechanism where NS4A induces membrane curvature toward the cytoplasm (Miller et 
al., 2007) that may be amplified by NS4A homo- or hetero-oligomerization (Mackenzie 




performance, where NS4A regulates ATPase activity, allowing for conservation of 
energy and for NS3 to sustain RNA unwinding efficiency under ATP deficient conditis 
(Shiryaev et al., 2009).  NS4A also displays the ability to interfere with JAK/STAT IFN 
signaling (Munoz-Jordan et al., 2003) through inhibiting phosphorylation of STAT-1 and 
STAT-2 (Lin et al., 2008b). 
 NS4B is the largest of the small hydrophobic NS proteins, consisting of 248 
amino acids.  NS4B resides in cytoplasmic foci originating from the ER, colocalizing 
with NS3 and double-stranded RNA, arguing that NS4B is a part of the membrane bound 
viral replication complex (Miller, Sparacio, and Bartenschlager, 2006).  NS4B was found 
to not only colocalize with NS3, but to also bind the C-terminal region of NS3, 
dissociating it from ssRNA, enabling binding to a new duplex and enhancing the helicase 
activity of NS3 (Umareddy et al., 2006).  Similar to NS2A and NS4A, NS4B is a potent 
IFN antagonist by inhibiting signaling (Munoz-Jordan et al., 2003).  Additionally, 
coexpression of NS4A and NS4B enhances the inhibition of interferon-stimulated 
response element promoter activation in response to IFNα/β stimulation (Munoz-Jordan 
et al., 2005). 
 NS5 is the largest and most conserved of the flavivirus proteins, composed of 
approximately 900 amino acids.  NS5 is essential in replication containing domains for 
RNA-dependent RNA polymerase (RdRp) and 5’ capping.  The original identification of 
NS5 as a capping enzyme was determined by a sequence motif conserved in Ado-Met-
dependent methyl-transferases located in the N-terminal region of NS5 (Koonin, 1993).  
Subsequent examination showed purified N-terminal NS5 could transfer methyl groups 




Comparative sequence analysis found sequence motifs in the C-terminal region of NS5 
conserved in other viral RdRp (Rice et al., 1985; Sumiyoshi et al., 1987).  RdRp activity 
of NS5 without the presence of other viral or host cellular components was demonstrated 
using bacterially expressed NS5 and showing the ability to produce template-sized 
products of negative polarity (Tan et al., 1996).  Subsequently, NS5 was demonstrated to 
initiate RNA syntheses de novo without the need of a primer (Ackermann and 
Padmanabhan, 2001).  However, the conserved stem-loop structure in the 5’ NCR is 
essential for binding of NS5 and the methyltransferase and RdRp activities (Dong et al., 
2007a).  NS5 forms a complex with NS3 (Cui et al., 1998; Kapoor et al., 1995) and 
stimulates the NTPase (Cui et al., 1998) and RTPase activity of NS3 (Yon et al., 2005).  
NS3 only complexes with NS5 when in the cyotplasmic hypophosphorylated form 
(Kapoor et al., 1995) and the complex is able to bind the 3’ NCR stem-loop structure of 
the viral genome (Chen et al., 1997).  As with other NS proteins, NS5 is able to 
antagonize the host IFN response in a flavivirus specific manner.  Langat virus NS5 
inhibits IFN signaling by binding to IFNα/β receptor subunit IFNRAR2 (Best et al., 
2005).  JEV NS5 may activate phosphatases to inhibit JAK/STAT signaling rather than 
directly interfering with signaling (Lin et al., 2006).  In contrast, DENV-2 NS5 is able to 
induce interleukin (IL)-8 production and secretion (Medin, Fitzgerald, and Rothman, 
2005).  
Dengue virus 
 DENV serocomplex is composed of four distinct species within the flavivirus 
genus, which includes four genetically different, yet antigenically related serotypes 




genus, DENV are unique and most restricted in terms of their natural vertebrate host 
range, which only includes primates.  All four serotypes circulate in urban environments 
of the tropics and subtropics between humans and the peridomestic Aedes aegypti 
mosquito.  This distribution puts nearly a third of the global population at risk for DENV 
infection (Farrar et al., 2007).  DENV-1,-2, and -4 also circulate in a sylvatic cycle in the 
forests of Asia between Macaca and Presbytis monkeys vectored by Ae. nivues (Peiris, 
Dittus, and Ratnayake, 1993).  A sylvatic cycle of DENV-2 in west Africa (Rico-Hesse, 
1990) occurs between Erythrocebus patas monkeys and Ae. taylori, furficer, viattus, and 
leutocephalus mosquitoes (Traore-Lamizana et al., 1994).  DENV-3 has yet to be isolated 
from a sylvatic cycle but DENV-3 antibody seroprevalance suggests the cycle exists 
(Rudnick, Marchette, and Garcia, 1967).   
 Dengue virus diversity:  Within each of the four DENV serotypes, the viruses 
are further grouped into genotypes (Rico-Hesse, 1990).  DENV-1 contains five 
genotypes, generally correlated with the geographic origin of the strains: genotype I 
contains strains from Southeast Asia, China, and east Africa; genotype II contains strains 
isolated from Thailand in the 1950s and 1960s; genotype III contains the sylvatic strains 
from Malaysia; genotype IV contains strains from the west Pacific Island  and Australia; 
and genotype V consists of isolates from the Americas, west Africa, and a few from Asia.  
(Goncalvez et al., 2002; Rico-Hesse, 1990; Wang et al., 2000).  DENV-2 isolates are 
generally accepted to be subdivided into five genotypes: genotype I contains the Asian I 
strains from Malaysia and the Asian II strains from Vietnam, China, Taiwan, Sri Lanka 
and Philippines; genotype II contains Cosmopolitan strains; genotype III contains the 




isolated in the 1950s and 1960s; genotype IV contains strains from Thailand, Vietnam, 
and the American isolates within the past 30 years; and genotype V contains the sylvatic
strains from west Africa and Southeast Asia (Lewis et al., 1993; Rico-Hesse, 1990; Wang 
et al., 2000). DENV-3 can be divided into five genotypes: genotype I contains isolates 
from Indonesia, Malaysia, the Philippines and the South Pacific islands; genotype II 
contains isolates from Thailand; genotype III contains isolates from Sri Lanka, India, 
Africa and Samoa; genotype IV contains isolates from Puerto Rico and Tahiti in 1965 
(Lanciotti et al., 1994); and genotype V contains isolates from China, Philippines and 
Malaysia that were originally grouped in genotype I (Wittke et al., 2002).  DENV-4 can 
be divided into four genotypes: genotype I contains isolates from Thailand, Philippines, 
Sri Lanka, and Japan (isolated from a Japanese traveler); genotype II contains isolates 
from Indonesia, Malaysia, Tahiti, Caribbean and the Americas; genotype III contains 
isolates from Thailand; and genotype IV contains the sylvatic isolates (Lanciotti, Gubler, 
and Trent, 1997; Wang et al., 2000).     
 Dengue virus history and epidemiology:  The first description of a dengue-like 
illness is found in Chinese literature during the Chin Dynasty (CE 265), Tang Dynasty 
(CE 610) and Northern Sung Dynasty (CE 992) (Gubler, 1997), describing a disease 
called “water poison” and the association with water-associated flying insects.  A similar 
description of illness did not occur until 1635 and 1699 in the French West Indies and 
Panama (Gubler, 1997).  An entire century later (1779-1788), the first reports of possible 
DENV pandemic in Indonesia, Egypt, North America, and Spain were described as the 




disease behavior in Southeast Asia, India, and the Philippines had changed from the 
sudden onset of urban epidemics, to endemicity (Smith, 1956). 
 The events of World War II brought immense changes to DENV ecology, 
epidemiology, and disease.  Destruction of water distribution systems leading to omestic 
water storage created an abundance of ideal habitats for Ae. aegypti larvae.  In addition, 
transportation of troops and supplies resulted in the importation of susceptible hosts, and 
the movement of Ae. aegypti into new geographic regions (Vasilakis and Weaver, 2008).  
Between 1941 and 1945, DENV epidemics were raging among military personnel in East 
Africa, the Caribbean, and the Pacific theater (Sabin, 1952b), leading to a heighten d 
awareness and DENV disease study.  DENV-1 was first isolated in Japan, followed by 
the isolation of DENV-1 and DENV-2 from U.S. soldiers.  Research also led to the 
identification of homotypic immunity following infection, and the development of 
hemmagglutination inhibition tests for serodiagnosis (Sabin, 1952b).  By the end of the 
1960s, all four serotypes were circulating in Southeast Asia and India. 
  Although the occurrence of severe and fatal hemorrhagic disease associated with 
DENV infection was reported in the 1780 Philadelphia outbreak, it was probably rare and 
did not pose a serious public health problem (Vasilakis and Weaver, 2008).  The first 
well documented cases of DHF were associated with epidemics in Thailand and the 
Philippines in the 1950s and thought to be a new disease (Hammon et al., 1960).  
Through epidemiological studies, an association between secondary DENV infection and 
severe DENV disease was elucidated (Halstead et al., 1967; Russell, Udomsak i, and 




dependent enhancement (ADE) theory of DHF pathogenesis (Halstead, 1970; Halstead, 
Chow, and Marchette, 1973). 
The first DENV outbreak in the Americas occurred during the 1778 pandemic that 
included Philadelphia.  DENV did not appear again until 1828, when an epidemic swept 
west across the Caribbean, Gulf, and Atlantic regions including the seaports of the Virgin 
Islands, Cuba, Jamaica, Venezuela, and the United States- Pensacola, Charleston, 
Savannah and New Orleans (Ehrenkranz et al., 1971).  Outbreaks of DENV continually 
developed in these seaport cities throughout the Civil War and Reconstruction Era, 
including a large outbreak in New Orleans in 1873 where 40,000 people became ill.  The 
westward movement of DENV into Texas began in 1885 involving the port cities of 
Houston and Galveston and spread inland along the rail-roads resulting in hemorrhagic 
manifestations (Ehrenkranz et al., 1971).  Outbreaks of DENV continued in Texas into 
the 20th century when in 1922 epidemic DENV began in Galveston and swept east into 
Louisiana, Florida, Georgia, and into the Caribbean.  A major DENV epidemic occurred 
in 1934 beginning in Miami and spreading throughout Florida into southern Georgia.   
The last outbreak of DENV in the United States occured in Texas in 1944 
(Ehrenkranz et al., 1971), with an additional outbreak of DENV in Hawaii from 1943-44 
(Gilbertson, 1945).  In the 1940s the Pan American Health Organization began an Ae. 
aegypti eradication program to minimize urban epidemics of yellow fever.  This program 
successfully eradicated the vector from 19 countries (Gubler, 1997); however, by 1970 
the program was not sustained and reinfestation of the mosquito mimicked previous 
distributions.  Between 1946 and the 1990s no cases of DENV acquired in the United 




along the Texas-Mexico border, associated with large DENV outbreaks in neighborin  
Mexican cities (CDC, 1996; CDC, 2007).  In September of 2001, an outbreak of DENV-1 
occurred on several of the Hawaiian islands, associated with a large outbreak in the 
French Polynesian islands (Effler et al., 2005).  Sporadic cases of locally transmited 
DENV disease occurred in these regions until 2009, when DENV infections in Key West, 
Florida residents without a history of travel were confirmed (CDC, 2010) with cases 
continuing into 2010, suggesting sustained transmission of the virus, possibly leading to 
endemicity.   
A large Caribbean epidemic began in 1963.  The introduction of an Asian 
genotype DENV-3 into Puerto Rico and Jamaica led to several epidemics in the 
Caribbean, northern Colombia, and Venezuela (Ehrenkranz et al., 1971; Morales et al., 
1973; Russell et al., 1966; Spence, Jonkers, and Casals, 1969).  The introduction of an 
Asian genotype DENV-2 into Cuba in 1981 was followed by an increase in disease 
severity in Cuban and Venezuelan epidemics (Kouri et al., 1983; Kouri et al., 1989; 
Uzcategui et al., 2001).  The Cuban epidemic of 1981 led to the observations of the 
importance of genetics, gender, age, and secondary infection in the development of 
severe DENV disease (Guzman et al., 1991; Guzman et al., 2002; Guzman et al., 1984).  
The introduction of new genotypes and the increased circulation of multiple serotypes 
resulting in the increased disease severity in the Americas, mirroring the events that 
occurred in Southeast Asia in the 1950s and 1960s (Vasilakis and Weaver, 2008). 
Dengue virus disease:  The most common clinical disease caused by DENV 
infection is dengue fever (DF), a febrile illness of older children and adults.  DF is 




arthralgia, and frequently a generalized maculopapular rash on the trunk.  Treatment for 
DF is supportive and patients normally fully recover.  Severe manifestations of DENV 
infection include dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). 
Children under 16 are at the greatest risk for developing DHF/DSS.  Severe disease and 
shock is frequently observed the day following defervescence and rarely lasts more than 
48 hours.  DHF/DSS is characterized by fulminant hepatitis, massive hemorrhage 
including positive tourniquet test, petechia, intestinal hemorrhage and hemetamesis, 
organ failure, vascular leak with hypovolemic shock induced by plasma leakage, 
thrombocytopenia of less than 100,000 cells per mm3, elevated liver enzymes, and 
coagulation disorders including decreased fibrin and increased fibrin degradation 
products.  DHF/DSS is divided into four grades (I-IV) ranging from mild hemorrhage in 
the form of petechia, to profound shock and circulatory collapse.  DHF/DSS is managed 
through replacement of lost plasma and maintenance of circulatory volume.  (WHO, 
2009) 
Dengue hemorrhagic fever pathogenesis 
Much attention has been given to the pathogenesis of DHF/DSS since its first 
epidemic appearance in Thailand.  The mechanisms leading to the development of severe 
DENV disease are not fully understood but are likely multifactorial.  Several theories 
have been proposed to explain the manifestation of severe DHF/DSS.   
Virulent viruses:  The virus virulence hypothesis states that certain DENV 
strains are responsible for more severe disease.  This is supported by the fact that the first 
outbreak of DHF in the Americas coincided with the introduction of Southeast Asian 




Moreover, in a prospective study in Peru, no cases of DHF or DSS occurred when the 
infecting virus was an American genotype DENV-2 (Watts et al., 1999).   
Complement:  The complement system is one of the main humoral components 
of innate immunity.  During the time of defervescence, high levels of complement 
activation products, C3a and C5a, are present in plasma, followed by reduction of 
complement components in DSS patients’ sera (Churdboonchart, Bhamarapravati, and 
Futrakul, 1983; Nishioka, 1974; Shaio, Chang, and Hou, 1992).  Heterotypic antibodies 
may bind to surface expressed NS1 and result in complement activation (Avirutnan et al., 
2006).  In addition, NS1 released from infected cells can activate complement in the fluid 
phase (Kurosu et al., 2007).  The production of the C5b-C9 complex could trigger 
production of inflammatory cytokines associated with severe DHF/DSS (Avirutnan et al., 
2006).   
Autoantibodies:  Antibodies produced during a DENV infection have been 
shown to cross-react with self-antigens.  A portion of the DENV E protein (amino acids 
100-110) shares sequence similarity with several clotting factors such as prothrombin, 
plasminogen, and tissue plasminogen factor, and antibodies against E protein are reactiv  
with plasminogen (Huang et al., 1997; Markoff et al., 1991).  Anti-NS1 antibodies cross-
react with platelets causing thrombocytopenia and hemorrhage in mice (Lin et al., 2008a; 
Sun et al., 2007).  These NS1 cross-reactive antibodies can also inhibit aggregation and 
lyse platelets, where deletion of the C-terminal portion of NS1 ablated this ability (Chen 
et al., 2009).  Anti-NS1 IgM antibodies also cross-react with endothelial cells, inducing 
caspase-dependent apoptosis (Lin et al., 2003) and secretion of proinflammatory 




Cross-reactive T cells: CD8 positive T cells are a dichotomy in DENV infection 
as they play a role in viral clearance and in immunopathogenesis (An et al., 2004).  High 
avidity cross-reactive CD8+ T cells become activated and produce high concentrations of 
proinflammatory cytokines TNFα, IFNγ, and IL-13; however, these high avidity CD8+ T 
cells quickly undergo apoptosis and cannot be isolated from convalescent patients (Dong 
et al., 2007b).  Alternatively, low avidity cross-reactive CD8+ T cells to the infecti g 
virus can be preferentially expanded, known as original antigenic sin (Mongkolsapaya et 
al., 2003).  These low avidity cross-reactive CD8+ T cells are able to secrete 
proinflammatory cytokines but have lost ability to secrete cytotoxic granules 
(Mongkolsapaya et al., 2006).  Studies in mice have also revealed a preferential 
expansion of cross-reactive memory CD8+ T cells that secrete more TNFα during a 
secondary infection than during a primary infection (Beaumier et al., 2008).  This 
massive activation of cross-reactive T cells leads to increased levels of inflammatory 
cytokines such as IFNγ, TNFα, IL-6, IL-8, and IL-1β, which have been shown to exist in 
high levels in serum of DHF/DSS patients (Hober et al., 1993; Kurane et al., 1991; 
Raghupathy et al., 1998).  In addition, cross-reactive memory T cells have been shown to 
display altered secondary responses compared to primary responses, secreting higher 
proportions of TNF than IFNγ, dependent upon the sequence of DENV infection 
(Beaumier et al., 2008; Beaumier and Rothman, 2009; Friberg et al., 2010), which could 
contribute to the varying degrees of disease outcomes in secondary DENV infection. 
The participation of cross-reactive memory T cells in the development of severe 
DHF/DSS, the majority of which are restricted to non-structural proteins, has been widely 




2003).  Studies using murine models (Rothman, Kurane, and Ennis, 1996) have 
indentified CD8+ cytotoxic T lymphocyte (CTL) clones specific for prM, E, NS1/2a, and 
NS3. All DENV cross-reactive CTL clones identified targeted the non-structural proteins, 
while DENV specific CTL clones targeted structural proteins. Studies using human 
DENV immune sera have also identified a similar dominance in cross-reactive T cell 
repertoire.  CTLs isolated from a DENV-4 infected patient were shown to lyse fibroblasts 
infected with all four DENV serotypes, in addition to lysing fibroblasts expressing non-
structural proteins at higher efficiency than those expressing structural proteins 
(Bukowski et al., 1989).  Further investigation of DENV CTLs has led to the 
identification of NS3 as a dominant protein for eliciting T cell responses during infection.  
Interestingly, DENV specific and cross-reactive CD8+ CTL clones isolated from DENV-
4 immune patients were mapped to a single epitope on NS3, amino acids 500-508 
(Livingston et al., 1995), which suggests CD8+ CTL clones can recognize the same 
epitope yet display distinctive specificities.  In addition to NS3, NS1 and NS2a have been 
identified as eliciting DENV specific and cross-reactive CD8+ CTLs.  Following 
vaccination with live attenuated monovalent DENV vaccines, CTL clones isolated from 
all patients lysed fibroblasts expressing NS3 or NS1/2a while only few CTL clones lysed 
fibroblasts expressing E (Mathew et al., 1996).  This method also identified one donor 
who received DENV-4 live attenuated vaccine that elicited CTL clones that lysed prM 
expressing fibroblasts, marking the first description of CD8+ CTLs with prM secificity.  
A similar predominance of NS targeted CD8+ CTLs is seen following secondary 
infection.  All CD8+ CTL clones isolated from Thai donors following secondary DENV 




et al., 1998).  In addition, a large proportion of the CTL clones isolated recognized amino 
acids 221-232 on NS3.  Based upon these studies, the T cell response to DENV infection 
can best be described as highly variable, with multiple epitope specificities and a highly 
dominant recognition of NS3 and NS1.2a. 
 Despite the breadth of studies indicating the importance of cross-reactive T cells
isolated from DENV immune individuals, a recent prospective study questions this role 
during active DENV infection.  A kinetic study of activated CD8+ T cells in periph ral 
blood from primary and secondary DENV infected children suggests hemoconcentration 
and thrombocytopenia begin before the appearance of measurable levels of NS3 specific 
CD8+ T cells (Dung et al., 2010).   
Antibody-dependent enhancement:  Epidemiological evidence associates 
DHF/DSS with secondary DENV infections (Guzman et al., 1990; Halstead et al., 1967; 
Russell, Udomsakdi, and Halstead, 1967; Sangkawibha et al., 1984).  The observations of 
Halstead (Halstead, 1970; Halstead, Nimmannitya, and Cohen, 1970) noted severe 
DHF/DSS peaked in two key groups.   
The first peak is seen in infants experiencing primary DENV infection, for wh m 
maternally derived antibodies declined to subneutralizing levels.  Subsequent studies 
have revealed a correlation between maternal DENV neutralization titers and the age of 
the infant during the onset of DHF/DSS (Kliks et al., 1988); infants from mothers with 
high neutralizing titers were older at onset of illness than infants from mothers with low 
neutralizing titers.  Furthermore, a prospective study showed maternally derived 
neutralizing anti-DENV IgG declined below measureable levels in infants by six months 




al., 2009), suggesting a timeframe when maternal anti-DENV IgG can bind but not 
neutralize virus, potentially resulting in ADE. 
The second peak of severe DENV infection occurs in young children who have 
experienced a prior mild or subclinical DENV infection and were later infected with a 
different DENV serotype (Halstead, 1970; Halstead, Nimmannitya, and Cohen, 1970).  
These observations led to the conclusion that subsequent infection of preimmune 
individuals with a different DENV serotype could exacerbate disease.  This phenomenon 
is thought to be due to cross-reactive antibodies and termed antibody-dependent 
enhancement (ADE) of infection (Halstead, 1970; Halstead, Chow, and Marchette, 1973).  
Additional studies revealed the essential features of ADE in vitro: first, non- or weakly-
neutralizing antibodies are important as heterotypic DENV was only neutralized t low 
PRNT50 titers compared to homotypic DENV; second, Fc receptors on target cells are 
essential since anti-DENV F(ab)2 were unable to enhance infection; finally, the presence 
of immune complexes are crucial in the development of ADE as enhancing antibodies do 
not attach to mononuclear phagocytes before the formation of immune complexes 
(Halstead and O'Rourke, 1977).   
The Fc receptors (FcR) can be devided into three classes, FcγRI – FcγRIII, and 
are present on several immune cells depending on receptor type.  FcγRI is exclusively 
located on monocytes, while FcγRII is expressed on monocytes, neutrophils, eosinophils, 
platelets, and B cells (Unkeless, 1989).  FcγRI and FcγRII have been shown to participate 
in ADE (Kontny, Kurane, and Ennis, 1988; Littaua, Kurane, and Ennis, 1990), while 
association of FcγRIII has not been directly investigated.  Blocking the Fc receptor with 




to enhance the infection of WNV (Peiris et al., 1981).  In addition, modification of the Fc 
region ablates the ability of MAbs to induce ADE and severe disease in vitor and in vivo 
(Balsitis et al., 2010; Goncalvez et al., 2007), and Fc modificationlted has the potential to 
work as an effective therapeutic, as these Fc modified MAbs result in reduced viremia 
and viral tissue burden in AG129 mice without inducing severe disease (Balsitis et al., 
2010).     
FcR-mediated ADE could exacerbate DENV infection and severe disease.  ADE 
could lead to an increased infection rate of target cells or convert non-infectious, 
immature and/or structurally defective virions using FcR as an accessory viral receptor, 
resulting in the high viral load observed with DHF/DSS (Libraty et al., 2002; Vaughn et 
al., 2000; Wang et al., 2003; Wang et al., 2006).  In addition to increasing the overall 
viral burden, FcR-mediated ADE modifies the innate and adaptive intracellular antiviral 
mechanisms.  DENV infection via the FcR-mediated pathway was shown to suppress the 
transcription of proinflammatory cytokines IL-12, IFNγ, and TNFα, while up regulating 
the transcription of anti-inflammatory cytokines IL-6 and IL-10 (Chareonsirisuthigul, 
Kalayanarooj, and Ubol, 2007), suggesting FcR-mediated ADE may preferentially i duce 
a Th2 driven T cell response.  Moreover, DENV infection via ADE resulted in 
suppression of nitric oxide production by down regulating the activity of STAT-1 and 
IRF-1 (Chareonsirisuthigul, Kalayanarooj, and Ubol, 2007) and potentially inhibiting the 
innate antiviral defenses of host cells.   
Although ADE of DENV infection is commonly associated with FcR, studies 
have displayed the ability of non-Fc cell surface molecules in inducing ADE.  Original 




(Halstead and O'Rourke, 1977); however, a role for IgM in ADE has been elucidated.  
Studies demonstrate that IgM has the ability to enhance DENV infection through 
complement receptor 3 (CR3) (Cardosa, Porterfield, and Gordon, 1983).  It was 
demonstrated that IgM in the presence of sera that had been heat inactivated or treated 
with cobra venom factor, did not mediate ADE of DENV, while IgM in the presence of 
fresh serum did enhance DENV infection.  In addition, blocking CR3 also ablated the 
ability of IgM and fresh sera to enhance DENV.  These data show a direct role ofIgM in 
the development of ADE and severe DENV diseases during a natural infection.  
Additional cell surface molecules have also been implicated in ADE in vitro.  Through 
the use of bispecific MAbs containing Fab of DENV Mabs cross-linked to Fab of MAbs 
targeting cell surface molecules, the infection of DENV was increased when bispecific 
MAbs targeted β2-microglobulin, CD15 or CD33 (Mady et al., 1991).  These data 
suggest that FcR is not a unique requirement of ADE of DENV infection and the 
virus/antibody complexes formed during ADE may function as an accessory receptor to 
facilitate the interaction of DENV with its true cell surface receptor.    
The ability of antibody to enhance the infection of flaviviruses was well 
established before an understanding of their viral antigenic determinants was developed.  
Through the use of hybridoma technology, type-specific and group cross-reactive MAbs 
capable of enhancing infection of WNV (Peiris, Porterfield, and Roehrig, 1982) and YFV 
(Schlesinger and Brandriss, 1983) were determined to be reactive with the E protein, 
while MAbs against NS1 were unable to enhance YFV infection (Schlesinger ad 
Brandriss, 1983).  Recent studies have also revealed the importance of anti-prM 




was enhanced by anti-E MAbs, and not enhanced by anti-NS1 or anti-C MAbs; however, 
novel anti-prM MAbs were shown to enhance DENV infection in a FcR-mediated 
fashion (Huang et al., 2006).  Interestingly, anti-prM MAb could also enhance the 
infection of cells that did not bear FcR by binding to membrane proteins such as HSP60, 
suggesting that anti-prM antibodies have dual specificity and a unique method of ADE.  
Subsequently, anti-prM MAbs were shown to enhance the infection of immature DENV 
particles (Rodenhuis-Zybert et al., 2010) suggesting the ability of anti-prM antibodies to 
render non-infectious immature DENV particles infectious.     
The evidence for a role of in vivo ADE and the contribution of ADE to human 
severe DENV disease is limited.  Following sequential DENV infection, an enhanced 
viremia has been demonstrated in monkeys (Halstead, Shotwell, and Casals, 1973b).  
Additionally, passive transfer of DENV MAb to macaques resulted in an increased 
viremia titer (Goncalvez et al., 2007).  However, in both studies enhanced viremia could 
not be associated with enhanced disease, as monkeys do not develop severe DENV 
disease.  A recently described AG129 mouse model has shown the ability of DENV 
immune sera or cross-reactive MAb to enhance viremia and induce a DENV lethal 
disease similar to clinical disease in humans (Zellweger, Prestwood, and Shresta, 2010). 
Evidence for the role of ADE in human cases of severe DENV infection remains 
circumstantial.  Studies of both primary and secondary DHF/DSS have failed to reveal a 
link between ADE activity of plasma and severe disease.  In a prospective study of 
infants, an association of ADE activity at illness onset and the development of severe
DENV disease could not be established (Libraty et al., 2009).  In addition, in a 




of K562 cells; however, the enhancement did not correlate with clinical severity or viral 
burden (Laoprasopwattana et al., 2005).   
Flavivirus envelope protein antigenicity  
Flaviviruses exhibit three major antigenic classes: serotype-specific, complex 
cross-reactive, and flavivirus group cross-reactive (Clarke, 1960).  Through dia nostic 
serology, flavivirus E protein has been shown to be responsible for several serological 
attributes of flavivirus infection, including hemagglutination inhibition (HI), complement 
fixation, and virus neutralization (Cardiff et al., 1971; Hammon and Price, 1966; Qureshi 
and Trent, 1973).  The advent of murine MAbs allowed for dissection of the antigenic 
regions on E.  The flavivirus E has three non-overlapping antigenic regions termed A, B, 
and C (Guirakhoo, Heinz, and Kunz, 1989; Heinz et al., 1983), which were subsequently 
found to correlate with the three structural domains EDII, EDIII, and EDI respectively 
(Rey et al., 1995).  Through blocking studies of TBEV, MAbs mapping to antigenic 
domain A (EDII) were HI active, non-neutralizing, and flavivirus group cross-reactive.  
MAbs mapping to antigenic domain B (EDIII) were HI active, neutralizing, and 
contained complex cross-reactive as well as serotype specific epitopes (Heinz et al., 
1983).  MAbs mapping to antigenic domain C (EDI) are more variable in their HI and 
neutralization activity, and mostly sub-type specific (Guirakhoo, Heinz, and Ku z, 1989).  
Subsequent studies of DENV-2 confirmed the antigenic and biological activities of he
three flavivirus antigenic domains (Roehrig, Bolin, and Kelly, 1998).  
Domain A:  Flavivirus E protein antigenic domain A (EDII) contains the internal 
fusion peptide.  Antibodies directed against this domain are able to block pH-mediated 




1986; Roehrig, Bolin, and Kelly, 1998).  Subsequent studies have identified the highly 
conserved fusion peptide region as an important antigenic epitope determinant (Allison et 
al., 2001; Crill and Chang, 2004; Goncalvez, Purcell, and Lai, 2004; Oliphant et al., 
2006).  Site-directed mutational analysis at G104, G106, and L107 has shown that the 
fusion peptide is responsible for recognition of several cross-reactive MAbs including 
flavivirus group cross-reactive, and complex cross-reactive MAbs (Crill and Chang, 
2004; Trainor et al., 2007).  In addition, MAbs targeting the fusion peptide seem to 
recognize the region in a structurally specific manner.  The first studyto show this 
phenomenon used anti-peptide antibodies against DENV-2 and determined some anti-
peptides defining the fusion peptide were more efficient at binding low-pH treated virus 
than neutral pH treated virus (Roehrig et al., 1990).  Moreover, solubilization of WNV 
virions led to an increase in binding efficiency of fusion peptide targeted MAbs (Stia ny 
et al., 2006).   
A recent structural study of immature WNV virions demonstrates non-
neutralizing group cross-reactive MAbs bind with high affinity to spike structures found 
on immature and partially mature WNV virions but do not bind effectively to mature 
virions (Cherrier et al., 2009).  This same study demonstrated immature and partially 
mature WNV and DENV virions are present in virus preparations.  These data suggest 
broadly cross-reactive antibodies could promote ADE of infection by increasing 
infectivity of low infectious, partially mature virions. 
Studies using flavivirus infected human polyclonal sera have furthered our 
understanding of the importance of the fusion peptide in the flavivirus antibody response.  




reactivity to TBEV recombinant sub-viral particles (RSP) containing substit tions in the 
fusion peptide, leading to the  postulate that the fusion peptide is an immunodominant 
antigen (Stiasny et al., 2006).  Subsequent studies of human sera have examined the 
relative proportion of antibodies targeting the fusion peptide through competitive binding 
assays, western blots, or epitope-specific ELISA.  These studies reveal antibodies 
targeting the fusion peptide are cross-reactive, non-neutralizing toward heteologous 
serotypes, and make up a large, highly variable proportion of the antibody response in 
DENV infected human sera (Crill et al., 2009; Lai et al., 2008; Throsby et al., 2006).  The 
immunodominant production of these flavivirus group cross-reactive antibodies has 
enabled the utilization of diagnostic antigens containing substitutions in the fusion
peptide, which increase the accuracy of clinical flavivirus diagnosis (Chiou et al., 2008b; 
Roberson, Crill, and Chang, 2007a).   
Domain B:  The flavivirus antigenic domain B (EDIII) interacts with the putative 
cellular receptor and contains complex cross-reactive epitopes as well as serotype-
specific and protective epitopes.  Shortly after the passive transfer of MAbs was 
demonstrated to confer protection from challenge for several flaviviruses (Brandriss et 
al., 1986; Hawkes et al., 1988; Kaufman et al., 1987; Kimura-Kuroda and Yasui, 1988; 
Mathews and Roehrig, 1984), protective MAbs were determined to react with antigenic 
domain B (EDIII) (Cecilia et al., 1988).  Using truncated DENV-2 E polypeptides, th  
binding of a potently neutralizing serotype-specific MAb was elucidated to be between 
amino acids 255 and 422 in EDIII, with a more precise mapping to amino acids 386 to 
397 (Trirawatanapong et al., 1992).  Further characterization of DENV serotype-specific 




K305, P384 (Gromowski and Barrett, 2007) E383, P384 (Sukupolvi-Petty et al., 2007), 
and residues 307-312, 387, 389, and 391 of DENV-1 (Lisova et al., 2007).  Studies of 
JEV E protein using phage display have found residues 307-309, 327-333, and 386-390 
to bind with high affinity to JEV neutralizing MAbs (Wu and Lin, 2001).  Analysis of 
WNV neutralization escape mutants reveals residues 307, 330, and 332 are important in 
neutralization of WNV by MAbs (Beasley and Barrett, 2002).  Discrepancies between the 
exact locations of important serotype-specific residues could easily be due to ifferences 
in methods between phage display, RSPs, mutagenesis procedures, and different amino 
acid substitutions.  Despite slight variation in the exact location of EDIII neutralizing 
epitopes, these studies suggest the importance of the lateral ridge of EDIII in eliciting 
serotype-specific neutralizing antibodies.  Although EDIII plays a large role in the 
binding of murine MAbs, recent studies of EDIII depleted DENV infected human ser 
suggest antibodies against EDIII may play a smaller role in total DENV neutraliza ion as 
the EDIII depleted sera retained a relatively high neutralization titer (Wahala et al., 
2009).  This could be due to domains outside EDIII being implicated in flavivirus 
neutralization.  For example, human MAbs isolated from WNV infected human sera 
neutralize virus post attachment in a pH-sensitive manner and are inhibited by mutations 
in the EDII dimerization region and the EDII/EDI hinge region, demonstrating the 
binding of these MAbs to the EDII/EDI region (Vogt et al., 2009).     
In addition to serotype-specific neutralizing antibodies, EDIII elicits serocomplex 
cross-reactive neutralizing antibodies.  The complex-specific epitopes of DENV are 
localized to a similar overlapping region of EDIII:  residues 306, 307, 308, 310, 311, 312, 




Barrett, 2008; Matsui et al., 2008; Rajamanonmani et al., 2009; Sukupolvi-Petty et al., 
2007).  Although these serocomplex cross-reactive sites cluster within the neutralization 
epitopes previously described, the critical binding residues are not identical (Matsui et al., 
2008).  Additionally, the serocomplex-specific MAbs have more variability in 
neutralization efficiency, and require a significantly higher occupancy level of available 
binding sites on the virion in order for neutralization to occur (Gromowski, Barrett, and 
Barrett, 2008).   
  Domain C:  While a detailed mapping study of antigenic epitopes in antigenic 
domain C (EDI) has yet to be accomplished, several studies suggest the presence of 
serotype-specific or subtype-specific neutralizing antibodies.  Neutralization escape 
mutants of YFV type-specific murine MAbs, led to the identification of important 
neutralization residues at residues 155 and 158 in EDI (Ryman et al., 1997) acting as part 
of a conformational epitope in conjunction with amino acid 71 in EDII (Daffis et al., 
2005).  Similar neutralization escape mutants of DENV-4 identified residues 174 and 176 
in EDI as important serotype-specific neutralizing epitopes (Lai et al., 2007).   
Dengue virus vaccines 
The current means for DENV disease prevention are education and vector control.  
Despite over 70 years of effort, a licensed DENV vaccine has been unobtainable, unlike 
other flaviviruses such as YFV, JEV, and TBEV.  DENV vaccine research suffers several 
obstacles in the successful development of a licensed vaccine.  A main obstacle in 
vaccine development is the lack of an animal model that reproduces human disease.   
Among the most widely used animal models in preclinical DENV vaccine studies 




pathology in immune competent mice; therefore, different immune-compromised mouse 
models have been developed.  Humanized mice have been developed by irradiated 
immune-compromised newborn mice and reconstituting the immune system with a 
xenograft of human CD34+ hematopoietic stem cells.  Non-obese diabetic/severe 
combined immunodeficiency (NOD/SCID) mice, reconstituted with CD34 engraftment, 
develop viremia, fever, rash, thrombocytopenia, and elevated liver enzymes following 
infection with human DENV isolates; however, few mice developed anti-DENV 
antibodies (Bente et al., 2005).  NOD/SCID/IL2Rγnull mice, which are NOD/SCID mice 
laking the IL-2 receptor gamma chain, also develop viremia, rash, fever, and 
thrombocytopenia following infection, in addition to low levels of DENV IgG (Mota and 
Rico-Hesse, 2009).  RAG2-/-γc-/- mice do not produce B, T, or NK cells.  After 
engraftment, they have a relatively longer life than other humanized mice.  Following 
DENV infection, they develop viremia, fever and DENV specific human IgM and IgG 
(Kuruvilla et al., 2007).  Though humanized mice are advantageous by developing a 
human antibody response to DENV infection, the high cost and labor-intensive procedure 
has limited the extensive use of this model.   
Interferon-receptor deficient mice (AG129) can permit for the replication of all 
four DENV serotypes.  Though the tissue tropism of DENV in these mice is similar to 
that of human infections, infection with DENV-2 typically induces a paralytic phenotype 
(Johnson and Roehrig, 1999) and mouse adaptation is required to induce a vicerotropic 
infection (Shresta et al., 2006).  The phenomenon of ADE was also observed in AG129 
mice through passive transfer of either immune sera or MAbs followed by infectio  wi h 




tropism and ability of DENV infection to induce a disease similar to that of humans, in 
addition to these mice being commercially available.  However, this model is limited 
because infection does not induce the full spectrum of immune responses since these 
mice lack interferon receptors.  Additionaly, DENV-2 infection only results in a disease 
characteristic of humans after viral adaptation.  Similar animal models in les 
immunecomprimised hosts would be more desireable.   
The use of non-human primates (NHP) for preclinical research has also been 
widely used.  NHP can be infected with human clinical isolates and allow for viral 
replication without the need of adaptation; however, NHP do not develop overt disease 
following infection that resembles DF or DHF/DSS (Halstead, Shotwell, and Casals, 
1973a; Halstead, Shotwell, and Casals, 1973b).  NHP have been utilized to evaluate live 
attenuated vaccine candidates, however, they have not been able to predict the 
immunogenicity and reactogenicity of live attenuated vaccines in humans.  Additionally, 
this vaccine model is hindered by high costs and limited availability to the research 
community.   
In addition to the lack of a DENV animal model, obstacles include the need for 
development of separate vaccines for each of the four DENV serotypes and the risk of 
vaccine induced severe disease upon subsequent natural infection if neutralizing ant body 
titers to one of the four serotypes should decrease over time.  These concerns have led to 
the developmental philosophy that DENV vaccines should induce long-lasting, protective 
immunity against all four serotypes (Whitehead et al., 2007).  Despite these difficulties, 
DENV vaccine development has made considerable advances in recent decades, with two 




Phase I clinical trials, and many subunit, vectored, and DNA vaccine candidates in 
preclinical development (Durbin and Whitehead, 2010).  
Live attenuated vaccines:  Live attenuated vaccines are among the most 
rigorously pursued methods for DENV vaccination.  Biologically-derived live attenuated 
vaccines were the earliest candidates for live attenuated DENV vaccines during World 
War II (Hotta, 1952; Sabin, 1952a).  The intracerebral serial passage of DENV-1 or 
DENV-2 in mouse brain resulted in a mouse adapted DENV strain with reduced 
pathogenicity in humans.  Sabin observed that after the seventh mouse passage, DENV-1 
vaccine provided protection from exposure to DENV-1 infected A des aegypti 
mosquitoes (Sabin, 1952a).  The vaccination with mouse adapted DENV resulted in mild 
DENV symptoms usually accompanied by rash, but systemic symptoms were absent or 
negligible.  Hotta concurrently demonstrated mouse-brain passaged DENV-1 lost human 
pathogenicity, induced neutralizing antibody titers, and protected volunteers from highly 
viremic DENV infected human serum (Hotta, 1952).  Additionally, vaccinated volunteers 
remained well during the Osaka epidemic of 1945.    
In the 1980s the Center for Vaccine Development at Mahidol University in 
Bangkok, Thailand and the Walter Reed Army Institute of Research (WRAIR) in 
Washington, DC began the development of live attenuated DENV vaccines implementing 
tissue-culture derived live vaccines.  The original viruses were isolated from DENV 
infected patients and serially passaged in primary dog kidney (PDK) cells or primary 
green monkey kidney (PGMK) cells.  Passage of DENV-2 in PDK cell culture leads to 
accumulations of mutations associated with an attenuated phenotype that have been 




live attenuated vaccine candidates were tested as monovalent, bivalent, trivalent and 
tetravalent formulations in adult flavivirus-naïve Thai and American volunteers 
(Bhamarapravati and Sutee, 2000; Bhamarapravati and Yoksan, 1989; Bhamarapravati et 
al., 1987).  These vaccines were found to be generally safe, with fever, rash and elevated 
liver enzymes being the most common side effects.  The vaccines elicited seroconversion 
rates between 90 and 100% when tested as mono, bi, or trivalent formulations.  The seed 
viruses were licensed to Sanofi Pasteur for further clinical tetravalent evaluations.  In 
tetravalent formulations, there was increased reactogenicity when compared to 
monovalent formulations (Kanesa-thasan et al., 2001).  In addition, DENV-3 was 
preferentially replicated and induced the highest neutralization titers.  To avoid 
interference from DENV-3 replication, different dose formulations were evaluated, as 
well as a two-dose regimen (Sabchareon et al., 2002).  The first dose was most 
reactogenic, producing fever, headache, myalgia, eye pain or rash, with 71% tetravalent 
seroconversion after two-doses.  Tetravalent formulas in a three-dose regimn were tested 
in school age Thai children (Sabchareon et al., 2004).  After one dose fever, headache, 
rash, and elevated liver enzymes were reported.  These manifestations were reduced after 
second and third-dosages.  After three-doses 89-100% of the children developed 
tetravalent seroconversion.  A final Phase 1b trial of two different formulations was 
conducted on Australian adults; however, the trial was stopped by the sponsor after only 
one dose due to reactogenicity and problems with formulations related to DENV-3 
interference (Kitchener et al., 2006).   
    WRAIR has developed several live attenuated DENV vaccines through serial 




candidates were found to be unacceptably reactogenic in human trials, or over attenuated 
and non-immunogenic and therefore no longer pursued (Bancroft et al., 1984; Bancroft et 
al., 1981; Eckels et al., 1984; Innis et al., 1988; McKee et al., 1987; Scott et al., 1983).  
Increasing PDK cell passage of monovalent DENV vaccine candidates resulted in 
increased attenuation for volunteers, yet decreased immunogenicity, leading to the 
unavoidable difficulty of selection of appropriate attenuated serotype viruses for 
tetravalent formulations (Kanesa-Thasan et al., 2003).  Initial tetravalent studies 
confirmed appropriate reactogenicity in volunteers, as well as increased seroconversion 
and neutralization titers following three doses (Sun et al., 2003).  The selected 
monovalent vaccines were tested in 16 formula combinations including low and high 
dose formulations (Edelman et al., 2003).  All formulations were considered safe with 
variable reactogenicity after the first-dose and nearly non-reactogenicity following the 
second and third doses.  The most common side effects were low-grade fever, rash, and 
temporary leukopenia.  Reactogenicity was positively correlated with immunogenicity.  
The similar serotype specific seroconversion rate between monovalent and tetr valent 
formulations suggested a lack of heterologous interference between serotypes.  A Phase I 
trial evaluated the safety and immunogenicity of this vaccine in seven Thai children aged 
six to nine years old (Simasathien et al., 2008).  A two-dose regimen six months apart 
was implemented.  The vaccine was well tolerated with only one volunteer experiencing 
fever.  The vaccine, however, was poorly immunogenic after one-dose, with five of six 
volunteers developing tetravalent seroconversion following two-doses.  Phase 2 trial of 
the PDK vaccines was successful in decreasing the reactogenicity by increasing DENV-1 




in a formulation selected for further clinical evaluation (Sun et al., 2008).     This vaccine 
has been licensed by GlaxoSmithKline and is currently in Phase 2 clinical trials.        
Scientists at the National Institutes of Health engineered specific mutations in the 
3’ NCR that resulted in an attenuated phenotype.  The 3’ NCR contains nucleotide 
sequence predicted to form secondary structures essential in flavivirus replication; 
however, this region is not well conserved.  Upstream of the secondary structure is a 
highly conserved sequence that was the target of attenuation studies.  Deletion mutations 
into this region of the 3’ NCR of DENV-4 cDNA clones resulted in a range of attenua d 
phenotypes (Men et al., 1996).  These deletion mutants were restricted in growth in LLC-
MK2 cells, produced small plaques on C6/36 cells, and were immunogenic in monkeys 
without producing a viremia.  Of particular interest was the deletion mutation from 
nucleotides 172-143 from the 3’ end, later referred to as ∆30.  The DENV-4∆30 vaccine 
preformed well in human volunteers eliciting neutralizing antibodies and low 
reactogenicity (Durbin et al., 2001; Durbin et al., 2005).  A single-dose of vaccine 
resulted in 95-100% seroconversion.  The most common side effect was rash; however no 
recipient developed systemic illness or dengue-like symptoms.   In the wake of success 
from the DENV-4∆30 vaccine, the ∆30 mutation was engineered into the remaining 
DENV serotypes.  DENV-1∆30 resulted in an attenuated vaccine similar to DENV-4∆30 
(Whitehead et al., 2003).  DENV-2∆30 resulted in only moderate attenuation (Blaney et 
al., 2004b), while DENV-3∆30 failed to attenuate the virus and resulted in viremia levels 
similar to wild-type DENV-3 (Blaney et al., 2004a).  Chimeric DENV-3/DENV-4∆30 
and DENV-2/DENV-4∆30 vaccines, replacing the prM and E genes of DENV-4 with 




Chimeric DENV-3/DENV-4∆30 vaccine displayed attenuated phenotype in cell culture 
and elicited DENV-3 neutralizing antibody in monkeys.  Chimeric DENV-2/DENV-4∆30 
was well tolerated in dengue naïve adults and resulted in high DENV-2 neutralizing 
antibody titers for the entire study (Durbin et al., 2006).  Transient rash was the most 
common side effect, and RNA recovered from blood revealed the ∆30 mutation was 
stable.  Further attenuation studies of DENV-3 have revealed two deletions in the 3’ UTR 
of DENV-3, or replacement of DENV-3 3’ UTR with DENV-4 3’ UTR that result in 
infection without detectable viremia and protect monkeys from viral challenge (Blaney et 
al., 2008).  Phase 1 evaluation of these new candidates has been initiated.   
   Similar to the chimeric strategy described above, live attenuated tetraval nt 
chimeric DENV vaccine has been developed utilizing YFV 17D as a genetic backbone.  
Four DENV vaccines were created where the prM and E proteins of YFV were replaced 
by those of DENV 1-4 (ChimeriVax-DENV1-4) (Guirakhoo et al., 2001; Guirakhoo et 
al., 2000).  Preclinical trials in non-human primates demonstrate that ChimeriVax induces 
low level, detectable viremia in YFV immune and non-immune monkeys when compared 
to monkeys given wild-type DENV.  Neutralizing antibodies to all four DENV serotypes 
were demonstrated in post immunization sera; however, DENV-2 appeared to be 
immunodominant (Guirakhoo et al., 2001).  Lowering the dose of ChimeriVax DENV-2 
in the tetravalent formulation resulted in a more balanced neutralizing antibody response 
to DENV-1, -2, and -3 with modestly higher titers to DENV-4 (Guirakhoo et al., 2002).  
Testing four dose formulations of ChimeriVax DENV1-4 in a non-human primate 
challenge resulted in nearly complete protection from viremia and displayed decreas d 




trials of ChimeriVax DENV-2 in flavivirus naïve and YFV immune volunteers result d in 
mild side effects, similar to that of YF-Vax (Guirakhoo et al., 2006).  All volunteers 
vaccinated with high dose ChimeriVax DENV-2 seroconverted to DENV-2, and no 
volunteers seroconverted to DENV-1, -3, -4, or YFV.  In addition, YFV immunity did not 
interfere with ChimeriVax DENV-2 immunization and increased heterologous DENV 
seroconversion.  In an analysis of potential replicative or immune interference b tween 
the four serotypes, it was demonstrated DENV-1 and DENV-4 were dominant in 
neutralizing antibody titers regardless of dose or route of administration (Guy et al., 
2009).  When tetravalent ChimeriVax was given to non-human primates or adult 
volunteers, a longer time span between primary immunization and boost increased the 
seroconversion rates, suggesting interference could be prevented with a longer dose 
schedule (Morrison et al., 2010).  ChimeriVax, licensed by Sanofi Pasteur, is currently 
being evaluated in a three-dose format in Phase 2 studies in DENV endemic regions.      
A third chimeric method includes the use of the DENV-2 PDK-53 virus as the 
genetic backbone, which had a low infectious dose, was strongly immunogenic, and 
produced no clinical symptoms in humans.  The attenuation of the DENV-2 PDK-53 
vaccine has been attributed to substitutions in the 5’ NCR, NS1 and NS3 genes (Butrapet 
et al., 2000).  Chimeric DENV-2 PDK-53/DENV-1, where the prM and E genes of 
DENV-1 replaced those of DENV-2 PDK-53, elicited higher DENV-1 neutralizing 
antibody titers in mice when compared to the DENV-1 PDK-13 vaccine (Huang et al., 
2000a).  In a tetravalent formulation of DENV-2 PDK-53 and chimeric DENV-2 PDK-
53/DENV-1, -3, and -4, immunization of mice resulted in neutralizing antibody titers to 




lowest response (Huang et al., 2003).  In addition, vaccination of monovalent chimeric 
DENV-2 PDK-53/DENV-1 protected 100% of mice in an AG129 challenge model.  
Further preclinical evaluation of the tetravalent vaccine in non-human primates is 
completed.  The monovalent vaccines are currently undergoing Phase I clinicaltr als in 
flavivirus naïve adults. 
Live attenuated DENV vaccines have by far been the most rigorously pursued 
vaccine format, including several vaccines in human clinical trials.  In general, live 
replicating vaccine viruses have been shown to induce high levels of protective 
antibodies and also induce protective cytotoxic T lymphocytes, making these vaccines 
highly desirable.  However, plausible risks of vaccination with live attenuated viruses 
hold high concerns.  Though these vaccine viruses have been attenuated, biologically or 
engineered, to replicate at lower efficiency than the parental strains, these vaccines are 
not appropriate to administer to immune compromised individuals.  In addition, 
replicative multivalent vaccines suffer from replicative and/or immune interference (Guy 
et al., 2009).  Vaccine interference hinders the ability of multivalent vaccines to induce a 
balanced immune response, which is thought to be detrimental in DENV vaccination as 
there is a threat of vaccine-induced ADE.  Biologically derived live attenuad viruses are 
also at the risk of under attenuation, or reversion back to wild-type virulence, as sen 
with oral poliovirus vaccine (Minor, 2009).  Caution is also warranted in the use of 
chimeric live attenuated viruses as a risk of inter- and intraspecies reombination exists.  
Evidence of interspecies recombination of flaviviruses in nature has been controversial 
(Baillie et al., 2008; Twiddy and Holmes, 2003).  However, evidence of intraspecies 




patient harbored two genotypes of DENV-1 as well as a DENV-1 strain with inter-
genomic recombination events between the two genotypes.  Although many researcher 
believe the benefits of DENV vaccination out-weigh the theoretical risks of 
recombination (Monath et al., 2005), the risk of intraspecies recombination in DENV is 
still a concern that should not be overlooked.      
Whole virus inactivated vaccines:  Whole virus inactivated vaccines have 
perceived advantages over live attenuated vaccines.  These vaccines cannot go through 
reversion mutations to attain the virulent phenotype, they do not replicate and therefore 
cannot interfere with other strains in a tetravalent format, and they can be administered to 
immune compromised individuals.  However, these vaccine formats are hindered by 
lower immunogenicity than their live attenuated counterparts and therefore require more 
vaccinations to reach protective levels, and require booster immunizations since 
neutralizing antibody titers wane over time.   
A purified, inactivated (PIV) DENV-2 vaccine was developed by WRAIR in 1996 
(Putnak et al., 1996a; Putnak et al., 1996b).  Sucrose gradient purified virus was 
inactivated with formalin and tested for protective efficacy in mice or macaques.  
Vaccinated mice and macaques developed high titers of DENV-2 neutralizing antibody 
and were partially protected from viral challenge.  In macaques, the neutralizing ntibody 
response did not remain stable over a prolonged period, regardless of adjuvant used 
(Putnak et al., 2005) suggesting higher doses of vaccine or additional boosting may be 
required to maintain protective antibody levels. 
Recombinant subunit protein vaccines:  In addition to whole virus inactivated 




alternative to live attenuated vaccines.  Similar to whole virus inactivated vccines, 
subunit protein vaccines are also hindered by lower immunogenicity and required 
administration with an adjuvant, few of which have been approved for human use.   
Recombinant DENV proteins can be expressed in a variety of systems including, 
baculovirus, Escherichia coli, yeast, vaccinia virus, drosophila cells and mammalian cells 
and then purified for use as subunit vaccines.  As described earlier, the flavivirus E 
protein contains the major antigenic and protective epitopes; however, proper foldingof 
E ensures antigenic stability and requires the coexpression of prM (Allison et al., 1995b).  
Full-length E without prM is not secreted and fails to induce neutralizing antibodies in 
mice (Fonseca et al., 1994).    In addition, the coexpression of prM/E can induce the 
formation of flavivirus-like particles (VLP) (Sugrue et al., 1997).  Flavivirus VLPs are 
immunogenic and elicit neutralizing and protective antibodies in mice (Hunt, Cropp, and 
Chang, 2001; Konishi and Fujii, 2002; Konishi et al., 1992). 
The deletion of the C terminal 20% of the E gene resulted in increased 
extracellular secretion while maintaining antigenicity and inducing protective antibodies 
in mice (Deubel et al., 1991; Men, Bray, and Lai, 1991).  Recombinant subunit vaccine of 
80% DENV-2 E and prM (r80), expressed in Drosophila cells, was tested using four 
different adjuvants in macaques (Putnak et al., 2005).  Regardless of adjuvant used, these 
vaccines elicited high levels of DENV neutralizing antibodies; however, aft  viral 
challenge there was evidence of viral replication by qRT-PCR analysis and virus 
isolation, indicating there was not sterilizing immunity.  In a tetravalent formulation in 
macaques, 5µg of each serotype DENV r80 soluble E elicited serotype specific 




with lowest responses (Clements et al., 2010).  Low doses of tetravalent r80 resulted in 
detectable viremia in only one-of-four animals following viral challenge. 
An alternative subunit protein vaccine method is the use of recombinant EDIII, 
expressed mainly from E. coli or yeast.  Early attempts at EDIII vaccination involved 
fusing recombinant EDIII to various proteins.  Fusion of tetravalent EDIII with trpE from 
E. coli elicited antibodies binding EDIII that were non-neutralizing (Fonseca et al., 1991).  
Fusing DENV-2 EDIII to staphylococcal protein A resulted in increased levels of DENV-
2 neutralizing antibody that protected against DENV-2 challenge; however, 
staphylococcal protein A has high affinity for human IgG and unsuitable for vaccination 
(Srivastava et al., 1995).  Alternatively, fusion of DENV EDIII with maltose binding 
protein (MBP) from E. coli induces neutralizing antibodies and protection upon challenge 
(Simmons et al., 1998).  In a tetravalent formulation, DENV-MBP vaccine elicited 
equivalently high titers of DENV neutralizing antibodies for DENV-1, -2, and -3, and 
significantly lower levels for DENV-4 in mice (Simmons, Murphy, and Hayes, 2001).  
The carrier capacity and safety of MBP has not been evaluated for use in humans.  P64K 
protein from Neisseria menengitidis has also been evaluated as a fusion carrier for EDIII 
vaccines.  DENV-2 EDIII expressed from E. coli fused with P64K maintained 
antigenicity based upon reactivity with MAbs, elicited DENV-2 neutralizing a tibodies, 
and partially protected mice from challenge (Hermida et al., 2004b).  Immunogenicity of 
monovalent DENV-1, -3, and -4 EDIII fused with P64K have each been confirmed in 
mice (Hermida et al., 2004a; Lazo et al., 2008; Zulueta et al., 2006).  DENV-2 EDIII 
fused to P64K administered with Freund’s adjuvant was found to elicit neutralizing 




study found polysaccharide A of N. menigitidis was a suitable adjuvant eliciting 
neutralizing antibodies and partially protecting macaques from challenge (Valdes et al., 
2008).   
Several studies have explored the possibility of vaccination with recombinant 
EDIII without a fusion protein.  Using E. coli expressed DENV EDIII without a fusion 
partner (Jaiswal, Khanna, and Swaminathan, 2004), vaccination with bivalent DENV-2 
and DENV-4 EDIII linked by a flexible amino acid linker region maintained antige ic 
properties of the respective monovalent EDIII vaccines, and elicited neutralizing 
antibodies to both DENV-2 and DENV-4 (Khanam et al., 2006).  In a tetravalent 
formulation, DENV-1-4 EDIII expressed from yeast elicited neutralizing antibody titers 
in mice to all four serotypes, with DENV-4 the predominant response (Etemad et al., 
2008).  In addition, T cells from vaccinated mice proliferated and secreted IFNγ and IL-4 
in response to all four serotypes. 
An alternative approach for EDIII vaccination was investigated using DENV 
consensus sequences.  E. coli-expressed recombinant EDIII was developed using 
DENV1-4 consensus sequences (cEDIII) (Leng et al., 2008).  When vaccinated with 
cEDIII, mice developed neutralizing titers to all four DENV.  Titers ranged from 1:128 to 
1:8 in a 40% plaque reduction assay.  DENV-4 elicited the lowest level of neutralizing 
antibodies, related to DENV-4 having the lowest similarity to the cEDIII consensus 
sequence.  Further optimization of the consensus EDIII is needed to increase and 
equilibrate neutralizing antibody titers.   
Virus-vectored vaccines:  Recombinant poxviruses and adenoviruses that 




cellular immune responses against several human pathogens.  These viruses infect cells 
and express the antigen of interest de novo within the cell.  The genes are translated, 
leading to induction of an MHC I restricted immune response, and the antigens are 
processed and glycosylated naturally.  This vaccine format is advantageous due to the 
live nature of the vaccine; however, preexisting immunity to the vector can hinder 
vaccine efficacy.  Although a plethora of possible adenovirus vectors exists, continually 
tailoring the vaccine vector to the individual’s immune status is costly and ineffic ent. 
Early attempts at developing a vaccinia-vectored DENV vaccine elicited variable 
results.  Using prM/E/NS1/NS2a expression, vaccinia-vectored DENV-4 failed to in uce 
an anti-E immune response in cotton rats (Zhao et al., 1987) and E protein accumulated 
intracellularly.  However, when vaccinia-vectored DENV-4 full-length structural, or full-
length E protein were used to vaccinate mice, all mice survived intra cerebral challenge 
despite low level detection of DENV-4 antibodies to the structural proteins (Bray et al., 
1989). Although all mice survived challenge, mice vaccinated with full-length E did 
display encephalitic disease symptoms.  Interestingly, when the virion capsid, membrane 
and envelope structural protein genes of DENV-2 were cloned into a vaccinia-vector, 
DENV-2 antibody could not be detected in vaccinated mice, hamsters or monkeys 
(Deubel et al., 1988).  In addition, vaccinated monkeys developed levels of viremia after 
challenge similar to the control animals.  To improve the immunogenicity of vaccini -
vectored DENV vaccines, the 20% C terminal region was deleted from the E protein of 
DENV-2 and DENV-4 (Men et al., 2000).  DENV E was detected in extracellular 




antibody titers in mice.  When macaques were vaccinated with three doses, all monkeys 
were protected from challenge as shown by the absence of viremia (Men et al., 2000). 
Replication defective adenovirus-based vectors have also been studied for DENV 
vaccination.  Insertion of the DENV-2 E ectodomain coding region into the E1 early 
region of the adenovirus genome resulted in secretion of E from virus infected cells, 
elicited DENV-2 neutralizing antibodies following a booster immunization comparable to 
inactivated DENV-2 vaccine, and induced IFNγ secreting CD4 T cells (Jaiswal, Khanna, 
and Swaminathan, 2003).  Using two complex adenovirus vectors, expressing the prM/E 
of DENV-1 and DENV-2 (cAdVaxD1-2) or DENV-3 and DENV-4 (cAdVaxD3-4), a 
bivalent DENV vaccine was administered to mice (Holman et al., 2006).  These mice 
developed DENV cross-reactive antibodies as well as DENV serotype-specific 
neutralizing antibodies, in addition to IFNγ secreting CD4 T cells.  To test this two-
vaccine system in a tetravalent format (cAdVax-DenTV), macaques were vaccinated with 
adenovirus-vectors, cAdVaxD1-2 and cAdVaxD3-4, by combining the two bivalent 
vaccine constructs (Raviprakash et al., 2008).  Vaccinated macaques exhibited 
neutralizing antibody titers ranging from 200 (DENV-2) to 937 (DENV-3) following a 
booster vaccination.  All animals were protected from viremia from DENV-1 and DENV-
3; however, viremia was detected in one animal challenged with DENV-2 and all animals 
challenged with DENV-4.  Interestingly, both DENV-2 and DENV-4 prM/E were 
introduced into the E4 region of the adenovirus vector of their respective construct.  
Further investigation and optimization is warranted.   
In addition to full-length E protein, viral vectors have been investigated to express 




DENV-2 specific neutralizing antibodies in mice using either an adenovirus-DENV-2 
prime/plasmid expressing DENV-2 EDIII boost, or a plasmid prime/adenovirus boost 
(Khanam, Khanna, and Swaminathan, 2006).  This method elicited both Th1 and Th2 T 
cells, with a predominant Th1 response.  Alternatively, the pediatric measles vaccine was 
engineered to express EDIII of DENV-1 fused with the ectodomain of M (Brandler et al., 
2007).  The immunization of mice susceptible to measles virus resulted in the production 
of DENV-1 neutralizing antibodies.  In addition, the presence of ectoM in the vaccine 
acted as an adjuvant and stimulated the maturation of dendritic cells and the secretion of 
cytokines when compared to a vaccine that does not contain ectoM.  The possibility of a 
single vaccination against both DENV and measles virus makes this an interesting 
strategy.  Additionally, as with adenovirus vectors, the effect of previous immunity to 
measles virus on vaccine immunogenicity should be evaluated.  
DNA vaccines:  DNA vaccines represent a novel means of expressing antigens in 
vivo for generation of humoral and cellular immunity.  The DNA vaccines typically 
consist of a bacterial plasmid with a strong promoter, gene of interest, and 
polyadenylation/termination sequence.  The plasmids do not contain an origin of 
replication functional in eukaryotic cells, therefore plasmids cannot replicate in 
mammalian cells.  Common safety concerns of DNA vaccines include the potential 
integration of plasmid DNA into the host chromosome and the production of autoimmune 
anti-DNA antibodies.  However, studies have shown no demonstrable evidence of 
integration of plasmid into the host genome and no production of anti-DNA antibodies 




platform because it is stable for long periods of time, is resistant to temperature extremes, 
is less reactogenic and can be administered to immune compromised individuals.   
Using DNA as a DENV vaccine platform was first investigated by the Naval 
Medical Research Institute in Bethesda, Maryland.  Using a eukaryotic expression 
plasmid, the prM and 92% E of DENV-2 were shown to be expressed in tissue culture 
with proper size and folding when compared to naturally infected DENV-2 cell cultures 
(Kochel et al., 1997).  When Balb/C mice received three-doses, the DNA elicted DENV-
2 neutralizing antibodies in all mice vaccinated 22 weeks post vaccination.  However, 
these vaccinated mice were not protected from challenge at 6 weeks of age, likely due to 
the lack of a neutralizing antibody response 3 weeks post vaccination.  When mice 
received two vaccinations before challenge at 6 weeks of age, 60% of mice survived 
intracerebral inoculation (Porter et al., 1998).  These mice, however, still had lower 
neutralizing antibody titers prior to challenge compared to neutralizing titers from mice 
that received three-doses of DNA.  When DNA expressing DENV-1 prM and full length 
E were inoculated into Aotus monkeys and rhesus macaques, all monkeys developed 
DENV-1 neutralizing antibody titers following two boost vaccinations and most were
completely protected from viremia upon viral challenge.  Monkeys that developed 
viremia had a shorter duration than the control monkeys (Kochel et al., 2000; 
Raviprakash et al., 2000).  
Konishi and colleagues also developed a DENV DNA vaccine consisting of 
DENV-2 prM/E.  When mice were inoculated with 100 µg of plasmid, all mice 
developed DENV-2 neutralizing antibodies, and titers rapidly increased following viral 




et al., 2000).  When evaluated in a tetravalent formula containing 25 µ of each DENV 
plasmid, mice developed neutralizing antibodies to all four DENV serotypes and an 
anamnestic response to challenge (Konishi, Kosugi, and Imoto, 2006).  In addition, 
neutralizing antibody titers prior to challenge were similar in magnitude to neutralizing 
antibody titers elicited from the monovalent vaccines, indicating the tetravalent DNA 
vaccine is not impeded by interference as is common with live attenuated vaccines.   
Chang and colleagues developed DENV-2/JEV chimeric prM/E DNA vaccines to 
increase the biosynthesis and secretion of DENV-2 VLP.  Plasmids expressing DENV-2 
prM/E were constructed containing 10% or 20% C of the JEV E C terminus compared to 
100% DENV-2 E to identify possible retention sequences in DENV-2 E (Chang et al., 
2003).  All three plasmids caused release of DENV-2 VLP into tissue culture media; 
however, the plasmid containing 80% DENV-2/20% JEV E secreted significantly higher 
levels of VLPs, suggesting an unidentified retention sequence in the DENV-2 E between 
amino acids 397 and 436.  These VLPs were determined by MAb reactivity to express 
authentic DENV-2 E protein eptiopes, suggesting that the JEV E C terminal 20% had no 
effect on antigenicity.  When mice were vaccinated with two doses of 100 µg of 
plasmids, neutralizing antibody titers correlated with the ability of plasmids to secrete 
VLPs into tissue culture medium.  In addition, 11 out of 12 pups from mothers vaccinated 
with plasmid containing 80% DENV-2/20% JEV E survived intracranial DENV-2 
challenge while no pups from unvaccinated mothers survived.      
Several groups have investigated methods to increase the immunogenicity of 
DNA vaccines.  When DENV-2 plasmid expressing prM/E was coadministered with 




Terazawa, and Imoto, 2003), immunized mice developed significantly higher neutralizing 
antibody titers than when vaccinated with DNA or protein alone.  A similar trend was 
also observed in vaccinated macaques (Simmons et al., 2006).  Incorporation of bacterial 
CpG motifs into the DNA plasmid, or incorporation of the GM-CSF gene into the 
plasmid has also been shown to increase the immunogenicity of DENV-1 prM/E DNA 
vaccines in Aotus monkeys (Raviprakash et al., 2003).  The antibody titers elicited by 
these vaccines were increased and 87% of challenged monkeys were completely 
protected from viremia compared to 33% who received the prM/E plasmid alone.  
Methods to increase the immunogenicity of DNA vaccines for non-DENV pathogens 
include the simultaneous gene expression of interleukins or other cytokines.   
Summary 
Dengue is the most common arthropod-borne viral disease of humans and the 
virus exists as four closely related serotypes.  Dengue is a threat to global public health as 
it continues its rapid spread throughout the tropics and subtropics, leaving an estimated 
3.6 billion people at risk for dengue virus infection (PDVI, 2009).  Dengue disease 
presents as a wide range of clinical symptoms from subclinical, to the classic febrile 
disease, dengue fever, to the most severe manifestation and life threatening dengue 
hemorrhagic fever (DHF) and dengue shock syndrome (DSS).  Current treatments of 
severe manifestations of dengue disease include maintaining circulatory volumes and 
electrolyte balances.  This form of dengue is mainly seen in children and is the leading 
cause of pediatric hospitalizations in endemic countries (Hombach, 2007).  To control 
dengue virus disease, emphasis should be placed on prevention, includingvector control 




Dengue vaccine development has been hindered by the complexity of disease 
pathogenesis.  Epidemiological evidence associates severe dengue disease with secondary 
infections (Guzman et al., 1990; Sangkawibha et al., 1984).  Infection with any one 
dengue serotype induces life-long protection, though heterologous protection from the 
other serotypes lasts only months (Sabin, 1952b).  Though the mechanism of severe 
dengue disease is not fully understood, the pathogenesis is complex and most likely 
multifactorial.  One hypothesis to describe DHF is antibody-dependent enhancme t 
(ADE) (Halstead, Chow, and Marchette, 1973), which occurs when cross-reactive 
weakly-neutralizing antibodies bind to viruses and form antibody-virus complexes that 
enhance infection of Fcγ receptor bearing cells, resulting in an increase in virus load 
associated with severe disease (Wang et al., 2003).  The virion envelope (E) glycoprotein 
is responsible for eliciting the majority of the protective antibody response.  Recent 
studies suggest broadly cross-reactive, weakly-neutralzing antibodies directe  against the 
fusion peptide (FP) form a major proportion of the antibody response in DENV patients 
(Crill et al., 2009; Lai et al., 2008; Stiasny et al., 2006; Throsby et al., 2006).  The 
dominant production of  high avidity antibodies could compete with neutralizing 
antibodies recognizing overlapping epitopes through steric interference (Ndifon, 
Wingreen, and Levin, 2009) and promote severe disease through ADE.  For these 
reasons, DENV vaccines must induce a balanced protective immunity to all four 
serotypes to reduce the possibility for cross-reactive antibody induced sev re disease 
upon subsequent infection.   
Current DENV vaccines in clinical development include live-attenuated vaccines.  




between different virus serotypes.  The current solution to this problem has been to utilize 
a two- or three-dose vaccination schedule with an extended resting time period between 
primary immunization and boost.  The replicative and/or immune interference associated 
with these vaccines has resulted in a large proportion of non-responders following one- 
and two-doses (Morrison et al., 2010; Sun et al., 2008) with 100% tetravalent 
seroconversion requiring three doses spanning a year (Morrison et al., 2010).  The time 
required for full seroconversion spans the epidemic season, leaving a significant portion 
of vaccinated individuals without tetravalent protective immunity who are at risk for 
vaccine-induced severe disease following natural infection.  In order to control DENV 
human disease, new vaccine formats need to be investigated, taking into account the need 
for a balanced immune response and the importance of the cross-reactive antibody 






Humoral Immune Responses of Dengue Patients using Epitope-Specific Serotype-2 
Virus-like Particle Antigens 
Introduction 
Dengue virus (DENV) causes the quintessential 21st century re-emerging 
infectious disease.  Advances in post exposure treatment, epidemiological understanding, 
and vector control did much to reduce dengue disease burden in the post WWII era. 
However, in the last three decades, DENV has spread epidemically dramatically 
increasing in disease severity and range, with overlapping co-circulation of the four 
DENV serotypes spreading into geographic regions containing other pathogenic 
flaviviruses (Gubler, 2006; Mackenzie, Gubler, and Petersen, 2004; Solomon and 
Mallewa, 2001).  Approximately 40% of the world’s population, over 2.5 billion people, 
live at risk of infection in DENV-endemic areas, resulting in an estimated 50-100 million 
infections yearly (Farrar et al., 2007; Normile, 2007).  Significant effort and resources 
have been applied toward DENV vaccine development over the last 30 years, yet in spit 
of promising vaccine candidates in development and/or early-phase trials, a safe and 
efficacious vaccine appears to still be years away (Normile, 2007; Whitehead t al., 
2007). 
DENV consist of four closely related viral serotypes (DENV-1, -2, -3, and -4) and 
as with the other flaviviruses, infection with any single virus appears to provide life-long 




(Calisher et al., 1989; Kuno et al., 1998; Sabin, 1952b; Tesh et al., 2002).  Human 
infections with DENV result  in a range from asymptomatic to acute self-limiting febrile 
illness known as dengue fever (DF) or with increasing frequency, a life-threatening 
hemorrhagic fever and circulatory shock known as dengue hemorrhagic fever/dengue 
shock syndrome (DHF/DSS) (Gubler, 2006).   The DENV genome is a positive-sense 
single-stranded RNA molecule, approximately 11 kb in length.  It is translated into a
single polyprotein encompassing three structural proteins, capsid (C), premembran / 
membrane (prM/M) and envelope (E) proteins, and seven non-structural proteins 
(Lindenbach and Rice, 2003).  Mature virions contain an ER derived lipid bilayer 
covered with a dense lattice of membrane-bound prM/M and E proteins, organized into 
dimers on its surface (Kuhn et al., 2002).  The E protein elicits the majority of the 
protective immune response and contains a highly conserved internal fusion peptide and 
the cellular receptor-binding motifs, both essential for viral infectivity via receptor-
mediated endocytosis (Allison et al., 2001; Kuhn et al., 2002; Lindenbach and Rice, 
2003; Pokidysheva et al., 2006).  DENV and all flavivirus E proteins contain three 
structural and functional domains (Modis et al., 2003; Modis et al., 2005; Rey et al., 
1995).  The epitope specificity and biological characteristics of antibody responss t  the 
E protein are mostly known from murine MAb studies.  E protein domain I (EDI) is the 
central domain and contains both virus-specific and cross-reactive, predominantly non-
neutralizing epitopes; EDII, the dimerization domain, contains the internal fusion peptide 
that forms the epicenter of a series of overlapping immunodominant cross-reactive 
epitopes stimulating predominantly non- or weakly neutralizing antibodies; EDIII has an 




mice elicits serotype-specific, highly protective neutralizing antibodies and DENV 
complex cross-reactive antibodies (Chiou et al., 2008a; Crill and Chang, 2004; Crill and 
Roehrig, 2001; Gromowski and Barrett, 2007; Gromowski, Barrett, and Barrett, 2008; 
Roehrig, Bolin, and Kelly, 1998; Stiasny et al., 2006; Sukupolvi-Petty et al., 2007). 
Infection with any DENV serotype thus produces a wide spectrum of anti-E 
immunoglobulins varying from broadly cross-reactive, recognizing all flaviviruses, to 
those recognizing only subsets of viruses in different serocomplexes, to those recognizing 
only DENV-complex viruses to DENV serotype-specific antibodies.  The broadly cross-
reactive antibodies stimulated from the overlapping immunodominant epitopes 
surrounding the EDII fusion peptide are predominantly non-neutralizing as evidenced by 
the general lack of cross-protection between the flaviviruses (Calisher et al., 1989; Kuno 
et al., 1998; Oliphant et al., 2007a; Sabin, 1952b; Stiasny et al., 2006; Tesh et al., 2002). 
DENV complex and sub-complex cross-reactive antibodies stimulated from overlapping 
epitopes in EDIII vary in their neutralizing capabilities (Gromowski, Barrett, and Barrett, 
2008; Roehrig, Bolin, and Kelly, 1998; Sukupolvi-Petty et al., 2007) and these antibodies 
can be protective, as evidenced by occasionally documented transient cross-protection 
between DENV serotypes (Sabin, 1952b). Secondary infection with a heterologous 
DENV serotype stimulates a broadly cross-reactive anamnestic immune response, which 
although not efficiently cross-protective, can cause serious immune mediated disease.  
The presence of cross-reactive anti-E immunoglobulins in sera from recoverd humans 
can create difficulty for serodiagnosis and especially for estimates of di ease burden in 
regions with multiple co-circulating pathogenic flaviviruses.  In clinical serodiagnosis 




the difficulty of differentiating antibodies elicited by primary infections from those 
elicited in a secondary infection (Kuno, 2003; Martin et al., 2004; Roberson, Crill, and 
Chang, 2007a). For example, in Puerto Rico since 1997 all four DENV serotypes were 
co-circulating and the vast majority of patients were secondary DENV infect ons.  With 
the arrival of West Nile virus (WNV) into the Caribbean and apparent DENV infections 
with neurological manifestations, clinical serodiagnosis has become especially 
complicated (CDC Dengue Branch pers com., (2008; Barrera et al., 2008).  Serosurvey 
estimates of flavivirus disease burden are even more problematic due to cross-reactive 
IgG responses accumulated over a lifetime of multiple virus or vaccination exposures.  
The presence of cross-reactive anti-E immunoglobulins may enhance the 
pathogenicity of flavivirus infections via the process of antibody-dependent enhancement 
(ADE)(Takada and Kawaoka, 2003).  Although ADE has been demonstrated in vitro for 
encephalitic as well as hemorrhagic flaviviruses (Wallace et al., 2003) it is of greatest in 
vivo concern with DENV infections where the severe pathogenic manifestations dengue 
hemorrhagic fever and shock syndrome (DHF/DSS) are correlated with secondary 
infections and sub-neutralizing levels of heterologous anti-E immunoglobulins (Gubler, 
2002a; Guzman et al., 2007; Halstead, 1989).  Concern over ADE and its role in 
DHF/DSS has instilled a belief in the necessity for tetravalent DENV vaccines 
stimulating balanced immune responses across DENV serotypes to reduce this concern 
(Chang et al., 2004; Monath, 2007; Whitehead et al., 2007). However, multivalent DENV 
candidate vaccine trials have been severely hampered by difficulties in inducing  




An important research agenda necessary to successfully address the DENV global 
public health challenge is to improve our understanding of humoral immune responses to 
DENV infection, specifically the E-protein epitope-recognition of the immunoglobulin 
response and the relative quantities of epitope-specific antibody populations after vir l 
exposure and vaccination in humans, there infection neutralizing and/or enhancing 
capabilities of these immunoglobulin populations, and their role as correlates of 
protection in vaccine efficacy studies (Farrar et al., 2007; Goncalvez et al., 2007; 
Halstead, 1989; Hombach et al., 2007; Rigau-Perez, 2006; Senior, 2007; Sukupolvi-Petty 
et al., 2007).  As an initial step toward this goal, in this report we developed a series of E-
protein epitope-specific knock-out virus-like particles (VLPs) and use these antig ns to 
measure humoral immune responses in sera from DENV-2 infected humans from Puerto 
Rico and Taiwan.  We quantified immunoglobulin populations targeting four distinct E-
protein antigenic regions: the most broadly cross-reactive EDII fusion peptide epitopes, 
EDIII serocomplex cross-reactive epitopes, epitopes incorporating determinants from 
either or both of these domain regions, and EDIII DENV-2 type-specific epitopes.  
Humoral immune responses in DENV-2 infected patient sera were highly variable 
between individual sera and immunoglobulin class.  Immunoglobulin populations 
recognizing dominant cross reactive epitopes centered on the EDII fusion peptide were 
large and highly variable, averaging approximately 50% and 30% in primary and 
secondary DENV-2 infected sera respectively.  Immunoglobulin recognizing DENV 
complex cross-reactive epitopes in EDIII exhibited similar trends but the magnitudes 
were smaller overall and the EDIII cross-reactive IgM response was much greater than 




recognizing EDIII DENV-2 specific epitopes were very small, though larger in IgM than 
IgG. IgG recognizing this epitope averaged only 1% of the immunoglobulin response yet 
the magnitudes of EDIII virus specific IgG were significantly correlated with DENV-2 
specific neutralization.  The results presented in this report extend our understanding of 
the diverse nature of humoral immune responses to human DENV infection and we 
discuss their relevance in the context of understanding DENV disease and the 
development and testing of safe and efficacious DENV vaccine candidates.   
Results 
Monoclonal Antibody Epitope Mapping  
We examined the effects of substitutions in two distinct antigenic regions of the
E-glycoprotein, EDII and EDIII, on MAb reactivities.  The highly conserved fusion 
peptide located in EDII is an immunodominant region containing multiple overlapping 
epitopes typically eliciting weakly neutralizing and widely cross-reactive antibodies 
against viruses from several major serocomplexes (Crill and Chang, 2004; Crill, Trainor, 
and Chang, 2007; Goncalvez, Purcell, and Lai, 2004; Stiasny et al., 2006; Trainor et al., 
2007).  DENV EDIII elicits predominantly complex and sub-complex cross-reactiv  and 
serotype-specific antibodies, some of which can be potently neutralizing (Gromowski, 
Barrett, and Barrett, 2008; Roehrig, Bolin, and Kelly, 1998; Sukupolvi-Petty et al., 2007).  
Previous studies of flavivirus epitope mapping have demonstrated that different 
substitutions of an E-protein residue can have distinct effects on both MAb reactivities 
and VLP secretion, and that a specific substitution’s effect on MAb binding can vary 
between flaviviruses (Allison et al., 2001; Crill, Trainor, and Chang, 2007; Oliphant et 




determine the effect of individual E-protein amino acid substitutions on MAb reactivity 
and VLP secretion, then to combine substitutions in an attempt to maximize both MAb 
reactivity reductions and DENV-2 VLP secretion.   
In the fusion peptide of EDII we examined two, five and six different 
substitutions at Gly104, Gly106 and Leu107 respectively (Table 2.1).  As previously 
observed with different substitutions and in different viruses, G104 substitutions 
dramatically reduced VLP secretion from transiently transformed Cos-1 cells, thus G104 
substitutions were excluded from further analysis (Crill and Chang, 2004; Crill, Trainor, 
and Chang, 2007; Trainor et al., 2007).  Individual substitutions for G106 or L107 
residues reduced the reactivities predominantly against group-cross-reactive MAbs that 
recognize all flavivirus E proteins (data not shown).  Some of the group-reactive MAbs 
exhibited reactivity reductions for substitutions at either G106 or L107 (4G2), others only 
for G106 (6B6C-1 and 4A1B-9) or L107 (23-1), and one group-reactive MAb (23-2) was 
not affected by any of the individual substitutions. Additionally, DENV subcomplex 
reactive MAb 1B4C-2 exhibited dramatic reductions in reactivity for all indiv dual G106 
and L107 mutants.  Based upon these observations we combined three different 
substitutions at G106 with two at L107 to create six double-mutant constructs (Tables 2.1 
and 2.2).  As expected, the observed effects of the single substitutions on MAb 
reactivities and VLP secretion typically combined additively into the double mutants.  
However, the pattern of reductions in 4G2 reactivity for single substitutions at either
G106 or L107 did not completely extend to the G106/L107 double mutant DENV-2 
VLPs. G106W/L107K and G106D/L107D VLPs exhibited no reductions in MAb 4G2 




Table 2.1.  Nucleotide sequences of mutagenic primers used and % VLP secretion from resultant plasmids relative to wild-type 
(100%). 
Primer   Primer Sequence (5’-3’)1  Nucleotide SubstitutionAmino Acid 
Substitution 
% VLP     
Secretion2 
D2-G104E TTTCCAAATAGTCCACATTCATTTCCCCATCCTCTGTCTACC GGA-GAA Gly-Glu <50 
D2-G104H CCCTTTCCAAAT6AGTCCACAGTGATTTCCCCATCCTCTGTCTACC GGA-CAC Gly-His <50 
D2-G106M GCCTCCCTTTCCAAATAGCATACATCCATTTCCCCATCC GGA-ATG Gly-Met 100 
D2-G106R GCCTCCCTTTCCAAATAGACGACATCCATTTCCCCATCC GGA-CGT Gly-Arg 100 
D2-G106D GCCTCCCTTTCCAAATAGATCACATCCATTTCCCCATCC GGA-GAT Gly-Asp 150 
D2-G106W GCCTCCCTTTCCAAATAGCCAACATCCATTTCCCCATCC GGA-TGG Gly-Trp <50 
D2-G106Q GCCTCCCTTTCCAAATAGTGACATCCATTTCCCCA GGA-CAA Gly-Gln 150 
D2-L107Q GCCTCCCTTTCCAAATCTCCACATCCATTTCCCCATCC CTA-GAA Leu-Gln 150 
D2-L107D GCCTCCCTTTCCAAA TCTCCACATCCATTTCCCCATCC CTA-GAT Leu-Asp <<50 
D2-L107M GCCTCCCTTTCCAAACATTCCACATCCATTTCCCCATCC CTA-ATG Leu-Met 50 
D2-L107G GCCTCCCTTTCCAAACCTCCACATCCATTTCCCCATCC CTA-GGT Leu-Gly 100 
D2-L107K GGTCACAATGCCTCCCTTTCCAAAT TTCCACATCCATTTCCCC CTA-AAA Leu-Lys 75 
D2-L107F GCCTCCCTTTCCAAA AATCCACATCCATTTCCCCATCC CTA-TTT Leu-Phe 150 






























D2-K305E TATTTCCTTCACAACTTTAAACTCTCCTGTGCACATAGAG AAG-GAG Lys-Glu 6 
D2-K305N TATTTCCTTCACAACTTTAAAGTTTCCTGTGCACATAGAG AAG-AAC Lys-Asn 13 
D2-V308N CCATGTTGTGTTTCTGCTATTTCCTTCACATTTTTAAACTTTCCTGT GTT-AAT Val-Asn 19 
D2-K310E TGTGTTTCTGCTATTTCCTCCACAACTTTAAACTTTCCTGT AAG-GAG Lys-Glu 25 
D2-K310Q TGTGTTTCTGCTATTTCCTGCACAACTTTAAACTTTCCTGT AAG-CAG Lys-Gln 38 
D2-E311R CCATGTTGTGTTTCTGCTATTCGCTTCACAACTTTAAACTTTCCTG GAA-CGA Glu-Arg 100 
D2-E311K CCATGTTGTGTTTCTGCTATTTCTTCACAACTTTAAACTTTCCTG GAA-AAA Glu-Lys 38 
D2-E311Y CCATGTTGTGTTTCTGCTATGTACTTCACAACTTTAAACTTTCCTG GAA-TAC Glu-Tyr 6 








D2-R323E CCGTCCCCTTCATATTGCACTCGATAACTATTGTTCCAT AGA-GAA Arg-Glu 6 
D2-R323M CCGTCCCCTTCATATTGCACATGATAACTATTGTTCCAT AGA-ATG Arg-Met 17 
D2-K361D TATGTTGACTGGGCTATCATCTTCTGTCACAATTGGGTTG AAA-GAT Lys-Asp 38 
D2-P364R AGGTTCTGCTTCTATGTTGACCGGCTATCTTTTTCTGTC CCA-CGG Pro-Arg 25 
D2-P364E GGAGGTTCTGCTTCTATGTTGACTTCGCTATCTTTTTCTGTC CCA-GGA Pro-Glu 25 
D2-K388D GCTTCCTTTCTTAAACCAGTTGAGATCCAGTTGTCCCG AAG-GAT Lys-Asp 50 
D2-K388E GCTTCCTTTCTTAAACCAGTTGAGTTCCAGTTGTCCCG AAG-GAA Lys-Glu 50 
 
1 Mutated nucleotides are shown in bold. 
2 Average of triplicate experiments of mutant VLP secretion from transiently transformed Cos-1 cells, standardized against the wild-
type DENV-2 plasmid VLP secretion.
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significantly reduced the binding by this MAb.  These two G106/L107 mutant VLPs also 
exhibited the most limited reductions in overall group cross-reactive MAb recognition of 
the six DENV-2 double mutants examined. 
We also observed significant reductions in reactivity of G106/L107 mutants for 
MAbs unaffected by the individual fusion peptide substitutions.  Two of six double 
mutants exhibited reduced reactivity for group-reactive MAb 23-2.  The reactivity of 
MAb 5-1, a MAb generated against Japanese encephalitis virus (JEV) and recognizing 
only DENV-2 and JEV, was reduced by all six double mutants, although the single G106 
or L107 substitutions did not reduce the binding of this MAb.  We also observed 
reactivity reductions for DENV complex and subcomplex reactive MAbs D3-5C9-1, 
9D12, and 10A4D-2.  In general reactivity reductions to these MAbs were less 
pronounced than those observed with the more broadly cross-reactive MAbs.  However, 
MAb 10A4D-2, which was unaffected by the individual fusion peptide substitutions, did 
show significant reductions against three of the six double mutations (Table 2.2, some 
data not shown).  Similarly, previous studies in JEV, WNV and Saint Louis encephalitis 
virus (SLEV) demonstrated that the reactivity of group cross-reactive MAb 23-2 and JEV 
complex cross-reactive MAbs were only abrogated by combining G106 and L107 
substitutions (Chiou et al., 2008a; Crill, Trainor, and Chang, 2007; Trainor et al., 2007).   
Thus, combinations of substitutions acting as epitope determinants in the EDII 
fusion peptide have a greater effect than do individual substitutions on disrupting the 
binding of some antibodies in this region.  Moreover, in DENV-2, fusion peptide residues 
act as epitope determinants for antibodies with diverse patterns of cross reactivity, this  
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Table 2.2.  MAb reactivities for DENV-2 VLP mutants1.   



































Virus: D2 D2 SLEV MVEV WNV JEV JEV D2 JEV D3 D4 D2 D1 D2 D2 D2 
VLP construct                 
WT DENV-23 ≥6.0 ≥6.0 ≥6.0 5.1 ≥6.0 ≥6.0 ≥6.0 ≥6.0 ≥6.0 ≥6.0 5.1 ≥6.0 ≥6.0 ≥6.0 >4.2 ≥6 
G106R 25 <0.1 0.8 0.4 100 100 100 100 100 25 100 25 25 100 3 100 
L107D 100 <0.1 25 25 <0.1 25 100 100 100 100 100 50 100 100 3 100 
G106R/L107D 100 <0.1 <0.1 <3 0.2 0.2 100 3 100 100 25 100 100 6 nd 50 
K305E 100 Nd4 nd nd nd nd 100 100 100 100 50 3 100 100 5 <0.1 
K310E 100 nd nd nd nd nd 100 100 100 100 100 <3 <3 100 100 100 
E311R 100 nd nd nd nd nd <0.1 <0.1 100 100 50 3 100 100 2.5 100 
P364R 100 nd nd nd nd nd 100 100 100 25 50 6 50 25 2.5 100 
K388D 100 nd nd nd nd nd 100 100 100 100 100 6 100 100 100 100 
K310E/E311R/ 
P364R 








<0.1 0.2 <0.8 <0.1 0.2 <0.1 <0.1 100 100 1.5 0.1 0.4 100 <1.3 100 
1Percent of wild-type (WT) DENV-2 VLP reactivity for MAbs exhibiting varying levels of cross-reactivity (CR) and selected from 
different flaviviruses. 
2 MHIAF is polyclonal murine ascitic fluid; group CR antibodies recognize all viruses of the four major pathogenic flavivirus 
serocomplexes; sub-group CR MAbs recognize all or some members of two or more different flavivirus serocomplexes (e.g., 
MAbs 20, 5-1 and 5-2 recognize DENV-2 and JEV, JEV and DENV-2 and JEV, DENV-1 and -2 respectiv ly); omp. and sub-
comp CR MAbs recognize all four DENV complex viruses or a subset thereof respectively, and type MAbs recognize only 
DENV-2.   
3 MAb reactivities for wild-type (WT) DENV-2 VLP are presented as inverse log10 Ag-capture ELISA endpoint values and all mutant 
VLPs as percent of remaining reactivity compared to WT. 
4 nd denotes not determined. 
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included predominantly flavivirus group cross-reactive antibodies, but also for MAbs 
recognizing only individual viruses from different flavivirus serocomplexes to DENV 
complex cross-reactive MAbs. This appears to be a general phenomenon, as recent 
reports in other flaviviruses demonstrate that antibodies exhibiting varying levels of 
cross-reactivity recognize epitopes including the highly conserved fusion peptide residues 
(Chiou et al., 2008a; Crill, Trainor, and Chang, 2007; Oliphant et al., 2006; Stiasny et al., 
2006; Trainor et al., 2007). 
We next examined the effects of 15 amino acid substitutions at eight different 
residues in EDIII alone and in combinations (Table 2.1).  Because a major objective of 
this work is to determine the antigenic structure of E glycoprotein cross-reactive epitopes 
and differential immune responses to these epitopes, we selected EDIII residues most 
likely to be incorporated into such epitopes for mutagenesis.  The EDIII substitutions 
examined primarily altered the reactivity of DENV complex MAbs (Table 2.2).  The 
residues that had the greatest effects on MAb reactivities were K305, K310, E311 and 
P364 (Table 2.2). The MAbs affected by substitutions at these four residues exhibited 
three different reactivity patterns: those recognizing some but not all viruses in both the 
JEV and DENV serocomplexes (MAbs 20 and 5-1), MAbs recognizing only viruses 
within the DENV complex (1A1D-2, 9D12, and 10A4D-2) and DENV-2 type specific 
MAbs (3H5).  The K305 substitutions (K305E and K305N) were the only EDIII 
substitutions that significantly affected DENV-2 type-specific antibody recognition.  
Interestingly, K305 substitutions also affected DENV complex MAb 1A1D-2 in addition 
to the prototype DENV-2-specific MAb 3H5.  There were no significant effects of the 




epitope determinant for DENV complex MAbs, because substitutions at this residue had 
such strong effects on type-specific MAb recognition, K305 substitutions were not 
incorporated into the multiple EDIII complex cross-reactive epitope-knock-out 
constructs. 
Some of the same antibodies exhibiting reactivity reductions from the fusion 
peptide substitutions were also affected by EDIII substitutions (Table 2.2).  For example, 
MAb 5-1 had reduced reactivity to all six fusion peptide double mutant VLPs and also for 
one of three E311 substitutions.  VLPs containing the charge reversal substitution E311R 
lost all measurable ELISA recognition by MAb 5-1 yet VLPs containing the al ern tive 
charge reversal substitution E311K or E311Y, were unchanged. Similarly, DENV 
subcomplex MAb 10A4D-2 exhibited reactivity reductions for VLPs containing 
substitutions in either DIII or the DII fusion peptide.  These observations suggest and 
extend previous observations that some cross-reactive MAbs might recognize inter-E 
dimer epitopes spatially overlapping EDII and EDIII structural domains of independent 
monomers (Goncalvez, Purcell, and Lai, 2004).  MAbs 5-1 and 20 have the same cross-
reactivity, recognizing only DENV-2 and JEV; however, MAb 20 was raised against 
DENV-2 whereas 5-1 was raised against JEV.  Although MAb 20 was not affected by 
fusion peptide substitutions and MAb 5-1 was, VLPs containing charge reversal 
substitutions at E311 reduced the reactivity of both of these MAbs to similarly 
undetectable levels.  K310 and P364 substitutions alone did not alter these MAb 
reactivities; however, all VLPs containing combinations of these substitutions, with or 
without E311 substitutions showed similar complete losses of reactivity by both MAb 20 




The third class of antibodies recognizing epitope determinants in EDIII were th  
DENV complex and subcomplex MAbs.  The antibody panel contained six DENV 
complex cross-reactive MAbs, three raised from DENV-2 and one each from the other 
three serotypes.  The two MAbs exhibiting the greatest decreases in EDIII reactivity were 
1A1D-2 and 9D12, subcomplex reactive MAbs raised from DENV-2 and -1 respectively  
(Table 2.2).  1A1D-2 reactivity was reduced by single substitutions at all DIII residues 
investigated with the exception of K361, consistent with recent crystal structure results of 
the 1A1D-2 antigen-binding fragment complexed with recombinant DENV-2 EDIII 
(Tables 2.1, 2.2); (Lok et al., 2008).  MAb 9D12 reactivity was only affected by the 
individual K310 and P364 substitutions as well as multiple combinations of EDIII 
substitutions.  However, EDIII substitutions, both individual and in combination did not 
affect the reactivity of DENV complex reactive MAbs 1B7 or D3-5C9-1, antibodies 
raised against DENV-3 and DENV-4 respectively (Table 2.2). 
Substitutions from the EDII fusion peptide and from EDIII were combined into 
the same plasmid construct in an attempt to maximize reductions in cross-reactivity from 
these two disparate structural regions.  The general effect on MAb reactivities of 
combining substitutions was predictably additive.  In general there was little effect of 
DIII substitutions on the group cross-reactive MAbs, and limited effect of fusion peptide 
substitutions on most complex and subcomplex MAbs.  When substitutions were 
combined together the resulting VLPs exhibited reduced reactivities to both classes of 
antibodies (Table 2.2).  We also observed significant reductions in the reactivity of 
DENV-4 raised complex cross-reactive MAb D3-5C9-1.  This was unexpected since we 




either DII or DIII alone.  By combining epitope determinants from both domains we were 
able to construct mutant VLPs exhibiting significantly reduced or ablated reactivity to the 
majority of MAbs in the panel representing four distinct reactivity classes: group, 
subgroup, complex and subcomplex cross-reactive antibodies (Table 2.2).  Thus, this 
series of differential cross-reactivity reduced VLPs can be utilized as serodiagnostic 
antigens to describe the epitope-specific targeting of the polyclonal human 
immunoglobulin response to DENV infection.  
Epitope-specific Humoral Immune Responses of DENV-2 Infected Patients 
We selected a number of well-characterized sera from DENV-2 infected humans 
to examine the epitope-specific proportions of the polyclonal E protein-specific immune 
response using mutant VLP antigens described in the previous section of this report.  All 
serum specimens (6-18 days post onset of symptoms) were collected from acute DENV-2 
infected individuals suffering from dengue fever and were viral RNA positive as 
determined by a DENV-2 specific reverse transcriptase-PCR (RT-PCR) assay (Table 
2.3).  Primary and secondary sera, as defined by the IgM to IgG ratio, from DENV-2 
infected humanss were selected from both Puerto Rico and Taiwan (Table 2.3).  IgM and 
IgG end-point titers were determined using six distinct DENV-2 VLP antigens to 
estimate the proportions of immunoglobulin recognizing four distinct E-protein antigenic 
regions (Table 2.2).  Wild-type (WT) DENV-2 VLP was used to determine total anti-E 
IgM and IgG titers.  Immunoglobulin proportions targeting EDII fusion peptide epitopes 
were determined with EDII fusion peptide knock-out mutant G106R-L107D (RD).  
Immunoglobulin recognizing cross-reactive epitopes in EDIII was determin d with the 




Table 2.3.  Serological characterization of DENV-2 infected sera examined in this 
study. 








4 Taiwan 17 1° 46.0 20.4 1.65 
5 Taiwan 17 1° 27.8 10.3 2.53 
12 Taiwan 14 1° 33.7 29.0 1.19 
16  Taiwan 18 1° 5.02 3.59 1.25 
8882 Puerto Rico 6 1° 44.2 5.04 11.1 
0078 Puerto Rico 10 1° 65.0 12.1 4.23 
9 Taiwan 14 2° 35.6 24.4 0.91 
10 Taiwan 18 2° 15.6 24.1 0.41 
17 Taiwan 14 2° 6.1 24 0.21 
0169 Puerto Rico 6 2° 29.2 35.4 0.65 
9608 Puerto Rico 13 2° 33.4 39.8 0.78 
8867 Puerto Rico 7 2° 53.6 54.2 1.04 
 
1 DPO denotes days post onset of symptoms 
2 denotes primary (1°) or secondary (2°) DENV-2 infection. 
3 OD of positive sera/OD of negative sera 
4 This column denotes the ratio of the optical density (OD) for IgM/divided by IgG.  Each




immunoglobulin proportions recognizing all cross-reactive epitopes incorporating 
determinants in either or both EDII fusion peptide and/or EDIII were determined with an 
EDII-III combination of these two knock-out mutants (RDERR).  Finally the proportion 
of EDIII DENV-2 specific immunoglobulin was determined as the difference between 
the EDIII K305E and K388D antigen reactivities. End-point titers of each serum 
specimen were determined concurrently in IgM and IgG antibody-capture ELISA with 
each DENV-2 antigen and a negative antigen.  As described in the Materials and 
Methods section, immunoglobulin end-points were calculated for the different VLP 
antigens using asymptotic covariance matrix V method by regression analysis with four 
variables: antigen class, immunoglobulin class (IgM, IgG), primary or secndary 
infection status, and the resident country of infected patients (Puerto Rico or Taiwan); 
and a general least squares (GLS) approach was applied to determine endpoints.  Because 
the mutant antigens are epitope knock-outs, the domain-associated, epitope specific 
immunoglobulin percentages were determined by dividing the endpoint titer determined 
with a knock-out antigen by the titer of the WT antigen, subtracting this value from 1.0 
and multiplying by 100.  DENV-2 specific immunoglobulin percentages were determined 
as the difference between the percent recognizing the K305E and the K388D antigens. 
Results from ANOVA on the GLS regression indicated that the three-way 
interaction among antigen, immunoglobulin type and geographic origin was not 
statistically significant (p=0.68; Table 2.4).  This result suggests that the patterns 
observed in mean endpoints among the different antigens, within the same 
immunoglobulin class are similar for sera collected from two different geographic 




Table 2.4.  Analysis of variance table of calculated DENV-infected serum end-point 
data. 
Variable F-value p-value 
Antigen  370 <0.0001 
Immunoglobulin type  239 <0.0001 
1° or 2° Infection  362 <0.0001 
Geographic origin of Sera 3.36 0.071 
Antigen : Immunoglobulin type 17.7 <0.0001 
Antigen : Geographic origin of Sera 2.91 0.0189 
Antigen : 1° or 2° Infection 30.8 <0.0001 
Immunoglobulin type : 1° or 2° Infection 118 0.4367 
 
type and primary or secondary infection status (p<0.01), between antigen class and 
geographic origin (p=0.019), and between antigen class and immunoglobulin type 
(p<0.01) were statistically significant (Table 2.4).  There were highly significant effects 
of three of the four individual variables on epitope-specific end-point titers (p<0.01); the 
only individual variable not having a significant effect on antigen endpoints was the 
geographic origin of the sera.  In other words, there were no significant differences in 
total endpoint titer averaged across the different antigens, between the sera from Puerto 
Rico and from Taiwan (Table 2.4).  The significant interaction between antigen class and 
geography does, however, indicate that there could be significant geographical effe ts on 
the magnitudes of individual epitope-specific immunoglobulin populations. Such 
differences could arise either from differential immune status correlated with geography 
and/or from the different genetic backgrounds of patients from Taiwan and Puerto Rico.  
Because the ANOVA results suggest no generalized effect of geographic origin of 
test sera, the source of sera are not specified unless indicated.  End-point titers of E-
protein specific immunoglobulins in sera from DENV-2 infected (measured with the WT 
DENV-2 antigen) ranged from 21,400-1,510,000 (mean=299,000) for IgM and from 
12,400-11,000,000 for IgG (mean=2,400,000; Table 2.5).  Primary DENV-2 infected  
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IgM     
WT All  2.99x 105 2.14 x 104 – 1.51 x 106 100 100 
RD EDIIFP
4  1.66 x 105 6.07 x 102 – 4.79 x 105 <1 - 97 44 (34) 
ERR EDIIICR
5  1.71 x 105 1.59 x 104 – 8.32 x 105 <1 - 90 43 (39) 
RDERR EDIIFP/EDIIICR
6 1.26 x 105 5.00 x 102 – 3.98 x 105 <1 - 91 58 (67) 
K305E-K388D EDIIITS
7 1.79 x 104 2.19 x 102 – 7.98 x 104 <1 - 20 6 (4.5) 
IgG     
WT All  2.40 x 106 1.24 x 104 – 1.10 x 107 100 100 
RD EDIIFP  1.54 x 10
6 7.37 x 102 – 4.79 x 106 <1 - 94 36 (36) 
ERR EDIIICR  2.46 x 10
6 1.16 x 104 – 1.05 x 107 <1 - 26 5.8 (13) 
RDERR EDIIFP/EDIIICR 6.76 x 10
5 4.74 x 102 – 1.70 x 106 <1 - 96 72 (64) 
K305E-K388D EDIIITS 2.40 x 10
4 1.24 x 102 – 4.50 x 105 <1 - 8 1 (<1) 
 
1 The mutant antigens used are all knock-out mutants. The substitutions represented by RD, ERR, and RDERR antigens and MAb 
reactivities of all antigens are shown in Table 2. 
2 The endpoint titer determined with the knock-out antigen, thus representing immunoglobulins recognizing epitopes not targeted with 
the knock-out antigen. 
3 Because the mutant antigens knock-out antibody recognition of specific epitopes, the percent of immunoglobulin recognizing a 
particular epitope was determined for each individual sera by calculating the percent reactivity measured with a mutant antigen 
relative to that determined with the WT antigen and subtracting this value from 1.0;  
 (1- [Endpointmutant/Endpointwt]) x 100; for the percent DENV-2 specific reactivity we used (1-[(EndpointK305E/EndpointWT)-
(EndpointK388D)/EndpointWT)]) x 100.  




5 EDIIICR, antibodies recognizing the E-protein structural domain III cross-reactive epitop s do not bind to this antigen. 
6 EDIIFP/EDIIICR, antibodies recognizing either EDII fusion peptide or EDIII cross-reactive epitopes do not bind to this antigen. 
7 EDIIITS, antibodies recognizing only the DENV-2 type-specific EDIII epitope are represented by the reactivity difference between 
the K305E and K388D antigens. 
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patient sera exhibited similar IgM and IgG titers for individuals and as a class these sera 
had IgM and IgG titers ranging from 21,400-1,510,000 (mean=408,000) and 12,400-
1,020,000 (mean=376,000) respectively (Table 2.6). Secondary DENV-2 infected patient 
sera exhibited a distinctly different pattern with IgG titers ranging from seven to over 100 
times greater than IgM titers for individual sera (21,900-447,000; mean=189,000 for IgM 
and 2,290,000-11,000,000; mean=4,430,000 for IgG; Table 2.6).  The larger magnitude 
IgG response in secondary DENV infections could result from the rapid and strong 
memory B- and T-cell response and the reduced frequency of IgM responses in 
secondary DENV infections (Kuno, 2003).  Although all serum specimens were late 
acute to early convalescent phase (6-18 dpo) this is sufficient time for typicall rapid and 
strong anamnestic IgG responses. 
Cross-reactive immunoglobulin populations from two overlapping antigenic regions 
form the majority of the immune response and are greater in magnitude for IgM 
than for IgG. 
Immunoglobulin proportions targeting cross-reactive EDII fusion peptide epitopes 
were highly variable yet tended to be large, and were distinctly greater in primary than in 
secondary DENV-2 infected patients.  Immunoglobulin responses specific for EDII 
fusion peptide ranged from undetectable levels to 97% of IgM and from undetectable to 
94% of IgG.  The mean and median values were 44% and 34% of IgM and 36% and 36% 
of IgG respectively (Table 2.5).  The larger magnitude fusion peptide-specific 
immunoglobulin response in primary versus secondary DENV-2 infections was greater in 
IgM than in IgG (54% vs. 24% and 44% vs. 35% in IgM and IgG respectively (Table 
2.6).  EDII fusion peptide-specific IgM comprised a greater percentage of the total IgM  
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Table 2.6.  Epitope Specific Proportions of Envelope Protein Specific IgM and IgG from Primary and Secondary DENV-2 








point Titer 2 





                 IgM        
Primary WT All  4.08 x 105 2.14 x 104 – 1.51 x 106 100 
 RD EDIIFP
4  1.89 x 105 6.07 x 102 – 4.79 x 105 54  
 ERR EDIIICR
5  2.57 x 105 1.59 x 104 – 8.32 x 105 37 
 RDERR EDIIFP/EDIIICR
6 1.53 x 105 5.00 x 102 – 3.47 x 105 63 
 K305E-K388D EDIIITS
7 1.70 x 104 1.07 x 103 – 2.74 x 104 4 
      
Secondary WT All  1.89 x 105 2.19 x 104 – 4.47 x 105 100 
 RD EDIIFP  1.44 x 10
5 1.66 x 104 – 4.07 x 105 24 
 ERR EDIIICR  8.55 x 10
4 1.95 x 104 – 2.34 x 105 55 
 RDERR EDIIFP/EDIIICR 9.91 x 10
4 1.32 x 104 – 3.98 x 105 48 
 K305E-K388D EDIIITS 1.48 x 10
4 2.19 x 102 – 3.66 x 104 8 
                 IgG     
Primary WT All  3.76 x 105 1.24 x 104 – 1.02 x 106 100 
 RD EDIIFP  2.10 x 10
5 7.37 x 102 – 6.92 x 105 44 
 ERR EDIIICR  3.60 x 10
5  1.16 x 104 – 8.91 x 105 7.58 
 RDERR EDIIFP/EDIIICR 1.68 x 10
5 4.74 x 102 – 4.90 x 105 55 
 K305E-K388D EDIIITS 3.76 x 10
3 1.24 x 102 – 1.02 x 104 <1 
      
Secondary WT All  4.43 x 106 2.29 x 106 – 1.10 x 107 100 
 RD EDIIFP  2.87 x 10
6 1.45 x 106 – 4.79 x 106 35 
 ERR EDIIICR  4.57 x 10
6 2.00 x 106 – 1.05 x 107 4.0 
 RDERR EDIIFP/EDIIICR 1.18 x 10
6 7.08 x 105 – 1.70 x 106 73 
 K305E-K388D EDIIITS 8.86 x 10
4 2.29 x 104 – 4.50  x 105 2 
 
1 The mutant antigens used are all knock-out mutants. The substitutions represented by RD, ERR, and RDERR antigens and MAb 




2 The endpoint titer determined with the knock-out antigen, thus representing immunoglobulins recognizing the epitopes not targeted 
with the knock-out antigen. 
3 Because the mutant antigens knock-out antibody recognition of specific epitopes, the percent of immunoglobulin recognizing a 
particular epitope was determined for each individual sera by calculating the percent reactivity measured with a mutant antigen 
relative to that determined with the WT antigen and subtracting this value from 1.0;  
 (1- [Endpointmutant/Endpointwt]) x 100; for the percent DENV-2 specific reactivity we used (1-[(EndpointK305E/EndpointWT)-
(EndpointK388D)/EndpointWT)]) x 100.  
4 EDIIFP, antibodies recognizing E-protein structural domain II fusion peptide epitopes d  not bind this antigen. 
5 EDIIICR, antibodies recognizing the E-protein structural domain III cross-reactive epitop s do not bind to this antigen. 
6 EDIIFP/EDIIICR, antibodies recognizing either EDII fusion peptide or EDIII cross-reactive epitopes do not bind to this antigen. 
7 EDIIITS, antibodies recognizing only the DENV-2 virus specific EDIII epitope are repres nted by the reactivity difference between 
the K305E and K388D antigens. 
8 Two of six primary and three of six secondary infected DENV-2 sera had IgG endpoint titers with the ERR antigen greater than or 
equal to those with the WT antigen thus producing ERR epitope specific percentages that would have been negative.  The 





response in the sera from DENV-2 infected patients from Taiwan (51%) than it did for 
the sera from Puerto Rican patients (33%).  This was the only epitope-specific 
immunoglobulin subclass where there was a dramatic percent difference between serum 
specimens from the two geographic regions. The significance of these differ nces is 
supported by the ANOVA results: although there was non-significant trend towards an 
effect of geographic origin of the sera alone on the total immunoglobulin titers (p=0.071) 
there was a significant two-way interaction between epitope-specific antigen classes and 
the geographic origin of the sera on these end-points (p=0.040; Table 2.4).   
Immunoglobulins targeting cross-reactive EDIII epitopes showed similar trends as 
did EDII fusion peptide immunoglobulins but their variability and magnitudes were 
smaller and there was an even greater reduction in IgG titers relative to IgM.  EDIII 
cross-reactive immunoglobulin ranged from <1% to 45% in primary infections and <1% 
to 90% in secondary infections (Table 2.5).  IgM recognizing cross-reactive EDIII 
epitopes averaged 37% and 55% in primary and secondary infections respectively, 
whereas EDIII cross-reactive IgG averaged only 7.5% and 4% of primary and secondary 
DENV-2 infected patient sera (Table 2.6).  Thus, there was a much greater EDIII cross-
reactive IgM response than in IgG and for IgM this response was greater in secondary 
than in primary infections.   
In addition to the EDII fusion peptide and the EDIII cross-reactive epitope knock-
out antigens, serum specimens were screened with an EDII-EDIII knock-out antigen 
(RDERR) combing the same substitutions from the individual mutant antigens in these 
two antigenic regions (Table 2.2).  Using the RDERR antigen, immunoglobulins 




averaged 58% of IgM and 72% of the IgG present (median=67% and 64% respectively; 
Table 2.5).  There was a greater total cross-reactive IgM response in primary versus 
secondary DENV-2 infected sera (63% and 48% respectively).  However, this patern 
was reversed in IgG where 55% and 73% recognized these cross-reactive epitopes in 
primary and secondary DENV-2 infected sera respectively (Table 2.6).  Interestingly, the 
percent cross-reactive immunoglobulin as determined with the RDERR antigen was not 
the same as estimated by adding the percents of immunoglobulin recognizing the EDII 
fusion peptide (determined with the RD antigen) and cross-reactive EDIII epitopes 
(determined with the ERR antigen, Tables 2.5 and 2.6).  There were exceptions to this 
general observation for IgM or IgG for some individual serum specimens.  The total 
proportion of cross-reactive immunoglobulins determined with the RDERR antigen was 
greater than that estimated by adding the percentages determined with the RD and ERR 
antigens for IgG (72% and 42% respectively), yet the opposite pattern was observed for 
IgM (RDERR=58%; RD + ERR= 87%; Table 2.5).  These data suggest that there are 
differences in the epitope specificity of cross-reactive antibody responses between IgM 
and IgG.  In the MAb screening we observed significant reactivity reductions with DENV 
complex cross-reactive MAb D35C-9-1 for the inter-domain RDERR VLP, yet no 
reactivity reductions of this MAb for either the RD or the ERR VLPs alone (Table 2.2).  
These results suggest that a proportion of human IgG might recognize epitopes similar to 
murine MAb D35C-9-1 or that they might recognize epitopes not represented in our MAb 
panel, yet that similar to D35C-9-1 exhibit reduced recognition for the RDERR antigen 




Immunoglobulin populations targeting EDIII DENV-2 specific epitopes are small, 
yet of greater magnitude in IgM than in IgG and in secondary than in primary 
DENV-2 infected sera.  
To determine the proportion of immunoglobulin recognizing EDIII DENV-2 
type-specific epitopes identified as potently neutralizing in murine studie we used two 
different EDIII mutant antigens.  K305E knocks out the reactivity of MAb 3H5 (Table 
2.2) the prototype DENV-2 type-specific MAb recognizing this epitope. K305 has been 
demonstrated to be essential for the binding of MAb 3H5 and six other potently 
neutralizing DENV-2 specific MAbs (Gromowski and Barrett, 2007).  However, K305E 
also reduced the reactivity of subcomplex cross-reactive neutralizing MAb 1A1D-2 
(Table 2.2).  The K388D antigen only reduced the reactivity of MAb 1A1D-2 - to similar 
levels as K305 E - and both of residues have been identified as 1A1D-2 binding residues 
in a recent Fab-DENV-2 structural determination with this MAb (Lok et al., 2008).  The 
amount of EDIII DENV-2 specific immunoglobulin was therefore determined as the 
difference between the percent reduction in endpoint titer relative to WT, between the 
K305E and K388D antigens.  
EDIII DENV-2 type-specific immunoglobulin formed very small percentages of 
the antibody response and was greater in IgM than in IgG.  In contrast to the cross-
reactive immunoglobulins however, EDIII virus-specific antibody populations averaged 
twice as large in secondary as in primary DENV-2 infected sera (Tables 2.5 and 2.6).  
EDIII DENV-2 specific IgM averaged 6% across sera, 4% and 8% in primary and 
secondary DENV-2 infections, and ranged from <1% to 20% of the IgM response.  EDIII 




primary and secondary serum samples, and ranged from <1% to 8% of total IgG.  
Interestingly, there was no correlation between the magnitude of the IgM and IgG 
response to this epitope for individual DENV-2 infected patient sera. 
Neutralizing antibody responses of primary and secondary DENV-2 infected patient 
sera: EDIII DENV-2 specific IgG titer is significantly correlated with DENV-2 
neutralization. 
 Focus-reduction microneutralization (FRµNT) assays were conducted with the 
sera to see if homologous/heterologous virus neutralization correlated with differential 
percentages or titers of virus-specific or cross-reactive immunoglobulins acro s the sera.   
All sera were screened against five different viruses, DENV-1, -2, -3, -4, and JEV; the 
Puerto Rican sera were additionally screened against WNV.  Serum sample were diluted 
two-fold from 1:50 to 1:1600 and the 50%, 75%, and 90% FRµNT end-point titers were 
determined.  Predicted 90% endpoint titers were also determined from a non linear 
regression of the FRµNT data using a variable slope sigmoidal dose-response formula.  
The 90% FRµNT of sera from primary DENV-2 infected patients ranged from 1:200 to 
1:800 and all were greater than or equal to four-fold higher than for that of the next 
highest virus titer (Table 2.7).  Sera from secondary DENV-2 infected patients had much 
higher DENV-2 90% FRµNT titers ranging from 1:400 to >1:1600 (predicted 90% range: 
431->19,584 Table 2.8).  None of the sera from secondary DENV-2 infected patients had 
the highest 90% FRµNT for DENV-2.  This observation could have resulted from not 
diluting the sera beyond 1:1600; however, serum specimen 9608 with a DENV-2 90% 
FRµNT of 1:400 also had a DENV-4 90% FRµNT of 1:400.  The period of neutralizing 




Table 2.7. Focus reduction microneutralization test (FRµNT) titers for primary 
DENV-2 infected serum samples from dengue fever patients.    
    FRµNT Titers  




Virus 50% 75% 90% Pred. 
90%2 
        
4 Taiwan 17 DENV-1 200 50 <50 17 
   DENV-2 ≥1600 800 400 373 
   DENV-3 100 50 <50 18 
   DENV-4 200 50 <50 29 
   JEV <50 <50 <50 7 
        
5 Taiwan 17 DENV-1 50 <50 <50 3 
   DENV-2 ≥1600 ≥1600 800 706 
   DENV-3 50 50 <50 10 
   DENV-4 100 <50 0 16 
   JEV <50 <50 <50 4 
        
12 Taiwan 14 DENV-1 400 200 50 57 
   DENV-2 ≥1600 ≥1600 400 604 
   DENV-3 200 100 50 50 
   DENV-4 4700 50 <50 45 
   JEV 50 <50 <50 18 
        
16 Taiwan 18 DENV-1 50 <50 <50 4 
   DENV-2 ≥1600 800 400 412 
   DENV-3 <50 <50 <50 7 
   DENV-4 50 <50 <50 13 
   JEV <50 <50 <50 3 
        
8882 Puerto Rico 6 DENV-1 50 <50 <50 9 
   DENV-2 800 400 200 144 
   DENV-3 100 <50 <50 15 
   DENV-4 200 <50 <50 24 
   WNV <50 <50 <50 4 
   JEV <50 <50 <50 3 
        
0078 Puerto Rico 10 DENV-1 100 <50 <50 16 
   DENV-2 800 400 200 145 
   DENV-3 200 50 <50 31 
   DENV-4 800 50 <50 64 
   WNV 50 <50 <50 12 
   JEV <50 <50 <50 3 
1 days post onset of symptoms 
2  predicted actual 90% FRµNT titers based up a nonlinear regression of the FRµNT data 





Table 2.8. Focus reduction microneutralization test (FRµNT) titers for secondary 
DENV-2 infected serum samples from dengue fever patients.  
    FRµNT Titers  
Serum # Country of 
Origin 
DPO1 Virus 50% 75% 90% Pred. 
90%2 
        
9 Taiwan 14 DENV-1 ≥1600 ≥1600 ≥1600 na3 
   DENV-2 ≥1600 ≥1600 ≥1600 na 
   DENV-3 ≥1600 ≥1600 ≥1600 4095 
   DENV-4 ≥1600 ≥1600 ≥1600 1778 
   JEV 800 100 <50 83 
        
10 Taiwan 18 DENV-1 ≥1600 ≥1600 ≥1600 na 
   DENV-2 ≥1600 ≥1600 ≥1600 na 
   DENV-3 ≥1600 ≥1600 ≥1600 na 
   DENV-4 ≥1600 ≥1600 800 991 
   JEV ≥1600 100 50 103 
        
17 Taiwan 14 DENV-1 ≥1600 ≥1600 ≥1600 na 
   DENV-2 ≥1600 ≥1600 ≥1600 na 
   DENV-3 ≥1600 ≥1600 ≥1600 na 
   DENV-4 ≥1600 ≥1600 ≥1600 1795 
   JEV 200 <50 0 31 
        
0169 Puerto Rico 6 DENV-1 ≥1600 400 200 307 
   DENV-2 ≥1600 ≥1600 ≥1600 19,584 
   DENV-3 ≥1600 ≥1600 800 934 
   DENV-4 ≥1600 400 200 167 
   WNV 400 50 <50 59 
   JEV 50 <50 <50 17 
        
9608 Puerto Rico 13 DENV-1 400 200 50 79 
   DENV-2 ≥1600 800 400 431 
   DENV-3 800 200 100 95 
   DENV-4 ≥1600 800 400 526 
   WNV 400 100 50 74 
   JEV 200 <50 <50 25 
        
8867 Puerto Rico 7 DENV-1 ≥1600 800 200 366 
   DENV-2 ≥1600 ≥1600 ≥1600 5149 
   DENV-3 800 200 100 135 
   DENV-4 ≥1600 ≥1600 800 1341 
   WNV ≥1600 200 50 122 
   JEV 200 <50 <50 38 
1 days post onset of symptoms 
2 predicted actual 90% FRµNT titers based up a nonlinear regression of the FRµNT data 
using a variable slope sigmoidal dose-response model. 
3 these sera had either total virus neutralization (zero foci) at the 1600 dilution or too few 




heterologous DENV serotype has been shown to vary from less than a week to multiple 
weeks, so presumably this early convalescent phase patient serum has not yet switch d to 
DENV-2 dominance (Kuno, 2003).  Two of the remaining five sera from secondary 
DENV-2 infected patients had next highest 90% FRµNT of 1:800 for another DENV 
serotype, and the remaining three sera from secondary DENV-2 infected patients had 
90% FRµNT of ≥1:1,600 for three or four DENV serotypes.  All of the sera from primary 
DENV-2 infected patients had JEV 50% FRµNT titers <50, whereas all sera from 
secondary DENV-2 infections had JEV 50% FRµNT titers ≥50.  This was not surprising 
for the three Taiwanese sera since they were also IgG ELISA positive against JEV VLP 
antigen (Chiou et al., 2008a).  We were surprised that the three sera from secondary 
DENV-2 infected patients from Puerto Rico exhibited neutralizing antibodies against 
JEV, as the titers appeared to be greater than expected from DENV infected cross-
reactivity.  Because the Puerto Rico sera were collected in 2007 when WNV was known 
to be circulating on the island we decided post hoc to test these sera for neutralizing 
antibodies against WNV.  Two of these three sera from secondary DENV-2 infected 
patients had WNV 50% FRµNT titers of 1:400 and a third (8867) was ≥1:1,600; these 
three serum samples had predicted 90% FRµNT WNV titers of 59, 74, and 122 (Table 
2.8).  Sera from Primary DENV-2 infected patients from Puerto Rico had 50% FRµNT 
titers <1:50 for both JEV and WNV, and all four sera from primary DENV-2 infected 
patients from Taiwan had JEV 50% FRµNT titers ≤1:50.  Taken together these results 
suggest that there is limited cross-neutralization from infection by viruses in the DENV 
complex to viruses in the JEV serocomplex. Thus, for at least one, and possibly all three 




neutralizing antibody is consistent with JEV complex-cross-reactivity occurring from 
actual WNV exposure.  We did not observe any significant correlations between the 
proportions or the total magnitude of cross-reactive immunoglobulin populations and 
heterologous neutralization to other DENV serotypes or to JEV or WNV, implying that 
the large cross-reactive antibody populations were either weakly or non-neutralizing or 
that there was large variation in the neutralizing capabilities of these immunoglobulins 
between serum specimens.   
 To investigate if EDIII virus specific epitopes stimulate strongly neutralizing and 
protective immunoglobulin in humans as they do in mice, we regressed EDIII DENV-2-
specific IgM or IgG titers on the percent DENV-2 neutralization (calculated t the highest 
serum dilution of 1:1600) and performed an analysis of variance on the regression.  For 
IgM, the regression slope was actually negative and not significantly different from 0 
(m= -0.127, p=0.233), suggesting that IgM recognizing EDIII DENV-2 specific epitopes 
in these sera is not strongly neutralizing (Table 2.9).  However, when EDIII DENV-2 
specific IgG titers were regressed on percent DENV-2 neutralization the slope was 
positive and significant (m=0.182, p = 0.0482) indicating that increasing EDIII DENV-2 
specific IgG is correlated with increasing neutralization (Table 2.9).  These data suggest 
that the very small proportion of EDIII DENV-2 specific IgG is responsible for a 
significant proportion the DENV-2 specific neutralization, and that the potently 
neutralizing EDIII virus specific epitopes identified in mice also play a role in DENV-2 






Table 2.9.  Analysis of variance of the slope determined from EDIII DENV-2 
specific IgM and IgG titers each individually regressed on DENV-2 specific 
neutralization. 
 
Dependent Variable Explanatory Variable  Slope p-value 
EDIII DENV-2 specific IgM1 DENV-2 specific Neutralization2 -0.127 0.233 
EDIII DENV-2 specific IgG DENV-2 specific Neutralization 0.128 0.048 
1IgM and IgG titers were log transformed prior to analysis so that they would not violate 
assumptions of normality in the linear regression model. 
2DENV-2 neutralization was expressed as the percent plaque reduction at he maximum 
serum dilution of 1:1600. 
 
Discussion 
MAb Epitope Mapping 
Previous studies have indicated that the EDII fusion peptide region contains 
multiple, overlapping, broadly cross-reactive, immunodominant epitopes and that both 
serotype-specific and DENV complex cross-reactive epitopes are located in EDIII (Chiou 
et al., 2008a; Crill and Chang, 2004; Crill and Roehrig, 2001; Crill, Trainor, and Chang, 
2007; Goncalvez, Purcell, and Lai, 2004; Gromowski and Barrett, 2007; Gromowski, 
Barrett, and Barrett, 2008; Lisova et al., 2007; Oliphant et al., 2006; Roehrig, Bolin, and 
Kelly, 1998; Stiasny et al., 2006; Sukupolvi-Petty et al., 2007; Trainor et al., 2007).  The 
mutagenesis-based epitope mapping presented here supports and extends these results.  
For example, in a previous paper examining cross reactive epitope determinants in 
DENV-2 we demonstrated that flavivirus group cross-reactive MAb 4G2 lost recognition 
for VLPs containing either G106Q or L107K substitutions, whereas similar group-css
reactive MAb 6B6C-1 only exhibited reduced binding for VLPs containing the G106Q 




two E-protein residues in JEV, WNV and SLEV extend this pattern: substitutions at 
either G106 or L107 ablate MAb 4G2 recognition, however only substitutions at G106 
interfere with MAb 6B6C-1 recognition (Crill, Trainor, and Chang, 2007; Trainor et al., 
2007).  This pattern was upheld in this study with the exception of L107F, which did not 
significantly reduce the binding of 4G2 or of any other group cross-reactive MAbs(data 
not shown).  However in JEV, WNV, SLEV, and tick-borne encephalitis virus (TBEV) E 
proteins the L107F substitution has been shown to reduce cross-reactive antibody 
recognition, and L107F TBEV recombinant subviral particles have been shown to reduce 
the immunoglobulin recognition by polyclonal DENV infected human serum (Allison et 
al., 2001; Crill, Trainor, and Chang, 2007; Stiasny et al., 2006; Trainor et al., 2007).  In 
spite of the invariant nature of most fusion peptide residues, L107F does occur in a 
number of flaviviruses: Powassan and Deer tick viruses, JEV vaccine strain SA-14-14-2, 
and DENV-2 strain POU-280 (Blok et al., 1989; Kuno et al., 2001; Nitayaphan et al., 
1990).     
One of the novel findings of the DENV-2 epitope mapping is that substitutions in 
different structural domains of adjacent E-protein monomers can act as epitope 
determinants for a single antibody, suggesting that some antibodies might recogniz  
inter-monomer epitopes including the disparate structural domains EDII and EDIII.  
Perhaps the best example of this was DENV-4 raised DENV complex cross-reactive 
MAb D35C-9-1.  This MAb exhibited only minor reactivity reductions (50-25%) for all 
six G106/L107 fusion peptide mutants and for two individual EDIII mutants, E311R and 
P364R (50%).  However, when the EDII fusion peptide and EDIII substitutions were 




only 1.5% of WT DENV-2 reactivity.  Such synergistic effects of combining 
substitutions on antibody reactivity could occur when residues do not play a critical 
binding role within the antibody paratope and thus the introduction of single substitutions 
might not interfere with antibody recognition, yet when two or more substitutions of little 
to no individual effect are combined together they either decrease Ka or increase Kd to the 
point where a significant reduction in antibody recognition is observed.  Other examples 
of EDII-EDIII inter-monomer epitope determinants occurred with DENV subcomplex 
MAb 1B4C-2 and subgroup cross-reactive MAbs 5-1, and 5-2.  MAb 1B4C-2 is a 
DENV-2 raised non-neutralizing antibody recognizing a surface accessible epitope 
originally assigned to EDI on the basis of biophysical mapping (Roehrig, Bolin, and 
Kelly, 1998).   A previously published mutagenesis study identified EDII fusion peptide 
residues that could act as epitope determinants affecting the binding of this MAb (Crill 
and Chang, 2004), and this study confirms the effect of both fusion peptide substitutions 
and EDIII substitutions acting as 1B4C-2 epitope determinants.  Similar to MAb D35C-
9-1, the greatest decreases in binding of 1B4C-2 occurred for VLPs combining 
substitutions from EDII and EDIII.  
MAb 5-1 is a JEV-raised antibody that recognizes only JEV and DENV-2.  All 
VLPs containing G106/L107 substitutions exhibited reduced binding by this MAb, as 
were E311R VLPs.  Again, combinations of the EDII substitutions and EDIII E311R had 
the most dramatic effect, ablating our ability to measure any MAb recognition for this 
VLP at all.  MAb 20 is similar to MAb 5-1; it was raised against DENV-2 and also 
recognizes only JEV and DENV-2.  Although fusion peptide substitutions did not alter 




of E311 substitutions exhibited significant reductions in MAb 20 binding.  E311 is 
conserved across the DENV complex yet this residue is an asparagine in the JEV 
complex viruses (Fig. 2.1); adjacent residue K310 is almost completely conserved across 
the mosquito borne flaviviruses, however K310 substitutions did not alter the binding of 
either MAb 20 or 5-1.  Thus other shared residues between DENV-2 and JEV, possibly 
including fusion peptide residues, must be responsible for the identical cross-reactivity 
patterns of these two antibodies.  MAb 5-2 is another JEV-raised subgroup cross-reactive 
MAb, recognizing JEV, DENV-1 and DENV-2.  This study did not identify any 
substitutions in DENV-2 VLPs that disrupted the binding of this MAb.  However, in JEV 
and in DENV-1, substitutions in both the fusion peptide and in EDIII significantly 
reduced the binding of this MAb (Chiou et al., 2008a) and unpublished results).   
The only other published report of similar inter-monomer EDII-EDIII epitopes is 
for chimpanzee MAb 1A5, a flavivirus group cross-reactive MAb raised against DENV-2 
(Goncalvez, Purcell, and Lai, 2004).  G106 and H317 were independently identified by 
neutralization escape from MAb 1A5 and thus identified as epitope determinants.  
G106V significantly reduced antibody binding and neutralization whereas H317Q did not 
affect binding but did reduce neutralization by this MAb.  Although structurally closeto 
G106 (~15Å) H317 lies buried on the bottom membrane side of the E dimer in native 
virions, consistent with its lack of effect on 1A5 binding.  The EDIII residue we 
identified as cooperating with fusion peptide residues G106 and L107 as a cross-reactive 




                   300       310       320       330       340             
DENV-2  16681 : KGMSYSMCTGKFKIVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIM-DLEKR :   
DENV-1  16007 : .....V....S...E.............Q.K...TDA......SSQ-.EKGV :   
DENV-3  H87   : .....A..LNT.V.K...S.............K.EDA......STE-.G.G. :   
DENV-4  H241  : ............S.D..........T....K...A.A.....I..R-..N.E :  
JEV     SA-14 : ..T..G...E..SFA.NP.D.G......E.S.S.SDG.....IVS.AS.NDM :   
                                                                         
                                                                         
                  350       360         370       380       390               
DENV-2  16681 : HVLGRLITVNPIVTEKDSP--VNIEAEPPFGDSYIIIGVEPGQLKLNWFKKG :  
DENV-1  16007 : TQN.....A.....D.EK.--..........E......AGEKA...S..... :  
DENV-3  H87   : AHN.....A.....K.EE.--..........E.N.....GDKA......... :  
DENV-4  H241  : K.......ST..AENT..V--T...L.............GNSA.T.H..... :  
JEV     SA-14 : TP.........F.ATSSANSK.L..M............RGDK..NHH.H.A. :  
 
Figure 2.1.  EDIII Alignment of Representative Strains of the Four DENV Serotypes and JEV.  Single letter amino acid abbreviations 
are shown for EDIII of DENV-2 using DENV-2 numbering.  Amino acids conserved relative to DENV-2 in the other serotypes are shown as 
dots, and single letter abbreviations for non-conserved amino acids are depict. Colored residues depict epitope-specific determinants as 
determined in this report and previously published reports. DENV-2 residues demonstrated to be involved in DENV complex and subcomplex 
cross-reactive epitopes are highlighted in yellow, DENV-2 specific resdu  are highlighted in red, and residues from the region of overlap 
between these epitopes and hence affecting DENV complex and DENV-2 virus specific epitopes are highlighted green (Gromowski and 
Barrett, 2007; Gromowski, Barrett, and Barrett, 2008; Lok et al., 2008; Sukupolvi-Petty et al., 2007).  The mutated EDIII residues 
incorporated into antigens in this study are marked in black for the other DENV serotypes: DENV EDIII complex cross-reactive knock out 







Figure 2.2. Structural Locations of Envelope Protein Epitope-specific Knock-out 
Substitutions (A) Crystal structure of the DENV-2 E dimer (Modis et al., 2003) as it 
appears from above in mature virions and depicted as a ribbon diagram.  The structural 
domains are colored red (EDI), yellow (EDII), and blue (EDIII). The fusion peptide 
residues are colored green and the glycans in EDI (N153) and EDII (N67) are depict as 
ball and stick representation and colored brown.  Epitope specific knock-out substitution 
in the fusion peptide and EDIII are depicted as space filling representations nd colored 
magenta. 
(B) Side view of the same representation of the E protein dimer in mature virions with all 
structural depictions and colors the same as in panel A. 
(C) An enlarged view from panel B of the interface between the DII fusion peptide of one
monomer and DIII of the alternate monomer of the E dimer.  Residue locations of epitope-
specific knock out substitutions are depicted as ball and stick representations.  Substitutions of 
Gly106 and Leu107 in the EDII fusion peptide knock out the binding of broadly cross-reactive 
immunoglobulins, those recognizing viruses in the DENV complex and other flavivirus 
complexes.  Substitutions of Lys310, Glu311, Pro364, and Lys388 in EDIII knock out the 
binding of immunoglobulins recognizing all or subsets of the four serotypes of DENV, but do 
not interfere with DENV-2 specific immunoglobulin recognition.  Substitutions of Lys305 knock 




and is only 6-9Å from EDII fusion peptide residues G106 and L107 of the alternate 
monomer, well within the binding area of a typical Fab footprint (Fig. 2.2).  Competitive 
binding assays with DENV-2 identified three distinct MAb epitope binding clusters and 
the cluster recognized by the majority of the antibodies included MAbs recognizing 
epitopes from all three E structural domains.  This cluster not only included MAbs
recognizing fusion peptide epitopes such as 6B6C-1, but also included EDII-EDIII 
binding MAb 1B4C-2 (Roehrig, Bolin, and Kelly, 1998).  These results suggest that such 
inter-domain epitopes could be more common than previously recognized.  It has been 
noted in this report and elsewhere that there is a diversity of overlapping epitopes 
containing fusion peptide residues recognized by antibodies with variable patterns of 
cross-reactivity (Crill, Trainor, and Chang, 2007; Trainor et al., 2007). Due to the size of 
an antibody Fab footprint, it is expected that such epitopes will include residues outside 
of, and less conserved than those in the fusion peptide itself and that binding to these 
more variable residues must account for the different patterns of cross-reactivity observed 
for antibodies recognizing epitopes in this region. Thus, it is not unexpected that there are 
antibody epitopes incorporating EDII fusion peptide residues and residues within the 
structurally adjacent EDIII of the alternate monomer.  These results and interpretations 
suggest a point of caution for studies attempting to map antibody epitopes using only 
recombinant EDIII (rEDIII) protein or soluble E-protein monomers. 
Some of the general and specific epitope mapping results presented here are supported by 
recently published studies.  A number of studies have mapped DENV-complex and sub-
complex cross-reactive epitopes to the lateral surface of EDIII (Gromowski, Barrett, and 




Sukupolvi-Petty et al., 2007).  MAb 1A1D-2 is a DENV-2 raised subcomplex cross-
reactive antibody that recognizes DENV-1, -2, and -3 (Roehrig, Bolin, and Kelly, 1998). 
We identified six residues located on three different β-s rands in EDIII acting as epitope 
determinants for this antibody.  Four of these residues are in β-strand A (Lys305, Val308, 
Lys310, and Glu311), and one each in β−strand B (Arg323) and β−strand G (Lys388) 
(Modis et al., 2003). The seventh residue identified as an epitope determinant for this 
MAb, Pro364, is the last residue of the loop just prior to β−strand E.  Recently published 
analyses using yeast surface display mutagenesis of DENV-2 rEDIII also identified MAb 
1A1D-2 epitope determinants in β−strand A (Gly304, Lys305, Lys 307, and Lys310); 
(Sukupolvi-Petty et al., 2007).  In fact, a crystal structure of MAb 1A1D-2 Fab 
complexed with rEDIII was recently solved that confirms the principal involvement of 
EDIII β−strand A in 1A1D-2 binding (Lok et al., 2008).  Another recent study examined 
five DENV subcomplex MAbs with cross-reactivity profiles the same as 1A1D-2 but not 
including this MAb. All five of these MAbs recognized a single antigenic site including 
residues in β−strands A, B, and G and centered on K310 (Gromowski, Barrett, and 
Barrett, 2008).  It therefore appears that the well-characterized epitope recognized by 
MAb 1A1D-2 could be representative of most subcomplex antibodies recognizing 
DENV-1, -2, and -3. 
MAb 9D12 was raised against DENV-1 and recognizes DENV-1, -2, and -4.  This 
MAb appears to recognize an overlapping, yet distinct epitope from MAb 1A1D-2.  Two 
of the residues we identified as epitope determinants for 1A1D-2 had similar effects for 
9D12 reactivity, K310 and P364.  Yeast display mutagenesis of rEDIII also identified the 




either 1A1D-2 or 9D12 binding (Sukupolvi-Petty et al., 2007).  There was one direct 
conflict between the 9D12 results presented here and those from a previous study.  In this 
report there was no effect of either of the substitutions examined at K305 on 9D12 
reactivity, whereas a previous study using rEDIII found significant reductions in 9D12 
binding for a K305E mutant (Sukupolvi-Petty et al., 2007).  One possibility is that there 
could be subtle differences in EDIII conformational structure between VLPs and rEDIII. 
For example, there could be differences in local dynamic motions, and hence minor 
conformational perturbations of the K305E substitution when introduced into rEDIII 
compared to E protein dimers as displayed on the VLP surface.  Such local dynamic 
motions have recently been characterized in a recombinant EDIII system and 
demonstrated to be associated with specific substitutions that correlate with r ductions in 
MAb recognition and neutralization (Maillard et al., 2008).  DENV complex cross-
reactive MAb 4E11, which we did not examine, has been studied extensively in DENV-1 
and also binds to a discontinuous EDIII epitope centered primarily around four residues 
in β−strand A, including K310 (Lisova et al., 2007). 
DENV type-specific antibodies, specifically potently neutralizing murine MAbs, 
recognize epitopes in EDIII (Gromowski and Barrett, 2007; Hiramatsu et al., 1996; Lin et 
al., 1994; Lok, Ng, and Aaskov, 2001; Rey et al., 1995; Roehrig, Bolin, and Kelly, 1998; 
Sukupolvi-Petty et al., 2007; Trirawatanapong et al., 1992).  Although we purposefully 
selected amino acids that were likely to be incorporated into cross-reactive epitopes for 
this study we did identify one residue, K305 that reduced the binding of the DENV-2-
specific neutralizing MAb 3H5.  3H5 appears to be typical of many DENV-2 specific 




residues K305 and P384 (Gromowski and Barrett, 2007; Sukupolvi-Petty et al., 2007).  
Interestingly, in the same rEDIII yeast surface display mutagenesis study, P384 was 
identified as an important DENV-2 specific epitope determinant, yet not K305; despite 
the use of MAb 3H5 and K305 mutants in both the previous and this current study 
(Sukupolvi-Petty et al., 2007).  Sukupolvi-Petty et al. did identify G304 as a major 
DENV-2 specific neutralizing MAb epitope determinant and G304 substitutions were not 
examined in this study or by Gromowski and Barrett, and given its close proximity to 
K305, G304 could be included as a part of this epitope.  A clear consensus result from all 
of these studies is that there exist two different overlapping epitopic regions on the lateral 
surface of EDIII, one stimulating antibody with varying levels of cross-reactivity in the 
DENV serocomplex and second stimulating virus-specific antibodies (Fig. 2.2).  These
results all stem from studies of murine MAbs and a major still to be resolved issue is 
whether the outer lateral surface of EDIII contains protective virus-specific neutralizing 
epitope determinants for humans as well as mice (Lai et al., 2007). 
Characterization of Serum from DENV-2 Infected Patients  
Recently there has been increased interest and capability to examine and dissect 
complex polyclonal human immune responses to flavivirus infection.  The results 
presented in this study compliment and add to this nascent body of work with detailed 
epitope-specific antibody assignments of IgM in addition to IgG.  Stiasny et al. (Sti sny 
et al., 2006) measured total E protein-specific IgG titers from six sera from DENV-2 
infected patients that ranged in IgG titers from 104 to 106; similar magnitudes and 
variation as determined in this study. Another recent study of WNV epitope-specific 




from WNV-infected patients (103-104) (Oliphant et al., 2007a).  These sera from WNV-
infected patients were collected 4-7 months post onset of symptoms, although a few sera 
were less than one month post onset that had similar IgG titers.  The sera from DENV-2 
infected patients examined by Stiasny et al had low to no IgM, consistent with theirs 
being convalescent phase sera.  These observations suggest that the different magnitudes 
of E-specific IgG between sera from DENV-2 and WNV infected patients in these studies 
could be virus specific phenomea.  DENV viremia in humans lasts approximately 4-10 
days, whereas WNV viremia is more transient, lasting only 1-3 days.  Thus the larger 
magnitude IgG response in DENV-2 infected patients compared to WNV-infected 
patients could result from differences in the length of viremia between these two viruses.  
Clearly, more studies will be needed to determine if this is a general phenomenon.  In this 
study, E-specific IgM titers averaged across primary and secondary infected sera were 
also in the 104 – 106 range (Table 2.5); although IgM titers were not presented in the 
WNV study cited above, they would be expected to be lower based on the late 
convalescent timing of the serum collections. 
The importance of the EDII fusion peptide as an immunodominant antigenic 
region containing a series of overlapping epitopes stimulating broadly cross-reactive 
antibodies has been well established in mice (Crill and Chang, 2004; Crill, Trainor, and 
Chang, 2007; Oliphant et al., 2007a; Stiasny et al., 2006; Trainor et al., 2007). The results 
presented in this report and other recent studies confirm the extension of this observation 
to humans as well (Lai et al., 2008; Oliphant et al., 2007a; Stiasny et al., 2006).  In this 
study IgG recognizing EDII fusion peptide epitopes ranged from undetectable to 94% of 




variable levels of EDII fusion peptide recognizing IgG in DENV-2 infected s ra; they did 
not quantify this variation but estimated the proportion of IgG recognizing these epitopes 
to average about 30% and confirmed the limited neutralizing capability of these 
antibodies.  Because their study examined convalescent phase sera, the similar percentage 
estimates of IgG targeting EDII fusion peptide epitopes in these studies suggest that the 
high concentrations of these cross-reactive antibodies are long-lived.  This observation is 
supported by flavivirus serodiagnostic studies identifying high levels of cross-reactivity 
in IgG assays (Chiou et al., 2008a; Johnson et al., 2000; Kuno, 2003).  Interestingly, 
although 4-7 months is not particularly long, the continued persistence of large 
populations of weakly or non-neutralizing cross-reactive antibody is relevant to ibody-
dependent enhancement of infection and its potential role in increasing DENV disease 
severity leading to DHF/DSS (Gonzalez et al., 2005; Guzman et al., 2007; Halstead, 
2003).  Because antibody stimulated from EDII fusion peptide epitopes tends to be 
broadly cross-reactive, it is not surprising that the immunodominant nature of EDII 
fusion peptide epitopes is also supported by recent studies of WNV-infected human sera 
(Oliphant et al., 2007a; Throsby et al., 2006). 
We examined both primary and secondary DENV-2 infected patient serum and 
found EDII fusion peptide specific IgG was greater in primary than in secondary 
infections (mean= 44% and 35% respectively; Table 2.6).  Lai et al. (Lai et al., 2008) 
recently used western blots to examine late acute-early convalescent phase ser  from  
DENV-2 infected patients from Taiwan.  They also observed that the majority of the
cross-reactive antibody response targeted epitopes in the highly conserved EDII fusion 




response was greater in primary than in secondary DENV-2 infected patients, although 
they assayed total immunoglobulin and did not distinguish between IgM and IgG in their 
assays.  The results presented in this report suggest that the increased cross-rea tivity 
observed in primary relative to sera from secondary DENV-2 infected patients results 
more from IgM than from IgG.  IgM populations targeting these cross-reactiv  epitopes 
in primary infections were larger than IgG populations, and averaged twice as large as 
EDII fusion peptide specific IgM in sera from secondary infected patients (54% and 24% 
of IgM in primary and secondary infections respectively, Table 2.6).   
IgM responses to cross-reactive EDIII epitopes were similar in variability and 
magnitude as those for the EDII fusion peptide, but the proportion of IgG recognizing 
these epitopes was much smaller (Table 2.5 and 2.6).  Flavivirus immune responses 
targeting EDIII have not been examined in humans to the extent that they have for EDII 
fusion peptide epitopes, and neither of the DENV-2 infected patient sera studies cited 
above examined immune responses to EDIII.  Oliphant et al. (Oliphant et al., 2007a) 
recently studied epitope-specific immune responses in convalescent phase sera from 
WNV-infected patients, examining both total EDIII IgG and EDIII WNV-specific IgG, 
the latter epitope being homologous to that examined for DENV-2 in this report.  Total 
IgG recognizing EDIII epitopes in these WNV-infected sera averaged 7.3% and ranged 
from 0.6% to 50.5%, suggesting that the relatively small yet variable magnitude cross-
reactive EDIII IgG response we estimated from DENV-2 infected sera (me n=5.8%, 
range <1% - 26%) could be a generalized response to flavivirus infection.  More studies 
are needed to determine if the larger magnitude cross-reactive IgM response relativ to 




infections found in this study are typical for dengue or other flaviviruses. If so, the use of 
IgM titers or P/Ns (OD value of positive sera/OD value of negative sera) alone to attempt 
to assign current infecting serotype in secondary DENV infections could be highly
misleading.  Recent detailed IgM and IgG serodiagnostic analyses of a large number of 
primary and secondary DENV infected serum specimens confirm this observation (Chang 
et al, unpublished results).   
Lai et al (Lai et al., 2008) examined late acute to early convalescent serum
specimens from DENV-2 infected patients from Taiwan, similar to the Taiwanese serum 
specimens from this study.  Using western blot to assay total immunoglobulin they 
estimated the DENV-2 specific anti-E protein response in primary DENV-2 infected sera 
to range from 0% to 8.6% with a single specimen estimated at 21.5%.  They did not 
attempt to identify the epitopes recognized by these DENV-2 specific antibodies.  Our 
results in sera from primary DENV-2 infected patients were similar (<1% - 9 ) and 
indicate that the more of the DENV-2 specific immunoglobulin is IgM, with litle IgG 
(mean = 4% and <1% respectively).  We found the same pattern in sera from secondary 
DENV-2 infected patients, but the magnitude of IgM and IgG responses averaged twice 
as large as in primary infections.  Oliphant et al (Oliphant et al., 2007a) also found small 
proportions of EDIII recognizing virus specific IgG in WNV infected sera (mean = 1.6%, 
range 0% - 6.8%), they did not, however, investigate WNV-specific epitopes outside 
EDIII.   
 We were able to demonstrate for the first time that there is a significant and 
positive correlation between the magnitude of EDIII DENV-2 specific IgG titer and the 




there was no correlation between overall levels of EDIII WNV-specific IgG and clinical 
outcome or measurable difference in neutralization profiles between WT and EDIII 
WNV-specific knock-out reporter virus particles, suggesting a limited role for EDIII 
virus-specific IgG in WNV protective neutralization (Oliphant et al., 2007a).  One 
possible explanation for this apparent discrepancy between the importance of EDIII virus 
specific IgG as a correlate of protection in DENV-2 and WNV is the large titer 
differences between these two antibody populations in these studies, despite averaging 
about 1% of the IgG response against each virus.  Total DENV-2 IgG titers, and hence 
EDIII-DENV-2 specific IgG, ranged from 10-100-fold greater than WNV IgG in the 
primary DENV-2 infected sera and up to 1000-fold greater in sera from secondary 
DENV-2 infected patients.  A definitive test to see if these minor IgG populations are 
indeed protective would be to examine homologous DENV-2 (or WNV) secondary sera 
and determine if there is a marked anamnestic increase in this antibody population and if 
it is associated with increased protection.  Alternatively, there could simply be a 
difference between DENV-2 and WNV in the importance of EDIII virus specific IgG and 
neutralization or protection.  Although by no means definitive, our results suggest that the 
EDIII virus-specific epitopes identified as strongly neutralizing and protective in mice 
could play a similar role against DENV-2 infection in humans.  The conclusions and 
questions stemming from the results presented in this report begin to disentangle the 
complex polyclonal humoral immune responses to primary and secondary DENV 
infections and point a direction for future studies in this field that will be essential bo h 
for improving our understanding of DENV pathogenesis and for the development and 





Cell culture, construction of plasmids and virus-like particle (VLP) production.  
COS-1 cells (ATCC CRL 1650; Manassas, VA) were grown at 37°C with 5% CO2 on 
Dulbeco’s modified Eagle’s minimal essential medium (D-MEM, GIBCO, Grand Island, 
NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone 
Laboratories, Inc., Logan, UT), 110 mg/l sodium pyruvate, 0.1 mM nonessential amino 
acids, 2mM L-glutamine, 20 ml/l 7.5% NaHCO3, 100U/ml penicillin, and 100ug/ml 
streptomycin.  We used the recombinant expression plasmid pVAXD2i derived from 
pCBD2-2J-2-9-1, which has been previously characterized and described in detail (Chang 
et al., 2003; Crill and Chang, 2004).  This derivation is the same as same as described for 
constructing pVJE from pCBJE previously (Chiou et al., 2008a).  COS-1 cells were 
electroporated with WT pVAXD2i and mutant plasmids using the protocol described in 
(Chang, Hunt, and Davis, 2000).  Electroporated cells were recovered in 50 ml DMEM, 
seeded into three separate 75 cm2 ulture flasks for VLP expression and incubated at 
28°C with 5% CO2.  Tissue-culture medium was harvested 4-5 days post transformation 
for VLP antigen characterization including triplicate measurements of secretion levels 
and MAb reactivity screening.   
Selection and introduction cross-reactive epitope residue substitutions.  Cross-
reactive epitope residues selected for substitution in the fusion peptide were originally 
identified by Crill and Chang, (Crill and Chang, 2004) with numerous subsequent 
publications emphasizing the importance of overlapping immunodominant epitopes in 
this region eliciting cross-reactive antibodies (Crill, Trainor, and Chang, 2007; 




Roberson, Crill, and Chang, 2007b; Stiasny et al., 2006; Trainor et al., 2007).  E protein 
domain III (EDIII) prospective cross-reactive epitope residues were also selected based 
on previously described procedural algorithms (Crill and Chang, 2004; Trainor et al., 
2007).  Using this structure-based design approach we identified 22 different probably 
EDIII cross-reactive epitope residues.  We modeled the effects of side-chain substitutions 
at eight of these residues using the DENV-2 pdb E-protein structural coordinates a d the 
swiss-model workspace selecting those with the highest probability of disrupting 
antibody binding without altering E-glycoprotein structural conformation, particle 
formation, or secretion (Modis et al., 2003) (http://us.expasy.org/spdbv/).  Applying these 
criteria we selected 15 amino acid substitutions to introduce at these eight EDIII residue 
positions (Table 2.1). 
Site-specific mutations were introduced into the DENV-2 E gene using the 
Stratagene Quick Change® multi site-directed mutagenesis kit (Stratagene, La Jolla, CA) 
and pVAXD2i as DNA template following the manufacturer’s recommended protocols. 
The sequences of the mutagenic primers used for all constructs are listed in Table 1.    
Structural gene regions and regulatory elements of all plasmids were sequenced entirely 
upon identification of the correct mutation.  Automated DNA sequencing was performed 
using a Beckman Coulter CEQ™ 8000 genetic analysis system (Beckman Coulter, 
Fullerton, CA) and analyzed using Beckman Coulter CEQ™ 8000 (Beckman Coulter) 
and Lasergene® software (DNASTAR, Madison, WI).  
Characterization of wild-type (WT) and mutant pVAXD2i secreted VLP antigen.  
Antigen-capture ELISA (Ag-ELISA) was used to detect and quantify secreted antigen 




was captured in the inner 60 wells of Immulon II HB flat-bottom 96-well plates 
(Dynatech Industries, Inc., Chantilly, VA) with polyclonal rabbit anti-DENV-2 WT VLP 
sera, incubated overnight at 4°C, and wells were blocked with 300µl of StartBlock 
blocking buffer (Pierce, Rockford, Ill.) according to the manufacturer’s recommended 
protocol. Antigen was diluted 2-fold in PBS, incubated for 2 hr at 37°C and detected with 
murine hyper-immune ascitic fluid (MHIAF) specific for DENV-2 diluted in 5% 
milk/PBS.  MHIAF was detected using horseradish peroxidase conjugated goat anti-
mouse IgG (Jackson ImmunoResearch, Westgrove, PA) in 5% milk/PBS and incubated 
for 1 hr at 37°C.  Bound conjugate was detected with 3,3΄5,5́ -tetramethylbenzidine 
substrate (TMB; Neogen Corp., Lexington, KY), the reaction was stopped with 2N 
H2SO4 and measured at A450 using a Synergy HT Multi-Detection Microplate Reader 
(Bio-Tek Instruments, Inc., Winooski, VA).  WT and mutant antigens were screened 
against the MAb panel using the same ELISA protocol as above with the exception that 
2-fold dilutions of the specific MAb replaced the anti-DENV-2 MHIAF and antigens 
were used at a single standardized concentration producing an optical density (OD) of 1.0 
in the secretion ELISA.  Standardized concentrations of WT and mutant VLP antigens 
were analyzed in Ag-ELISA to determine MAb end point reactivities (Roehrig, Bolin, 
and Kelly, 1998).  
Monoclonal antibodies.  MAbs 4G2, 6B6C-1, 4A1B-9, 1B7, D3-5C9-1, 1A1D-9, 9D12, 
10A4D-2, 1B4C-2, 9A3D-8, and 3H5 were obtained from hybridomas in the collection of 
the Arbovirus Diseases Branch, Division of Vector-borne Infectious Diseases, US 
Centers for Disease Control and Prevention (CDC).  Many of these MAbs originated 




obtained by the CDC from the Walter Reed Army Institute (Henchal et al., 1985).  MAbs 
23-1, 23-2, 20, 5-1 and 5-2 were provided by Dr. L.-K. Chen of Tzu Chi University, 
Hualien, Taiwan.   
Serological characterization of sera from DENV-2 infected humans.  DENV-2 
infected human sera from dengue fever patients were obtained from the Dengue Branch, 
US Centers for Disease Control and Prevention, San Juan, Puerto Rico; and also from the 
Taiwan Center for Disease Control.  The Puerto Rican DENV-infected sera were 
collected from Puerto Ricans infected locally during the 2007 transmission season and 
the Taiwanese sera were from Taiwanese residents who contracted DENV-2 while 
traveling in SE Asia outside of Taiwan in 2005.  All sera were confirmed DENV-2 
positive by either virus isolation or RT-PCR either from these specimens or from paired 
acute-phase sera (data not presented and collected in either Puerto Rico or Taiwan). 
Sera were assayed for the presence of E-specific immunoglobulins with both IgM 
and IgG antigen capture ELISAs (MAC- and GAC-ELISA).  All VLP antigen 
concentrations were standardized using the same anti-DENV-2 polyclonal rabbit sera 
capture and MHIAF detection ELISA and methods described above in antigen 
characterization. Antigen concentrations were standardized at an OD of 1.4, within the 
region of antigen excess near the upper asymptote of the sigmoidal OD curve.  MAC- and 
GAC-ELISA were performed as previously described with some modifications 
(Roberson, Crill, and Chang, 2007b).  Briefly, Immulon II HB flat-bottom 96-well plates 
were coated overnight at 4°C with goat anti-human IgM or IgG (Kirkegaard & Perry 
Laboratories, Gaithersburg, MD) and blocked with StartBlock.  DENV-2 infected patient 




wells and incubated at 37°C for 90min.  WT DENV-2 and negative control antigens were 
diluted appropriately in wash buffer tested against each serum sample in triplicate and 
incubated overnight at 4°C.  DENV-2 virus-infected MHIAF was diluted in 5% milk/PBS 
and incubated for 1h at 37°C.  Horseradish-peroxidase conjugated goat anti-mouse IgG 
was diluted in 5% milk/PBS, 50µl, added to wells and incubated for 1h at 37°C.  Bound 
conjugate was detected with TMB substrate and plates incubated at room tempera ure fo  
8 min.  The reaction was stopped with 2N H2SO4 and OD was measured at A450.  
P/N ratios were calculated as previously described with test validation utilizing 
internal positive and negative control sera on each plate (Martin et al., 2002).  Positive 
values were determined as the average OD for the patient serum sample reacted with WT 
DENV-2 antigen and negative values as the average OD of the normal human control 
serum with WT DENV-2 antigen.  The primary or secondary DENV infection status of 
each specimen was determined by calculating the ratio of IgM/IgG OD each subtracted 
by two times the corresponding negative value; ratios ≥1.0 are indicative of primary 
infections and ratios <1.0 of secondary infections, Table 2.3).  
Determination of E protein epitope-specific immunoglobulin populations in sera 
from DENV-2 infected humans.  To quantify the epitope-specific humoral immune 
response following DENV-2 infection we used the same MAC- and GAC-ELISA format 
described above and serially diluted sera from 1 x 103 to 1 x 108.  In addition to WT 
DENV-2 VLP antigen we utilized a series of epitope-specific knock-out VLPs 
characterized in this study (Table 2.2).  Relative concentrations of WT and epitope-
specific knock-out antigens were standardized using the same rabbit sera-capture, 




and tested with WT, five different epitope-specific knock-outs, and negative antigen in 
duplicate at each serum dilution.  The five mutant DENV-2 VLP antigens used were an 
EDII fusion peptide G106R-L107D cross-reactive knock-out mutant (RD), an EDIII 
K310E-E311R-P364R complex cross-reactive knock-out mutant (ERR), EDII-EDIII 
combination of these two mutants G106R-L107D-K310E-E311R-P364R (RD-ERR) and 
two single EDIII mutants K305E and K388D (Table 2.2).   
The resulting OD data were modeled as a nonlinear function of the log10 dilution 
using a four-parameter logistic model.  In a four-parameter logistic curve, the lower 
horizontal asymptote is not constrained to zero.  This model was chosen over the three-
parameter model (which does constrain the lower asymptote to zero) because although 
the sera can be diluted to the point where there is no remaining immunoglobulin, the OD
values are not expected to reach zero.  The model was fit with the S-plus (v8.0) function 
nls that uses least squares to estimate the parameters.  Sera, immunoglobulin type, a d 
antigen type were included as covariates.  After fitting the model, endpoints were 
computed by finding where the OD curves for each antigen type crossed the OD curve 
for two times the negative control values at each serum dilution.  The asymptotic 
covariance matrix V for the endpoints was computed using the multivariate delta method 
(Lehmann, 1998).  Using V, general least squares was used to regress endpoints on 
antigen type, IgM/IgG, primary/secondary infection status, and Taiwan/Puerto Rico 
geographic origin class.  Statistically significant main effects and two- and three-way 
interactions were investigated further with multiple comparisons using Scheffe’s method. 
The model could not satisfactorily fit the data for Taiwan sera #16 into a logistic 




dilution (1:1000) only captured the tail end of the actual curve of signal vs. antibody 
concentration.  Nevertheless, for both WT and all three EDIII mutant antigens there was 
positive OD signal greater than two times the negative value at the higher serum 
concentrations.  For this serum sample we therefore used the following linear 
interpolation of the data to estimate the endpoint cut-offs, endpoint = (mean OD of the 
antigen of interest at the last positive serum dilution divided by two times the negative 
antigen OD at the same serum dilution) multiplied by the last positive dilution. Hence 
this is the percent remaining positive signal at the last positive dilution times hat last 
positive dilution.   
Epitope-specific IgM and IgG percentages were calculated by dividing the 
immunoglobulin end-point value obtained with a specific knock-out antigen by that 
obtained with the WT antigen on the same sera, subtracting this value from 1.0 and 
multiplying by 100.  The two EDIII single-mutant antigens were included to examine 
human immune responses to the protective EDIII virus-specific neutralizing epitop  
indentified in murine studies and were analyzed slightly differently.  K305E knocks out 
reactivity to neutralizing DENV-2 type-specific MAbs (e.g. 3H5 in this study) and 
complex cross-reactive MAbs such as 1A1D-2, Table 2.2 (Gromowski and Barrett, 2007; 
Lok et al., 2008).  K388 is not incorporated into the DENV-2-specific epitope typified by 
MAb 3H5 and the K388D substitution knocks out only complex cross-reactivity 
exemplified by MAb 1A1D-2 (Table 2, Fig. 2; (Lok et al., 2008).  Thus, the percent 
immunoglobulin recognizing the DENV-2 specific EDIII neutralizing murine epitope 
was calculated as 100 x 1.0-[(K305 endpoint/WT endpoint)-(K388D endpoint/WT 




greater than that with the WT antigen.  We interpreted these cases as undetectable l vels 
of antibody recognizing this epitope and the percent serum antibody recognizing th s 
epitope for further analysis was conservatively set to 1%. 
Focus-Reduction Micorneutralization Assays.  We utilized an immunostaining micro-
neutralization assay to measure the neutralizing capability of the human serum samples 
against all four DENV serotypes and JEV and WNV.  2.47 x 104 Vero cells in DMEM 
were added to 96 well black, clear flat bottom plates and incubated 16hr overnight at 
37°C and 5% CO2.  Serum specimens were diluted 1:50 in BA-1 and heat inactivated at 
56°C for 30 minutes, diluted 2-fold to a final dilution of 1:1600 and 320 virus pfu was 
added to each serum dilution.  Plates were then incubated for 1hr at 37°C, 5% CO2.  After 
incubation, serum and virus suspensions were transferred back to Vero cell monolayer 
containing plates.  These Vero cell plates were incubated at 37°C, 5% CO2 for 45 minutes 
rocking every 5 minutes to allow for virus infection.  Barry’s Ye Lah overlay media 
containing 6% sodium bicarbonate and 1% Carboxymethylcellulose sodium salt (Fluka 
biochemical) was added and plates were incubated at 37°C, 5% CO2.  Incubation times 
were as follows:  WNV (NY-99), JEV (SA-14-14-2): 24 hr; DENV-2 (16681) and 
DENV-4 (H241): 48 hr; DENV-1 (56BC94/95), DENV-3 (116RC1396): 70 hr.  
Following incubation plates were washed and fixed with 3:1 acetone, then decanted and 
plates were allowed to dry overnight.  Immunostaining was performed by adding virus-
specific MHIAFs diluted in PBS and incubated at 37°C for 30 min, washing and adding 
goat anti-mouse HRP diluted in 5% milk/PBS and similarly incubated for 30 min. and 
washed.  Infected virus foci were visualized using Vector-VIP peroxidase substrate kit 




microscope and Axiovision software version 4.6.  50%, 75% and 90% FRµNT dilution 
titers were calculated for each virus relative to the back that virus back-titration in BA-1. 
The predicted 90% FRµNT titers were determined using Graph pad Prism version 4 
(Graph Pad Software, San Diego, CA) sigmoidal dose response (variable slope) formula.  





Dengue vaccine candidates reduce potential antibody-dependent enhacement 
Introduction 
  Dengue virus (DENV) is a mosquito-borne flavivirus of global public health 
concern as two-fifths of the world’s population live in DENV endemic/epidemic regions 
(Farrar et al., 2007).    Infection with any one of the four closely related dengue virus 
(DENV) serotypes (DENV-1 to -4) can result in a wide range of clinical symptoms from 
subclinical, to classic dengue fever (DF), to life threatening dengue hemorrhagic fever 
(DHF)/dengue shock syndrome (DSS), characterized by a plasma leakage syndrome.  
Epidemiological evidence indicates severe DHF is associated with secondary DENV 
infection (Guzman et al., 1990; Sangkawibha et al., 1984).  Although the mechanism 
leading to severe disease is not fully understood, it is thought to be multifactorial.  Two 
non-mutually exclusive immunopathological mechanisms to describe the events leading
to DHF/DSS are antibody-dependent enhancement of infection (ADE) (Halstead and 
O'Rourke, 1977), and the involvement of cross-reactive memory T cells (Mongkolsapaya 
et al., 2003; Rothman and Ennis, 1999), known as original antigenic sin (Mongkolsapaya 
et al., 2003).  ADE occurs when cross-reactive, weakly-neutralizing antibodies bind to 
viruses and form antibody-virus complexes that enhance infection of Fcγ receptor bearing 
cells, resulting in an increase in virus load associated with severe disease (Wang et al., 
2003).  The hypothesis of original antigenic sin involves proinflammatory cytokine 




infection are of low-avidity to the secondary infecting virus serotype but are 
preferentially expanded during a secondary infection, leading to the release of 
proinflammatory cytokines.    
The envelope (E) glycoprotein is responsible for eliciting the majority of the 
protective antibody response.  The E protein covers the virion surface, arranged in anti-
parallel dimers containing three structural and antigenic domains (Rey et al., 1995).  E 
protein domain I (EDI), the central domain, contains virus specific and cross-reactive, 
predominantly non-neutralizing epitopes; EDII, the dimerization domain, contains the 
internal fusion peptide (FP) and overlapping immunodominant, broadly cross-reactive, 
weakly-neutralizing epitopes; EDIII has an immunoglobulin-like fold that is involved 
with receptor binding, and contains serocomplex cross-reactive and serotype specific
potently neutralizing epitopes (Crill and Chang, 2004; Crill and Roehrig, 2001; Lisova et 
al., 2007; Matsui et al., 2008; Roehrig, Bolin, and Kelly, 1998; Sukupolvi-Petty et al., 
2007).  Recent studies suggest that broadly cross-reactive antibodies directed against the 
fusion peptide (FP) form a major proportion of the antibody response in DENV patients 
(Crill et al., 2009; Lai et al., 2008; Oliphant et al., 2007a; Stiasny et al., 2006).  The 
dominant production of  high avidity, weakly-neutralizing antibodies could compete with 
neutralizing antibodies, recognizing overlapping epitopes through steric interference 
(Ndifon, Wingreen, and Levin, 2009) and promote severe disease through ADE.  
Structural studies of immature West Nile virus virions suggest cross-reactive weakly-
neutralizing antibodies recognizing the FP bind with high affinity to immature and 




2009).  These data suggest that broadly cross-reactive antibodies could promote ADE of 
DENV infection by increasing infectivity of low infectious, partially mature virions.   
DENV vaccine development has been a WHO priority for over thirty years.  
Despite all efforts, a licensed DENV vaccine is not yet available.  A DENV vaccine must 
induce a balanced, protective, tetravalent immunity to reduce the possibility of vaccine-
related severe disease upon subsequent infection.  We have designed DENV-2 DNA 
vaccine candidates, pVD2i, based upon a previously described DENV-2 DNA vaccine 
expressing prM and E proteins, which was shown to protect mice from DENV-2 
challenge (Chang et al., 2003) and contains an intron modification to increase antigen 
secretion.  These candidates are engineered with specific substitutions in 
immunodominant E protein B cell epitopes that reduce the recognition by a panel of 
murine monoclonal antibodies (MAbs) (Crill et al., 2009).  By introducing specific 
substitutions into the FP (at G106 and L107) and into serocomplex cross-reactive 
eptiopes of EDIII (at K310, E311 and P364), we have constructed cross-reactivity 
reduced (CRR) DENV-2 DNA vaccine candidates in an attempt to dampen or eliminate 
the induction of cross-reactive, enhancing antibodies recognizing weakly or non-
neutralizing epitopes.   
Results and Discussion 
The immunologic profile stimulated by the wild-type vaccine pVD2i (WT) in 
mice is compared to that of CRR vaccines: pVD2iG106R/L107D (RD) containing 
substitutions in EDIIFP; pVD2iK310E/E311R/P364R (ERR) containing substitutions in 
EDIII; and pVD2iG106R/L107D/K310E/E311R/P364R (RDERR) a combination of both 




post vaccination we evaluated the immunogenicity of WT and CRR vaccines using a 
focus-reduction micro-neutralization assay (FRµNT) against DENV-2 (Figure 3.1a).  All 
vaccinated mice exhibited high levels of DENV-2 specific neutralizing antibody (Nt-Ab) 
with mean reciprocal 50% endpoint titers ranging from 211 to 378.  Although there was a 
significant difference in DENV-2 Nt-Ab titer in mice between the vaccine treatments as 
determined by an analysis-of-variance (p=0.03), a Tukey’s post-test revealed only RD 
vaccinated sera to be significantly different from RDERR vaccinated sera (p=0.02).  In 
 
Figure 3.1. CRR vaccines elicit neutralizing IgG.  a) DENV-2 neutralizing-antibody 
(Nt-Ab) titers elicited by WT and CRR vaccines as determined by 50% FRµNT.  b) 
DENV-1 Nt-Ab titers.  c) DENV-3 Nt-Ab titers.  d) DENV-4 Nt-Ab titers.  Data are 
expressed as mean+/-s.e.m. for n=10.  ANOVA were performed on log transformed data 
for each neutralization followed by a Tukey’s post-test; p<0.05 were considered 




CRR vaccines containing substitutions in EDIII, ERR and RDERR, there was a trend 
toward a decrease in neutralization relative to WT.  This supports the observation that 
antibodies against the FP are weakly neutralizing, while antibodies against EDIII can be  
more potent (Heinz et al., 1983).  Interestingly, CRR vaccines displayed a trend to 
increase the capability to neutralize heterologous DENV-1 (p=0.07), DENV-3 (p=0.27), 
and DENV-4 (p=0.47) (Figure 3.1 b-d).   
The FP of EDII is immunodominant and stimulates a large proportion of the total 
E protein antibody response, with antibodies that have limited neutralization capabilities 
(Stiasny et al., 2006).  These antibodies have been implicated in ADE (Cherrier et al., 
2009) and could block the binding of neutralizing antibodies through steric interference 
(Ndifon, Wingreen, and Levin, 2009).  Recent studies demonstrate the capability of FP 
recognizing antibodies to induce severe DENV disease similar to DHF via ADE in a 
mouse model (Zellweger, Prestwood, and Shresta, 2010).  Studies with immunotoxin and 
other therapeutic proteins have shown amino acid substitutions can dampen the 
immunogenicity of B cell epitopes (Onda, 2009; Onda et al., 2008).  We utilized an 
epitope-specific IgG ELISA (Crill et al., 2009) to determine if substitutions in the 
EDIIFP reduced or eliminated its immunodominance, (Table 3.1).  Similar to studies 
examining DENV infected human sera (Crill et al., 2009; Lai et al., 2008; Oliphant et l.,
2007a; Stiasny et al., 2006), the WT vaccine elicited a large proportion of the total E 
response directed against the EDIIFP epitope (average 67%), which was highly variable 
between individual outbred mouse sera.  The response against the serocomplex cross-
reactive epitopes of EDIII (EDIIICR) made up a much smaller proportion (average 6%), 















pVD2i E 1.77x105 8.60x104-2.91x105 100 100 
EDIIFP 5.95x104 6.95x103-1.16x105 67 45-94 
EDIIICR 1.73x105 1.02x105-2.71x105 6 <1-16 
  Remaining 5.02X104 1.42X104-1.87X105 20 <1-76 
RD E 4.26x105 7.14x104-1.24x106 100 100 
EDIIRD 1.61x105 2.91x102-9.77x105 67 <1-99 
EDIIICR 1.41x105 1.19x102-7.61x105 26 <1-98 
  Remaining 1.4X105 1.2X102 - 7.1X105 34 <1-100 
ERR E 2.19X105 1.03X102-5.71X105 100 100 
EDIIFP 9.09x104 1.29x102-1.78x105 81 59-100 
EDIIIERR 2.00x105 1.08x102-5.16x105 5 <1-28 
  Remaining 9.10x104 1.02X102-1.78X105 31 <1-64 
RDERR E 4.23X105 7.68X104-1.29X106 100 100 
EDIIRD 7.14x105 1.16x105-2.25x106 73 32-86 
EDIIIERR 9.06X104 2.1X104 - 2.75X105 <1 <1 
Remaining 1.14X105 2.9X104 - 3.4X105 38 21 -68 
 
1 Epitopes targeted by specific antibody populations.  E denotes antibodies recognizing 
all E-protein epitopes.  EDIIFP denotes broadly cross-reactive WT epitopes of the E 
domain II fusion peptide.  EDIIRD denotes the epitope of the RD FP substitutions.  
EDIIICR denotes WT serocomplex cross-reactive epitopes in EDIII.  EDIIIERR denotes 
the epitope containing the ERR substitutions in EDIII.  Remaining refers to the epi opes 
outside EDIIFP and EDIIICR investigated in this study. 
‡ Endpoint titers determined with knock-out antigens, thus representing immunoglobulins 
not targeted by the knock-out antigen. 
* Percentages below limit of detection are expressed as <1. 
 
proportion (average 20%) and also highly variable between mice.  CRR vaccines 
containing substitutions in the FP (RD and RDERR) did not elicit antibodies that 
recognized epitopes encoded by the WT EDIIFP (Figure 3.2) and should therefore not 
induce ADE.  A large proportion of the RD and RDERR vaccinated IgG response, 





Figure 3.2.  RD and RDERR vaccines do not elicit IgG recognizing the WT FP 
epitope.  Percent of total anti-E antibody response that recognizes the epitopes of th  
EDIIFP WT epitopes or antibodies that recognize the EDIIRD substituted epitope.   
 
antibodies recognizing the EDIIRD FP epitope were 67% and 73%, in RD and RDERR 
vaccinated mouse sera respectively, a proportion similar to that recognizing WT EDIIFP 
in WT vaccinated mice.  This suggests that the substitution of G106R and L107D did not 
dampen or eliminate the immunodominance of the WT EDIIFP but created a novel 
epitope with distinct specificity.  These findings are in agreement with Rajamani et.al. 
(Rajamani et al., 2004), who identified arginine as a main anchor residue in several
protein-protein interactions. These data suggest instead of dampening the recognition f 
the EDIIRD FP epitope by B cell receptors, the substitution of G106R allowed anchoring 
of the B cell receptor and the subsequent production of antibodies.   ERR vaccine, with 
substitutions in the serocomplex cross-reactive epitopes of EDIII, also elicited antibodies 
directed against the EDIIIERR epitope (average 5%) in proportions similar to that f WT 




variability than did the WT response against EDIIICR.  Sera from mice vaccinated with 
RDERR did not contain antibodies directed against the ERR epitope.  This suggests that 
the combination of EDIIFP and EDIII substitutions was able to reduce the antigenicity of 
the EDIII cross-reactive epitopes.  Consistent with this, RDERR vaccinated sera 
displayed the greatest increase to stimulate antibodies recognizing E epitopes outside 
EDIIFP and EDIIICR (Table 3.1).  This could be due to the lack of steric interference 
from cross-reactive antibodies, allowing for better binding of antibodies to E epitop s 
outside those we investigated.  
 Severe DHF is associated with secondary DENV infections in older children and 
adults, or primary infections in infants.  We tested CRR vaccines to determine whether 
altered cross-reactive epitopes can increase vaccine safety by reducing the potential for 
ADE in vitro.  FcRII bearing human K562 cells were infected with DENV alone, with 
DENV-immune complexes formed in the presence of vaccinated mouse sera, or with 
DENV-immune complexes formed in the presence of EDIIFP recognizing MAb 4G2 
(positive enhancing control).  Sera from mice vaccinated with WT significantly e hanced 
the infection of homologous DENV-2 at a peak titer of 1:1,250 compared to RD 
(p=0.01), ERR (p=0.021), and RDERR (p=0.01) (Figure 3.3a), while the average 50% 
neutralization titer of WT vaccinated sera was 1:318. These results were interpreted to 
mean that as the IgG concentration decreases, the proportion of potently neutralizing 
antibodies becomes insufficient to neutralize virus, allowing for ADE.  This 
interpretation is evident in primary DHF in infants, where maternal DENV neutralizing 
antibody titers were correlated to infant age at onset of severe disease (Klik  et al., 1988) 





Figure 3.3.  CRR vaccinated sera have a reduced potential to participate in ADE in 
vitro compared to WT vaccinated sera.  Enhanced infection of K562 cells as 
determined by focus assay of cultured supernatants compared to the virus-only infection 
control (dotted line) a) DENV-2 enhancement reported as percent infection compared to 
the virus input control.  b)  DENV-1 enhanced percent infection.  c)  DENV-3 enhanced 
percent infection.  d)  DENV-4 enhanced percent infection.  All data represent the 
mean+/-s.e.m. of two independent experiments.  Two-way ANOVA were performed on 
square-root transformed data with a Bonfferoni post test; p<0.05 were considered 
significant; single asterisk, p<0.05; two asterisks, p<0.01. 
 
DENV virions but could not neutralize virus (Chau et al., 2009).  This situation sets the 
stage for ADE and severe disease in infants.  In contrast to antibodies in WT vaccinated 
mice, none of the CRR vaccinated sera enhanced homologous DENV-2 infection at any 
concentration.  This could be due to the lack of cross-reactive antibodies that recogniz 
WT enhancing epitopes (i.e. FP eptiopes).  In heterologous ADE assays, sera from 




tested (1:2) compared to RD (p=0.04), ERR (p=0.02), and RDERR (p=0.01), and also 
enhanced DENV-1 infection at a 1:10 dilution compared to ERR (p=0.04) and RDERR 
(p=0.03).  WT vaccinated sera also significantly enhanced DENV-3 infection at a dilution 
of 1:10 compared to RD (p=0.01) and RDERR (p=0.01) (Figure 3.3c), while no CRR 
vaccinated sera significantly enhanced any heterologous DENV at any dilution tested.  
Only RD and RDERR vaccinated sera significantly reduced DENV-3 enhancement, 
whereas the 400% increase seen in ERR vaccinated sera was not significantly different 
from WT vaccinated sera.  This suggests a role of the immunodominant FP targeting 
antibody response in the enhancement of severe disease, because RD and RDERR 
vaccines do not produce antibodies that recognize WT EDIIFP.  None of the serum from 
vaccinated mice significantly enhanced DENV-4 infection (Figure 3.3d).  This agrees 
with the findings of Nisalak et al. (Nisalak et al., 2003) where DENV-4 was not 
associated with DHF outbreaks in Thailand, although 97% of DENV-4 isolates were 
from secondary infections.   
 In addition to reducing the circulating cross-reactive antibody response f llowing 
vaccination, we investigated the potential role of memory B cells in secondary ifection 
to increase the proportion of cross-reactive, potentially enhancing antibodies.  Swiss 
Webster mice were vaccinated with 100 µg of pVD2i WT or RDERR vaccines at week 0, 
boosted with 100 µg DENV-1 DNA vaccine, pVD1i, on week 4 to simulate a secondary 
immune response, and sacrificed on week 12.  The immune response to secondary 
stimulation by pVD1i was measured by epitope specific ELISA.  Mice who were
vaccinated with pVD2i WT followed by pVD1i elicited a large proportion of the 




Table 3.2.  WT and RDERR EDIIFP-specific antibody responses following 












EDIIFP 2.7X102 1.0X102-3.8X102 90 76-98 
  
DENV-1  
EDIIFP 8.0X102 1.0X102-1.8X103 72 27-97 
RDERR 
DENV-2 
EDIIRDFP 2.3X103 7.5X102-6.3X103 46 14-70 
DENV-1  
EDIIFP 2.6X103 1.4X102-7.6X103 45 <1-91 
 
1 Epitopes targeted by specific antibody populations.  E denotes antibodies recognizing 
all E-protein epitopes.  EDIIFP denotes broadly cross-reactive WT epitopes of the E 
domain II fusion peptide.  EDIIRD denotes the epitope of the RD FP substitutions.  
2Endpoint titers determined with knock-out antigens, thus representing immunoglobulins 
not targeted by the knock-out antigen. 
3 Percentages below limit of detection are expressed as <1. 
 
who were vaccinated with pVD2i RDERR followed by pVD1i elicited a significantly 
lower percentage toward the cognate DENV-2 FP, EDIIFPRD (average 46%) (p=0.03) 
(Figure 3.4).  Moreover, mice vaccinated with pVD2i WT followed by pVD1i elicited a 
large proportion of the antibody response that also recognizes the DENV-1 EDIIFP 
(average 72%) while mice vaccinated with pVD2i RDERR followed by pVD1i elicit d a 
lower antibody response toward the DENV-1 EDIIFP (average 45%), though this 
difference was not significant due to the highly variable nature of the immune respons  
toward the EDIIFP (Crill et al., 2009).  Of particular interest is that mice va cinated with 
pVD2i RDERR followed by pVD1i elicited a nearly identical proportion of antibodies 
directed against either the cognate DENV-2 antigen, EDIIFPRD, or the DENV-1 EDII 






Figure 3.4.  RDERR vaccine does not elicit memory B cells that recognize the 
EDIIFP.   Mice were immunized with DENV-2 WT or RDERR at week 0 and 
reimmunized with WT DENV-1 DNA vaccine at 4 weeks.  Sera were collected at week 
12 and the percent of total anti-E antibody response that recognizes either the cognat
DENV-2 EDIIFP (EDIIFP or EDIIFPRD) antigens or the DENV-1 EDIIFP antigen was 
determined.  All graphed data represent the mean+/-s.e.m.  A Student’s t-tes  with 
Satterthwaite correction was used to make the appropriate comparisons.  p<0.05 were 
considered significant; single asterisk, p<0.05. 
 
stimulation with DENV-1.  Together, these data suggest mice vaccinated with RDERR 
do not elicit memory B cells that can recognize the highly conserved EDIIFP and  
potentially act to reduce the potential of vaccine-induced ADE from the rapid expansion 
of memory B cells in a secondary infection.   
 Several studies have identified CD4+ and CD8+ T cell epitopes on DENV 
proteins, many of which have been identified on the non-structural proteins while few 
have been identified in E (Mathew et al., 1996; Roehrig et al., 1994; Rothman, Kurane, 
and Ennis, 1996; Wen, Duan, and Jiang).  Many of the T cell epitopes identified in E 
have mapped to EDIII.  To determine whether mice that received CRR vaccines had a 
reduced memory T cell response as compared to the response of WT vaccinated mice, 
mice were splenectomized 10 weeks post vaccination and single cell suspensions were 





Figure 3.5.  CRR vaccines elicit virus-specific memory CD4+ and CD8+ T cells 
similar to WT vaccine.  a) Representative dot plot of CD4+ and IFNγ positive 
splenocytes.  b) Representative dot plot of CD8+ and IFNγ positive splenocytes.  c)
Percent of CD4+, IFNγ positive gated splenocytes stimulated ex vivo with inactivated 
DENV-2 or PHA.  d) Percent of CD8+ and IFNγ positive splenocytes.  All data reported 
as mean+/- s.e.m. of four independent experiments.  ANOVA was performed; p<0.05 
were considered significant. 
 
DENV-2 or phytohemagglutinin (PHA) mitogen, the positive control, for 6 hours in the 
presence of brefeldin A and stained for CD4 or CD8 and interferon γ (IFNγ) (Figure 3.5).   
Based upon flow cytometric analysis, splenocytes from CRR vaccinated mice elicited 
IFNγ producing CD4+ and CD8+ T cells in proportions similar to WT vaccinated 
splenocytes (p>0.05) suggesting the substitutions introduced into E did not interfere with 
the CRR vaccine’s ability to elicit DENV-2 specific memory T cells. 
While DENV serotype specific CD8+ T cells have been shown to play a role in 
viral clearance in mice (Yauch et al., 2009), the primary focus of DENV T cell resea ch 




During secondary DENV infections, cross-reactive low-affinity CD4+ (Beaumier and 
Rothman, 2009) and CD8+ T cells (Beaumier et al., 2008; Mongkolsapaya et al., 2003) 
expand preferentially and secrete proinflammatory cytokines (Dong et al., 2007b).  
Moreover, DHF patients’ sera have increased levels of tumor necrosis factor α (TNFα), 
interleukin-6 (IL-6) (Hober et al., 1993), and IL-10 (Green et al., 1999).  To determine 
the response of CRR vaccinated splenocytes to  DENV stimulation, MLR were 
stimulated with 2 µg of UV inactivated DENV-1, -2, -3, or -4 for 18 hours.  Supernatants 
were clarified and analyzed with a BD™ cytometric bead array (CBA) (Figure 3.6).  
MLR from WT vaccinated mouse splenocytes secreted high levels of TNFα, MCP-1, and 
IL-6 in response to DENV while CRR vaccinated mice secreted levels similar to those of 
the naïve control.  RD vaccinated splenocytes secreted significantly reduced levels of IL-
6 (p=0.04) and reduced levels of TNFα, and MCP-1 (p>0.05) compared to WT 
vaccinated splenocytes when stimulated with DENV-4.  These results suggest CRR 
vaccines have a reduced potential to stimulate secretion of proinflammatory cyt kines 
upon secondary stimulation with heterologous DENV.  IL-6 increases vascular 
permeability (Avirutnan et al., 1998; Huang et al., 2000b), enhances the production of 
anti-platelet auto-antibodies, elevates levels of tissue plasminogen activator, and causes a 
deficiency of coagulation factor XII, (Lei et al., 2001) all of which could lead to the 
plasma leakage and bleeding seen in severe DENV infection.  It has been observed that 
serum IL-6 levels correlate with human mortality from DSS (Suharti et al., 2002).  All 
vaccinated splenocytes in our studies showed marked decreases in the production of IL-






Figure 3.6.  CRR vaccinated splenocytes secrete reduced levels of proinflammatory 
cytokines compared to WT vaccine.  Secretion of cytokines into tissue culture medium 
by splenocytes from vaccinated mice stimulated ex vivo with inactivated DENV.   All 
data reported as mean+/-s.e.m. of two or three independent experiments.  Two-way 
ANOVA were performed on log transformed data with a Bonfferoni post test; p<0.05 
were considered significant; single asterisk, p<0.05. 
 
maintenance of a Th1 driven response and the switch from a Th1 to a Th2 driven 






None of the splenocytes harvested from any vaccinated mouse in this study produced 
levels of IL-4 or IL-5, Th2 driven cytokines, above levels of naïve animals (Figure 3.6). 
To our knowledge, this is the first description of an approach to increase vaccine 
safety by limiting the production of cross-reactive antibodies.  The presented data 
demonstrate the direct involvement of vaccine induced cross-reactive, weakly-
neutralizing antibodies in the development of ADE in vitro.  In addition, this same 
strategy may be expandable to other vaccine formats and other viruses with the potential 
to exacerbate disease through ADE such as HIV (Takeda, Tuazon, and Ennis, 1988).  
Unfortunately, this approach may not be applicable to DENV live-attenuated vaccines, 
since substitutions in the FP can be lethal (Huang et al., 2009). 
The lack of an appropriate animal model has made it difficult to study the 
contribution of ADE in the development of severe disease in vivo.  The 
immunopathology of DHF/DSS in regards to ADE has been difficult to fully elucidate 
and most studies have relied on in vitro systems.  We have shown that the CRR 
vaccinated murine immune response, in regards to immunodominant epitopes, is similar 
in magnitude and proportion to studies of immunodominant epitopes in DENV infected 
humans (Crill et al., 2009; Lai et al., 2008; Oliphant et al., 2007a; Stiasny et al., 2006).  
We have demonstrated the importance of these eptiopes in inducing ADE in vitro.  With 
the recent demonstration of ADE induced severe DENV disease in AG129 
mice(Zellweger, Prestwood, and Shresta, 2010), our ongoing studies include increasing 




approach to the remaining three DENV serotypes, and the evaluation of protective 
efficacy and safety of CRR vaccines to prevent ADE in this new DENV disease model. 
 
Materials and Methods 
Vaccines.  Characterization of DENV-2 DNA plasmids with substitutions in the EDIIFP 
and EDIII have been described and characterized previously (Crill et al., 2009).  
Selection of vaccine candidates was based on virus-like particle secretion and reductions 
in reactivity to the MAb panel (Crill et al., 2009).  Vaccines were manufactured by 
Aldevron. 
Mice.  Swiss Webster mice from the DVBID colony (n=10) were vaccinated with 100 µg 
intramuscularly at 0 and five weeks.  Sera were collected 10 weeks post vaccination. 
Swiss Webster mice (Charles River) (n=10) were similarly vaccinated with WT or 
RDERR vaccines at 0-week and similarly boosted with 100 µg pVD1i at 4-weeks.  Sera 
were collected 12 weeks post vaccination. 
C57BL/6J mice (Jackson laboratory) (n=5) were similarly vaccinated.  10 weeks post 
vaccination mice were splenectomized and single cell suspensions were made.  Animal 
experiments were approved by Institutional Animal Care Use Committee. 
Antibody-dependent enhancement.  Heat inactivated mouse sera were pooled, diluted, 
and titrated.  5 x 103 pfu of virus was added to each sera dilution and incubated for 1 hour 
at 37°C.  K562 cells (MOI=0.5) were added to the antibody-virus complexes and 
incubated 2 hours at 37°C.  After infection, cells were centrifuged, supernatants removed, 




infection alone was used as virus control; MAb 4G2 was used as a positive enhancing 
antibody control.   
Focus assay.  Supernatants from DENV infected K562 cells were collected 48 hours post 
infection, clarified by centrifugation, and serially titrated.  2.47 x 104 Vero cells in 
DMEM (Gibco) with 10% FBS (Atlas) were added to 96-well black, clear flat bottom 
plates (Corning/Costar), and were infected with each titration in duplicate. Vero plates 
were incubated at 37°C, for 45 min, and overlaid with media containing 1% 
Carboxymethylcellulose sodium salt (Fluka BioChemika).  Plates were incubated, cells 
acetone fixed and immunostained according to the FRµNT assay procedure.  Virus foci 
were counted using Zeiss KS300 microscope and Axiovision version 4.6 (Carl Zeiss) and 
pfu/mL of each original sera dilution calculated and compared to DENV infection alone
as percent infection.   
Virus neutralization.  A focus reduction microneutralization (FRµNT) technique was 
utilized.  Briefly, 2.47 x 104 Vero cells in DMEM (Gibco) supplemented with 10% FBS 
(Atlas) were added to 96-well black, clear bottom plates (Corning/Costar) and incubated 
16 hours overnight at 37°C.  Vaccinated mouse sera (n=10) were diluted 1:10 and heat 
inactivated at 56°C for 30 min, titrated 2-fold to the volume of 40 µL, and 320 virus 
pfu/40 µL was added to each serum dilution.  Plates were incubated 1 hour at 37°C.  
After incubation, 25 µl of serum and virus suspension (100 pfu) was transferred to the 
Vero cell monolayer containing plates.  Vero plates were incubated at 37°C for 45 min, 
overlaid with media consisting of 1% Carboxymethylcellulose sodium salt (Fluka 
BioChemika), Earle's balanced salt solution without phenol red, 6.6% Ye-lah media, 2% 




were as follows: DENV-2 (16681) and DENV-4 (H241) 48 hours; DENV-1 (56BC94/95) 
and DENV-3 (116RC1396) 70 hours.  Following incubation, plates were washed and 
fixed using 3:1 Acetone in PBS, decanted and allowed to dry.  Immunostaining was 
performed by adding virus-specific mouse hyperimmune ascitic fluid diluted in PBS and 
incubated at 37°C for 30 min, washing and adding goat anti-mouse HRP conjugated 
(Jackson ImmunoResearch) secondary antibody diluted in 5% skim milk/PBS and 
similarly incubated for 30 min and washed.  Infected virus foci were developed using 
Vector-VIP peroxidase substrate kit SK-4600 (Vector Laboratories) as per 
manufacturer’s instructions.  Foci were counted using Zeiss KS300 microscope and 
Axiovision software version 4.6 (Carl Zeiss).  FRµNT titers were calculated for each 
virus relative to the virus back titration.  Exact FRµNT titers were modeled using Graph 
Pad Prism version 4 (Graph Pad Software) sigmoidal dose response (variable slope) 
formula.  Values are the average of two independent replicates and reported as 50%
reduction.  
Epitope-specific IgG ELISA.  To quantify the epitope-specific IgG in vaccinated mouse 
sera, the same IgG-capture ELISA protocol as described previously (Crill et al., 2009) 
was used with a few modifications.  Vaccinated mouse sera (n=10) were diluted 1:100 
and serially titrated.  In addition to WT DENV-2 virus-like particle antigen, we utilized 
previously characterized epitope-specific knock-out antigens (Crill et al., 2009).  The 
resulting OD values were modeled as a non-linear function of the log10 sera dilution using 
a Gaussian non-linear regression in Graph Pad Prism version 4.0 (Graph Pad Software) 
and the endpoint dilutions determined as the titer where the OD value was equal to two-




The EDII and EDIII epitope-specific IgG percentages were calculated as 
described (Crill et al., 2009) with minor modification for CRR sera.  Briefly, the EDII 
and EDIII epitope specific IgG percentages for WT vaccinated mice were calculated by 
dividing the IgG endpoint titer obtained with specific knock-out antigens by the endpoint 
titer obtained by WT antigen on the same sera, subtracting this value from 1.0 and 
multiplying by 100.  Since CRR sera contained antibodies that do not recognize WT 
antigen (WT antigen acts as the knock-out antigen) but recognize epitopes of the knock-
out antigens, the cognate knock-out antigen was used to determine 100% E reactivity (i.e. 
RDERR sera reacted on RDERR antigen represents 100% reactivity).  CRR vaccinated 
epitope-specific percentages were calculated as 100 x [1.0-(epitope knock-out antigen/ 
RDERR antigen)].  
The DENV-2 or DENV-1 EDIIFP specific IgG responses following secondary 
stimulation were calculated similarly with minor modification.  Specific IgG percent for 
WT vaccinated mice followed by DENV-1were determined utilizing DENV-2 EDIIFP 
knock-out antigen and DENV-1 EDIIFP knock-out antigen (Chang et al. unpublished 
data).  Specific DENV-2 or DENV-1 EDIIFP percentages were calculated as 100 x [1.0-
(EDII knock-out antigen endpoint/ DENV-2 WT antigen endpoint + DENV-1 WT 
antigen endpoint)].  Mice vaccinated with RDERR followed by DENV-1, EDIIFP 
percentages were calculated utilizing DENV-2 EDIIICR knockout antigen and DENV-1 
EDIIFP knock-out antigen:  100 x [1.0-(DENV-2 EDIIICR knock-out antigen or DENV-
1 EDIIFP knock-out antigen endpoints/ RDERR + DENV-1 WT antigen endpoints)].      
Mixed leukocyte reactions.   Single cell suspensions made from freshly harvested 




buffer (BD Biosciences).  1 x 106 cells in culture media, RPMI (Gibco) supplemented 
with 20% FBS (Atlas), were plated in 96-well plates for intracellular cytokine staining.  1 
x 107 pooled splenocytes in culture media were plated in 24-well plates for CBA.  
Splenocytes were stimulated with 2 µg of UV inactivated DENV; PHA (Roche 
Diagnostics) was used as a positive control and naïve splenocytes in cell culture medium 
as a negative control.  24-well plates were incubated 18 hours at 37°C, supernatants 
harvested, and clarified by centrifugation.  96-well plates were incubated 2 hours at 37°C, 
and 1µg of Golgi plug (BD Biosciences) was added to each well, incubated for an 
additional 4 hours before intracellular cytokine staining.   
Intracellular cytokine staining.  Stimulated splenocytes were centrifuged, washed with 
BD Stain buffer (BD Biosciences), 0.5 µg mouse BD Fc block (clone 2.4G2, BD 
Biosciences) was added to each well for 20 min at 4ºC, and washed twice.  Splenocytes 
were labeled with 0.2 µg phycoerythrin (PE)-conjugated anti-CD4 (clone GK1.5, BD 
Biosciences) or 0.25 µg PE-congugated anti-CD8 (clone 53-6.7, BD Biosciences), 
incubated for 30 min at 4ºC, washed twice, and fixed with BD cytofix/cytoperm buffer 
(BD Biosciences) for 20 min at 4ºC. Cells were washed twice with BD perm/wash buffer 
(BD Biosciences) and labeled with 0.1 µg fluorescein isothiocyanate (FITC) anti-IFNγ 
(clone XMG1.2, BD Biosciences) per well for 30 min at 4ºC, washed twice, and 
resuspended in BD Stain buffer.  Fluorescence was detected with BD FACSCalibur and 
Cell quest software (BD Biosciences).  The lymphocyte population was gated on a FSC 
and SSC plot, and 20,000 gated events were collected and analyzed for FITC and PE 




subtracted from each sample before statistical analysis.  Values are averages of four 
independent experiments.  Dot plots are representative of a single replicate. 
Cytometric bead array.  Supernatants from splenocytes stimulated for 18 hours were 
used in detection of cytokines in mouse Th1/Th2 CBA (BD Biosciences) and mouse 
Inflammatory CBA (BD Biosciences) as per manufactures protocol.  Fluorescence was 
detected on BD FACSCalibur and analyzed with CBA software (BD Biosciences).  
Values are averages of two or three independent experiments. 
Statistical analysis.  All graphed original values are means+/-s.e.m.  Data were natural-
log transformed to achieve homogenous variances (Leven’s test) and normality 
(Kolmogrovo-Smirnov test).  Transformed data was analyzed with a student’s t-test with 
Satterthwaite correction when necessary, or ANOVA and Tukey’s post-test or Bonferroni 






A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus 
serotype 2 vaccines 
Introduction 
Dengue virus (DENV), which exists as four closely related serotypes, is a single-
stranded RNA virus in the flavivirus genus.  With the global resurgence of DENV 
infections, including the DENV-1 outbreak in Key West, Florida (CDC, 2010), dengue 
has evolved into one of the world’s most important arboviral disease.  DENV infection 
causes either mild dengue fever, or severe life-threatening dengue hemorrhagic fever and 
dengue shock syndrome (DHF/DSS).  Severe dengue is a common occurrence in childre 
residing in hyperendemic countries and is strongly associated with secondary heterotypic 
infections (Sangkawibha et al., 1984).  Currently, vector control and education programs 
are all that are available for dengue prevention; and the development of dengue 
vaccination has been hindered by concerns of waning or imbalanced tetravalent immu ity 
leading to vaccine induced DHF/DSS.  However, a handful of vaccines are in the early 
stages of clinical trials (Durbin and Whitehead, 2010).   
DNA vaccination has become a fast growing field in vaccine technology since the 
1990s following the first reports of plasmid DNA inducing an immune response to 
plasmid-encoded antigen (Tang, DeVit, and Johnston, 1992).  Although DNA vaccines 
are considered by some to be one of the most important discoveries in the field of 




immunogenicity and efficacy.  Thus various strategies to improve the immune response 
following DNA vaccination have been developed.  Earliest attempts to increase DNA 
vaccine immunogencitiy have included optimization of route, dosage, and timing of 
administration; DNA encoded or exogenously administered co-stimulatory molecules and 
cytokines; and prime-boost regimens (Leitner, Ying, and Restifo, 1999).   
We have previously described the development and demonstrated the protective 
efficacy of a West Nile virus (WNV) DNA vaccine directing the expression of 
premembrane and envelope (prM/E) proteins.  A single 100 µg intramuscular (im) 
injection of WNV DNA vaccine in mice induced a high level of WNV neutralizing 
antibodies and protected 100% of mice challenged by either intraperitoneal (ip) or 
mosquito inoculation (Davis et al., 2001).  In addition, a single im injection of WNV 
DNA vaccine protected vaccinated horses from viremia by mosquito inoculation.    In 
comparison, our previously described chimeric DENV-2 DNA vaccine, expressing prM 
and 80% DENV-2 E/ 20% JEV E to enhance the secretion of virus like particles, required 
two im vaccinations of 100 µg to elicit a high enough neutralizing antibody titer to 
passively protect neonatal mice from challenge (Chang et al., 2003).  Both DNA vaccines 
contain identical enhancer, promoter, translational control element and JEV signal 
sequence (Chang, Hunt, and Davis, 2000); however, the difference in immunogenicity of 
the two vaccines is quite striking.  Moreover, three days post vaccination of 100 µg of 
WNV DNA vaccine, 100% of mice were protected from virus challenge (Chang et. al. 
unpublished data), suggesting a rapid cell mediated and innate immune response to the 
vaccine.  These observations led to the hypothesis that there are differential antigenic 




cellular mediated arm of the immune system.  Here, we describe the identification and 
application of a potent WNV CD4 positive T cell epitope to increase the immunogenicity 
of DENV-2 DNA and virus-like particle (VLP) vaccines.  
Results 
Strong CD4 positive epitope in transmembrane domain of WNV.  In order to better 
understand the nature of the cellular immune response to pVWN, we developed a peptide 
library scanning the entire prM and E protein coding sequences of pVWN and pVD2i to 
determine differential immune responses between the two vaccine constructs.  We 
initially screened the library using 23 peptide pools (data not shown).  Each peptide 
consisted of 15 amino acids, with 10 amino acid overlapping regions for both pVWN and 
pVD2i.  C57BL/6J mice were immunized with pVWN or pVD2i, boosted at three weeks 
and sacrificed at 6 weeks.  Spleens were homogenized and used in a mixed leukocyte 
reaction for determination of positive peptide pools by FACS analysis.  From positive 
pools we identified individual peptides for further analysis.  Splenocytes from vaccinated 
mice were incubated with 2 µg of each individual peptide and stained for CD4 or CD8 
and IFNγ for determination of positive peptides.  We indentified weak CD4 positive 
epitopes in DENV-2 E protein amino acids 1-20, 31-50, and 356-385. Weak CD4 
positive epitopes to both pVWN and pVD2i vaccinated splenocytes were identified in the 
conserved fusion peptide region of E from amino acids 99-110, and also in E domain II 
amino acids 186-215.  Interestingly, a very strong CD4 positive epitope was identifie  i  
WNV E at amino acids 466-495, that was present, but much weaker in 20% JEV E 
(Figure 4.1).  This CD4 epitope of WNV E is located in two transmembrane domain 









Figure 4.1.  WNV transmembrane domain region contains a strong CD4 epitope not 
present in JEV.  Splenocytes from mice vaccinated with pVWN or pVD2i (containing C 
terminal 20% JEV E (Chang et al., 2003)) were stimulated ex vivo with 2µg of envelope 
peptide (pVWN E93-E95 or pVD2i E93-E95).  Cells were stained for CD3, CD4 and 
IFNγ and 10,000 of the CD3/CD4 gated population was counted.  While E peptide 95 of 
both pVWN and pVD2i elicited IFNγ producing CD4 T cells, the response to pVWN E95 
was greater than that of pVD2i E95.  Dot plots are representative of a single experiment.    
 
E, amino acid alignment reveals the transmembrane domain amino acids 466-495 are 
entirely conserved between WNV and JEV with the exception of four amino acids at 474, 
484, 488, and 493 (Figure 4.2).  Using ProPed I to predict CD8 epitopes and ProPed to 
predict CD4 epitopes revealed that the transmembrane region of WNV contains 
promiscuous CD8 and CD4 epitopes with potential to bind to several human HLA alleles 
(Table 4.1).  Though the important 9 core amino acids (Table 4.1, highlighted blue) for 
each allele varies, the core frequently utilizes one or more of the four amino cids we 
have identified, suggesting the incorporation of this epitope may increase the 
immunogenicity of DENV-2 DNA vaccination in an outbred population.     
Incorporation of WNV CD4 epitope to pVD2i increases vaccine immunogenicity.  
The identification of a strong CD4 epitope in the WNV transmembrane domain, and its 
ability to potentially be a promiscuous CD4 and CD8 epitope led us to investigate the 
ability of this transmembrane domain (TMD) epitope to increase the immunogenicity of 
our DENV-2 DNA vaccine, pVD2i.  Using site-directed mutagenesis, the four amino 
acids at the C-terminal 20% JEV E in pVD2i were sequentially changed to the 
corresponding amino acids in pVWN.  These changes produced the plasmids 
pVD2iV474I (pVD2i-I), pVD2iV474I/A484T (pVD2i-IT), pVD2iV474I/A484T/T488V 
(pVD2i-ITV), and pVD2iV474I/A484T/T488V/V493L (pVD2i-ITVL).  To first 





Figure 4.2.  The transmembrane domain region is well conserved between WNV and JEV.  Single letter amino acid 
abbreviations are shown for the transmembrane domain of WNV E protein using WNV numbering.  Amino acids conserved relative to 
WNV in the other viruses are shown as dots, and single letter abbreviations for non-conserved amino acids are depicted.  Four amino 




Table 4.1.  WNV TMD CD4 epitope may bind to several human HLA alleles. 




DRB1_0306 GALLLWMGINARDRSIALTFLAVGGV LLFLSVNVHA 
DRB1_0307 GALLLWMGINARDRSIALTFLAVGGV LLFLSVNVHA 
DRB1_0308 GALLLWMGINARDRSIALTFLAVGGV LLFLSVNVHA 








DRB1_0701 GALLLWMGINARDRSIALTFLAVGGVLL FLSVNVHA 















DRB1_1506 GALLLWMGINA RDRSIALTFLAVGGVLLFLSVNVHA 
DRB5_0101 GALLLWMGINARDRSIALTFLAVGGVLLFLSVNVHA 
DRB5_0105 GALLLWMGINARDRSIALTFLAVGGVLLFLSVNVHA 
   
CD8 
HLA-A*0201 GALLLWM GINARDRSIALTFLAVGGVLLFLSVNVHA 
HLA-A*0205 GALLLWMGINARDRSIALTFL AVGGVLLFLSVNVHA 
HLA-A24 GALLLWMGINARDRSIAL TFLAVGGVLLFLSVNVHA 
HLA-A3 GALLLWMGINARDRSIALTFLAVGGVLLFLSVNVHA 
HLA-A*3101 GALLLWMGINARDRSIALTFLAVGGVLLFLSVNVHA 
HLA-A*3302 GALLL WMGINARDRSIALTFLAVGGVLLFLSVNVHA 
HLA-A2.1 GALLLWMGINARDRSIALT FLAVGGVLL FLSVNVHA 
HLA-B14 GALLLWMGINAR DRSIALTFLAVGGVLLFLSVNVHA 
HLA-B*2702 GALLLWMGIN ARDRSIALTFLAVGGVLLFLSVNVHA 
HLA-B*2705 GALLLWMGINARDRSIALTFLAVGGVLLFLSVNVHA  
HLA-B*3501 GALLLWMGI NARDRSIALTFLAVGGVLLFLSVNVHA 
HLA-B*3701 GALLLWMGINA RDRSIALTFLAVGGVLLFLSVNVHA 
 
HLA-B*3901 GALLLWMGINAR DRSIALTFLAVGGVLLFLSVNVHA 




HLA-B*5102 GALLLWMGI NARDRSIALTFLAVGGVLLFLSVNVHA  
HLA-B*5103 GALLLWMGI NARDRSIALTFLAVGGVLLFLSVNVHA  
HLA-B*5401 GALLL WMGINARDRSIALTFLAVGGVLL FLSVNVHA 
HLA-B*51 GALLLWMGINARDRSIALT FLAVGGVLL FLSVNVHA 
HLA-B*5801 GALLLWMGINARDRSIALTFLAVGGVLLFLSVNVHA 
HLA-B7 GALLLWMGI NARDRSIALTFLAVGGVLLFLSVNVHA 
HLA-B*0702 GALLLWMGINA RDRSIALTFLAVGGVLLFLSVNVHA 
HLA-B8 GALLLWMGI NARDRSIALTFLAVGGVLLFLSVNVHA 
   
 
1WNV TMD sequence shown includes E amino acids 466-501 
2Positive ProPed nanomers highlighted in blue and obligatory P1 binding residues in red 
 
inbred mouse strain where the epitope was initially described.  C57BL/6J mice were 
immunized with each construct, boosted on week-4 and sacrificed on week-8.  To 
compare differential immunogenicity between the constructs, focus reduction 
microneutralization (FRµNT) was performed on individual mouse sera.  Eight weeks post 
vaccination pVD2i-I did not appear to increase the neutralizing antibody titer compared 
to pVD2i (p=0.20) (Figure 4.3).  However, pVD2i-IT (p=0.02), pVD2i-ITV (p=0.11), 
and pVD2i-ITVL (p=0.04) elicited increased levels of neutralizing antibodies compared 
to pVD2i vaccine. This suggests that amino acid 474, located in the first transmembrane 
helix, may not be an integral part of the CD4 epitope, as vaccines with the subsequent 
amino acid substitutions at WNV E positions 484, 488, and 493 elicited higher levels of 
neutralizing antibodies compared to pVD2i.  This also suggests that the second 
transmembrane helix may be more important in the CD4 epitope since amino acid 474 
lies in the first transmembrane helix while amino acids 484, 488, and 493 all lie within 
the second transmembrane helix.   
 We previously described the development of cross-reactivity reduced DENV-2 
DNA vaccines that limit the production of cross-reactive antibodies and vaccine induced 





Figure 4.3.  The incorporation of the WNV TMD CD4 epitope increases the 
immunogenicity of the pVD2i vaccine.  DENV-2 neutralizing antibody (Nt. Ab.) titers 
8 weeks post vaccination of C57BL/6 mice vaccinated with pVD2i with sequential 
addition of the WNV TMD amino acids (pVD2i-I: pVD2iV474I; pVD2i-IT: 
pVD2iV474I/A484T; pVD2i-ITV: pVD2iV474I/A484T/T488V; pVD2i-ITVL: 
pVD2iV474I/A484T/T488V/V493L).  Data are expressed as mean+/-s.e.m. for n=5.  
ANOVA and Tukey’s post test was performed on transformed data, p<0.05 were 
considered significant: single asterisk, p<0.05.  
 
vaccines, however, showed a reduced but not significant, neutralizing antibody titer when 
compared to the wild type pVD2i vaccine (WT).  To determine if the incorporation of the
WNV TMD CD4 epitope could increase the immunogenicity of our DENV-2 cross-
reactivity reduced vaccine, we introduced the WNV CD4 epitope 
V474I/A484T/T488V/V493L (TMD) into our cross-reactivity reduced DENV-2 DNA 
vaccine pVD2iG106R/L107D/K310E/E311R/P364R (RDERR) to create 
pVD2iG106R/L107D/K310E/E311R/P364R/V474I/A484T/T488V/V493L (RDERR-




V474I/A484T/T488V/V493L (WT-TMD), RDERR, and RDERR-TMD by FRµNT.  
Outbred Swiss Webster mice were immunized, boosted at 4 weeks, and sacrificed at 12 
weeks.  DENV-2 neutralizing antibody titers at 4 and 8 weeks post vaccination were ot 
significantly different when comparing vaccines without TMD modification to vaccines 
with TMD modification, however there was a visible trend for WT-TMD and RDERR-
TMD to elicit increased neutralizing antibody titers compared to WT and RDERR 
respectively (Figure 4.4).  Twelve weeks post vaccination WT-TMD (p=0.008) and 
RDERR-TMD (p=0.02) elicited significantly more DENV-2 neutralizing antibodies 
compared to WT and RDERR respectively.  Moreover, with the incorporation of the 
WNV TMD CD4 epitope, there was no significant difference in neutralizing antibody 
titers between WT-TMD and RDERR-TMD (p=0.71).  These data suggest the addition of 
the WNV TMD CD4 epitope significantly increases the immunogenicity of both WT and 
cross-reactivity reduced DENV-2 DNA vaccines. 
 In addition to determining the neutralizing antibody response elicited by vaccines 
containing the WNV TMD CD4 epitope, we also investigated the epitope specificity of 
the total antibody response.  In order to accomplish this, we utilized an epitope-specific 
IgG ELISA previously described and detailed in the previous section.  WT-TMD vaccine 
elicited a large proportion of the total anti-E antibody response toward the wild type 
fusion peptide, EDIIFPWT (mean 66%) (Table 4.2), while RDERR-TMD elicited a large 
antibody response against the novel FP epitope, EDIIFPRD (mean 57%).  Unfortunately, 
the mice immunized with WT and RDERR vaccines did not elicit an anti-E IgG antibody 
response in a magnitude that could be detected by our methods.  This correlates with the 





Figure 4.4.  The incorporation of WNV TMD CD4 epitope increases the 
immunogenicity of DENV-2 CRR vaccines.  DENV-2 Nt. Ab. titers of Swiss Webster 
mice 4, 8, and 12 weeks post vaccination.  Data are expressed as mean+/-s.e.m. for n=10.  
Student’s t-test with Satterthwaite correction was used to compare vaccine treatments as 


















TMD E 2.2X103 1.7X102-4.8X103 100  
 EDIIFP 3.0X102 2.5X101-1.3X103 66 <1-99 
 EDIIICR 4.8X102 7.6X101-1.8X103 71 48-93 
  Remaining 1.8X102 2.5X101-8.3X102 18 <1-74 
RDERR-
TMD E 1.2X103 1.1X102-2.0X103 100  
 EDIIRD 4.3X102 5.7X101-1.6X103 57 <1-95 
 EDIIIERR 1.7X103 1.0X102-3.1X103 18 <1-83 
 Remaining 1.2X103 1.7X102-2.9X103 63 5-99 
 
1Epitopes targeted by specific antibody populations.  E denotes antibodies recognizing all 
E-protein epitopes.  EDIIFP denotes broadly cross-reactive WT epitopes of the E domain 
II fusion peptide.  EDIIRD denotes the epitope of the RD FP substitutions.  EDIIICR 
denotes WT serocomplex cross-reactive epitopes in EDIII.  EDIIIRR denotes the epitope 
containing the ERR substitutions in EDIII.  Remaining refers to the epitopes outside 
EDIIFP and EDIIICR investigated in this study. 
2Endpoint titers determined with knock-out antigens, thus representing immunoglobulins 
not targeted by the knock-out antigen. 
3 Percentages below limit of detection are expressed as <1. 
 
anti-FP proportions are similar in magnitude to what we observed previously in mice, and 
also similar to recent studies using DENV infected human sera (Crill et al., 2009; Lai et 
al., 2008; Oliphant et al., 2007a; Stiasny et al., 2006).  Interestingly, the proportion of 
antibodies recognizing the cross-reactive epitopes of EDIII, EDIIICR, were greatly 
increased in WT-TMD (mean 71%) than what we have observed in non-TMD vaccinated 
mice or than that of infected human sera (mean 5%).  Moreover, the proportion of 
antibodies recognizing E epitopes other than EDIIFP or EDIIICR, denoted ‘remaining’, 
were also higher in RDERR-TMD (mean 63%) than WT-TMD (mean 17%).  A similar 




proportions than previous RDERR mice (mean 21%).  These data suggest the WNV 
TMD CD4 epitope may be enhancing or redirecting the production of antibodies to 
previously non-dominant epitopes.   
WNV CD4 epitope upregulates CD154 on CD4 T cells.  Cell to cell interactions play a 
pivotal role in the regulation of the immune response.  CD154 is expressed on a variety 
of cells, including but not limited to, activated CD4 T cells, CD8 T cells, mast cell ,
basophils, and eosinophils (Grewal and Flavell, 1998).  CD154 is the ligand for CD40, 
which is expressed on B cells, antigen presenting cells, epithelium cells and endothelial 
cells among others.  The binding of CD154 and CD40 results in T cell activation, B cell 
activation, and APC activation, and extravasation.  The expression of CD154 and CD40 
on a variety of immune cells suggests the importance of these molecules in both the 
initiation and effector functions of these cells.  Studies in mice blocking the CD154 and 
CD40 interaction reveal a primary role of CD154 in regulating B cell prolife ation, 
production of immunoglobulins (Ig), Ig class switching, germinal center formation, and 
generation of memory B cells (Clark, Foy, and Noelle, 1996).  The incorporation of 
WNV TMD CD4 epitope into pVD2i resulted in an increase of neutralizing antibody 
titers in vaccinated mice.  To better understand the mechanism of this antibody increase 
we investigated the potential of the WNV TMD CD4 epitope to increase the expression 
of CD154 on CD4 T cells.  C57BL/6J mice were vaccinated im with 100µg of WT, WT-
TMD, RDERR, or RDERR-TMD.  One and two weeks post vaccination three mice from 
each group were sacrificed, spleens were homogenized and stimulated in a mixed 
leukocyte reaction with 2µg of UV inactivated DENV-2, pVWN peptide 95, which 




sequence, Figure 4.2).  The extracellular expression of CD4 and CD154 was measured by 
FACS analysis.  One week post vaccination WT-TMD and RDERR-TMD vaccinated 
splenoctyes displayed higher extracellular expression of CD154 compared to WT and 
RDERR (Figure 4.5) when stimulated with UV inactivated DENV-2 or pVWN peptide 
95, while WT and RDERR vaccinated splenocytes expressed higher levels of CD154 
when stimulated with pVD2i peptide 95, although these trends are evident, the 
differences were not statistically significant.  Two weeks post vaccination, there were no 
similar trends of CD154 expression between vaccine groups (data not shown), suggesting 
the WNV TMD CD4 epitope may elicit the early activation of CD154 expressing CD4 T 
cells and play a role in the activation of B cells to produce higher neutralizing antibody 
titers. 
ProPed promiscuous epitope predictions revealed the WNV TMD CD4 epitope 
may be a promiscuous epitope binding to several human HLA alleles (Table 4.1).  To 
validate the incorporation of this epitope into the DENV-2 DNA vaccines, outbred Swiss
Webster mice were vaccinated with 100µg of WT, WT-TMD, RDERR or RDERR-TMD 
on weeks-0 and 4.  Five mice per group were sacrificed one-week post vaccination, and 
the remaining 10 mice were sacrificed 12 weeks post vaccination.  Freshly harvested 
spleens were homogenized and stimulated in a MLR with 2µg of UV inactivated DENV-
2.  Extracellular expression of CD4 and CD154 was measured by FACS analysis.  One 
week post vaccination WT-TMD vaccinated splenocytes elicited significantly higher 
levels of CD154 expressing T cells (p=0.013) compared to WT vaccinated splenocytes, 
while RDERR-TMD vaccinated splenocytes also displayed a trend for increased CD154 





Figure 4.5.  WNV TMD CD4 epitope may increase CD154 expression of CD4 T cells.  
C57BL/6 splenocytes were stimulated x vivo with 2µg of indicated antigen.  CD154 
expression of CD4 T cells was analyzed by FACS.  Vaccines containing WNV TMD 
CD4 epitope respond with higher expression of CD154 when stimulated with inactivated 
DENV-2, pVWN peptide E95, pVD2i peptide E95, or PHA one week post vaccination.  
Data are expressed as mean+/-s.e.m. for n=3.  Student’s t-test with Satterthw i  
correction was used to compare vaccine treatments as indicated or ANOVA and Tukey’s 
post test was performed on transformed data.  p<0.05 were considered significant. 
 
significant (Figure 4.6a).  This data suggests the WNV TMD CD4 epitope may act early 
in the immune response to up regulate CD154 on CD4 T cells, potentially increasing the 
neutralizing antibody titers as observed in C57BL/6J mice.  In addition, stimulated 
splenocytes one-week post vaccination elicited a higher percentage of IL-4 positive CD4 
T cells (Figure 4.6c) than IFNγ positive CD4 T cells (Figure 4.6e) suggesting the 
predominance of a Th2 driven T cell response.  All vaccinated splenocytes elicited 
similar levels of IL-4 (p=0.1) and IFNγ positive T cells one-week post vaccination.   
Twelve weeks post vaccination, all stimulated splenocytes are eliciting a balanced 





Figure 4.6.  WNV TMD CD4 epitope induces early CD154 expression of CD4 T cells 
and a predominant Th2 driven response.  FACS analysis of T cell responses of 
vaccinated Swiss Webster mice.  Splenocytes were stimulated ex vivo with 2 µg 
inactivated DENV-2 1 and 12 weeks post vaccination (pv).  CD154 expression of CD4 T 
cells a) one and b) 12 weeks pv.  Th1 driven T cell responses of vaccinated mice c) one 
and d) 12 weeks post vaccination.  Th2 driven T cell responses e) one and f) 12 weeks 
pv.  Data are expressed as mean+/-sem for n=5 (1 week pv) or n=10 (12 weeks pv).  
Student’s t-test with Satterthwaite correction was used to compare vaccine treatments as 





higher levels of Th1 driven CD4+/IFNγ+ T cells than WT or WT-TMD vaccines 
(p=0.05) (Figure 4.6d).  All vaccines elicited similar levels of Th2 driven CD4+/IL-4+ T 
cells (p=0.19) (Figure 4.6f).  Additionally, 12 weeks post vaccination there were no 
significant differences in CD154 expression on CD4 T cells between WT and WT-TMD 
or RDERR and RDERR-TMD (Figure 4.6b), also suggesting WNV TMD CD4 epitope 
induces CD154 expression as an early event in the immune response toward the vaccines.   
WNV CD4 epitope increases immunogenicity of DENV VLP vaccine.  Protein 
vaccines are a commonly used platform for several pathogens.  Using protein as a 
vaccine alleviates common concerns of DNA vaccine formats such as potential 
integration into the host chromosome and the development of anti-DNA autoantibodies.  
To investigate the potential benefit of WNV CD4 epitope to alternative vaccine formats, 
we immunized Swiss Webster mice with 1µg of purified WT, WT-TMD, RDERR, 
RDERR-TMD VLPs, or β-propiolactone inactivated DENV-2, all formulated with 8% 
Alum.  Mice were boosted at 4 weeks and sacrificed at 8 weeks.  The neutralizing 
antibody titer of WT-TMD VLP (p=0.055) and RDERR-TMD VLP (p=0.015) was 
increased compared to the WT VLP and RDERR VLP vaccines respectively (Figure 4.7).  
These results were similar to that observed for the DENV-2 DNA vaccines (Figure 4.4) 
and suggest the incorporation of the WNV TMD CD4 epitope can increase vaccine 
immunogenicity of additional vaccine formats and not solely functional in DNA vaccine 
formats. 
 In addition to determining the antibody response toward the VLP vaccines, we 
investigated any potential differential T cell responses between the vaccine treatments.  





Figure 4.7.  WNV TMD CD4 epitope increases immunogenicity of DENV-2 VLP 
vaccines.  DENV-2 Nt. Ab. titers 8 weeks post vaccination of Swiss Webster mice.  Data 
are expressed as mean+/-s.e.m. for n=5.  Student’s  t-test with Satterthwait  correction 
was used to compare vaccine treatments as indicated.  p<0.05 were considered 
significant: single asterisk, p<0.05 
 
ex vivo with 2µg inactivated DENV-2.  Cells were labeled for CD3, CD4 or CD8, and 
IFNγ or IL-4 and analyzed by FACS.  Mice immunized with VLP vaccines elicitd a 
predominant Th2 driven response as all groups had measurable levels of CD4+/IL-4+ T 
cells (Figure 4.8a).  VLP vaccinated mice also elicited low levels of CD4+/IFNγ+ T cells 
with the exception of RDERR VLP that did not elicit measurable levels of CD4+/IFNγ+ 
T cells (Figure 4.8b).  The helper T cell responses between vaccine treatments were not 
significantly different based on ANOVA.  Interestingly, the VLP vaccines elicited 
CD8+/IFNγ memory T cells in all groups tested (Figure 4.8c).  WT-TMD, RDERR, and 
RDERR-TMD VLP vaccines elicited significantly higher amounts of CD8+/IFNγ+ T 





Figure 4.8.  DENV-2 VLP vaccines elicit a predominant Th2 driven response and a 
Th1 independent CD8 memory response.  FACS analysis of vaccinated Swiss Webster 
splenocytes stimulated ex vivo with 2 µg inactivated DENV-2.  a) Percent CD4 positive 
IL-4 producing Th2 driven T cells.  b) Percent CD4 positive IFNγ producing Th1 driven 
T cells.  c) Percent CD8 positive IFNγ producing memory cells.  Data are expressed as 
mean+/-s.e.m. for n=5.  ANOVA and Tukey’s post test was performed on transformed 




other intracellular pathogens such as simian immunodeficiency virus (Tsukamoto et al., 
2009) and Listeria monocytogenese (Grenningloh et al., 2008), and is described by the 
“licensing” model (Lanzavecchia, 1998) where activated dendritic cells are able to 
activate CTL cells without the direct involvement of CD4 T cells.  These data sugge t the 
VLP vaccines, like the DNA vaccines, induce a predominant Th2 driven T helper cell 
response and yet also induce the development of CD8+ memory T cells without a strong 
Th1 driven response.   
Discussion 
 We analyzed potential differences in CD4 T cell epitopes in the pVWN E and 
pVD2i chimeric-E protein.  Several T cell epitopes have been described for the 
flaviviruses using T cell clones, many of which are localized to the non-structural 
proteins while fewer eptiopes have been identified in the E protein using this approach 
(Rothman, Kurane, and Ennis, 1996).  Using pVWN or pVD2i vaccinated splenocytes ex 
vivo stimulation with an overlapping peptide scanning library, we identified the 
conserved fusion peptide of E domain II harbored CD4 T cell epitope that stimulated 
CD4 T cell proliferation and IFNγ secretion in both WNV and DENV-2 vaccinated mice.  
This observation is in agreement with Roehrig et al. (Roehrig et al., 1994) where after 
immunizing mice with synthetic peptides, peptide 4-6 corresponding to the highly 
conserved fusion peptide elicited anti-DENV antibodies that only bound to virus exposed 
to low pH.  The fusion peptide has previously been identified as an immunodominant B 
cell epitope eliciting a large proportion of the total anti-E antibody response (Crill et al., 
2009; Lai et al., 2008; Oliphant et al., 2007a; Stiasny et al., 2006) directing the immune 




implicated in antibody-dependent enhancement and exacerbate DENV disease.  The 
immunodominant nature of the FP in eliciting cross-reactive antibodies may be a result of 
a potential CD4 T cell epitope in the same region.  It was previously shown that a CD4 T
cell epitope can increase the immunogenicity of homologous and heterologous peptides, 
however the response was significantly greater for the homologous peptide.  In addition, 
the response was greatest when the T-B cell epitopes were collinearly synthesized 
(Roehrig et al., 1992).   
The participation of cross-reactive memory T cells in the development of severe 
DHF/DSS has also been widely documented (Beaumier et al., 2008; Beaumier and 
Rothman, 2009; Mongkolsapaya et al., 2003), although the majority of these cross-
reactive T cells are restricted to non-structural proteins.  Our results, along with Roehrig 
et al. (Roehrig et al., 1994), indicate the presence of a T cell epitope in this conserved 
region in WNV and DENV-2.  Though cross-reactivity was not measured in our or 
previous works, the highly conserved nature of this epitope warrants further investigation 
of the fusion peptide as a potential cross-reactive T cell epitope participating in he 
development of severe DENV disease.  The cross-reactivity reduced DENV-2 DA 
vaccine, RDERR, was specifically designed to reduce the production of cross-reactive 
antibodies and limit vaccine induced ADE.  With the potential CD4 T cell epitope in the 
FP, the ability of the RDERR to increase vaccine safety by limiting the induct on of 
memory CD4 T cells that recognized the highly conserved FP deserves further
investigation.   
  We also identified a strong CD4 T cell epitope in the transmembrane domain 




our DENV-2 DNA vaccine.  To our knowledge, this is the first description of a T cell 
epitope present in this region of any flavivirus E protein.  This epitope spanning amino 
acids 466-495 encompasses the two transmembrane helices of the E protein, is highly 
conserved between the pVWN and pVD2i with the exception of four amino acids.  The 
first amino acid, 474 lies in the first transmembrane helix while amino acids 484, 488, 
and 493 all lie within the second transmembrane helix.  Helical wheel projections 
indicate amino acids 484 and 488 in the second transmembrane helix all reside on the 
same side of the alpha helix while amino acid 493 lies on the opposite side of the helix.  
When looking at the entire peptide, amino acids 466-495, amino acids 474, 484, and 488 
are all on the same side of the alpha helix.  In contrast, amino acid 493 lies on the 
opposite side of the helix along with N475 and R479, which are predicted to be important 
anchor residues in MHCII binding.  These projections indicate the probable involvement 
of amino acids 474, 484, and 488 in the CD4 T cell receptor epitope that correlates nicely 
with the neutralization data (Figure 4.3) showing an increase in neutralizing antibody titer 
following the incorporation of the first two amino acid residues into pVD2i.      
Increasing the immunogenicity of DNA vaccines has been an active area of 
investigation as some DNA vaccines are hindered by low immunogenicity and efficacy.  
The incorporation of the WNV TMD CD4 epitope significantly increased the 
immunogenicity of DENV-2 DNA vaccine (WT, pVD2i) and also the cross-reactivity 
reduced DENV-2 DNA vaccine, RDERR.  This increased immunogenicity appears to be 
due in part to an early increase in activated CD154 CD4 T cells.  Traditional methods to 
increase the immunogenicity of DNA vaccination have included the use of genetic 




as CpG motifs, cytokines, chemokines, GM-CSF, and ubiquitin (Chiarella et al., 2008).  
Immunostimulatory epitopes have also been investigated in several vaccine fields. One 
such method includes the fusion of a foreign universal T cell epitope sequence to the 
target gene of interest.  Zhu et al. fused the FrC fragment of tetanus toxin to a DNA
vaccine containing the sequence for the protective epitope of PorA protein of Neisseria 
meningitides (Zhu et al., 2008).  The incorporation of the tetanus epitope significantly 
increased the immunogenicity of the DNA vaccine and induced bacteriocidal antibodies.  
In a similar approach, a polyepitope DNA vaccine was constructed using the strong CD8 
immunostimulatory properties of the hepatitis B small surface antigen simultaneously 
encoding cytotoxic T lymphocyte epitopes from six different viruses (Chen et al., 2010).  
The new plasmid using the HBsAg epitopes as an adjuvant resulted in significant 
development of CTL responses to all six viruses compared to the polyepitope DNA 
without the HBsAg.  One concern with this method is the presence of HBsAg antibody 
present in human sera due to HBV vaccination potentially interfering with vaccination 
efficacy or unbalanced HBV immune responses. 
Although DNA vaccination in clinical trials has been proven safe, concerns about 
tumorigenic potential due to DNA integration and the development of DNA 
autoimmunity remain.  The incorporation of the WNV TMD CD4 epitope into the 
DENV-2 VLPs resulted in a significant increase in neutralizing antibody titers compared 
to DENV-2 VLPs without the WNV TMD CD4 epitope.  Similar to strategies of DNA 
vaccination, the use of T helper epitopes to increase the immunogenicity of protein 
vaccines has also been investigated utilizing a universal T cell epitope.  Lu et al. (Lu et 




peptide DNA vaccine by herterologously boosting with a recombinant protein that also 
contained a foreign T helper epitope of HSP70.  Similar to use of tetanus toxin, HBsAg 
universal T helper epitopes, the potential development of anti-carrier immunity hindering 
vaccination should be addressed.   
Our approach to increase the immunogenicity of the DENV-2 DNA and VLP 
vaccines utilizes a naturally occurring flavivirus CD4 epitope in contrast to previous 
studies using foreign universal T cell epitopes.  There is limited concern of immunity 
toward the WNV TMD CD4 epitope from previous exposure interfering with the vaccine 
efficacy.  The transmembrane domain of flaviviruses is either of low B cell antigenicity 
or antigenically inert, as vaccination with DENV-2 DNA plasmid containing 80% 
DENV-2 E and the C terminal 20% JEV E did not elicit any measurable antibody 
response against JEV (Chang et al., 2003) and no B cell epitopes have previously been 
identified.  Utilizing this WNV TMD CD4 epitope to increase vaccine immunogenicity 
has additionally advantageous since the transmembrane domain does not affect the proper 
antigenic folding of E. 
Incorporating a naturally occurring dominant CD4 epitope may offer advantages 
in additional flavivirus vaccination formats.  The variable yet highly conserved nature of 
the flavivirus transmembrane domain (Figure 4.2) suggests potential differential T cell 
antigenicity across the flaviviruses, which can be readily manipulated as demonstrated in 
this study.  With the global resurgence and expansion of flaviviruses, there will b  
increasing demand and utility for multivalent flavivirus vaccines.  Multivalent vaccine 
interference is a frequently observed phenomenon that may be caused by competition for 




regulatory T cells, and replicative interference (Dagan, Poolman, and Siegrist, 2010; Guy 
et al., 2009).  These data show the incorporation of the strong WNV CD4 epitope into 
DENV-2 vaccines of different immunogenicity produces similar monovalent antibody 
titers.  Moreover, the incorporation of this natural flavivirus epitope into live attenua d 
vaccines may alleviate previous observations of interference (Guy et al., 2009) and 
induce a more balanced immune response.  We are currently examining the potential use 
of this flavivirus epitope to help balance tetravalent DENV vaccine immunogenicity and 
its application to multivalent flavivirus vaccines beyond DENV deserves further 
investigation.   
The incorporation of naturally occurring dominant CD4 epitopes in one 
component of a multivalent vaccine to increase vaccine immunogenicity of a weaker 
component may be a possible generalized strategy for multivalent vaccines hindered by 
imbalanced immunogenicity or interference.  For example, serotype specific immune 
interference affecting vaccine immunogenicity of multivalent human papilloma virus 
(HPV) VLP vaccine was recently demonstrated (Zhang et al.).  Licensed tetraval nt 
vaccine containing VLP for HPV serotypes 16/18/6/11 elicited a balanced serotype 
specific neutralizing antibody response, while the trivalent HPV 16/18/58 displayed 
significant decreases in type specific neutralizing antibodies to serotyp  58.  Identifying 
and manipulating different immunogenic elements such as the CD4 T cell epitope 
identified here, and/or altering cross-reactive B-cell epitopes - as with the pVD2i-
RDERR vaccine candidate in this study (Crill et al., 2009; Miller, 2010) could prove the 
strategy to understanding and alleviating the antigenic differences between virus 




Materials and Methods 
Vaccines.  West Nile plasmid, pVWN, was previously constructed and described (Chang 
et al., 2007; Davis et al., 2001).  Construction and characterization of DENV-2 DNA 
plasmid optimized with C terminal 20% JEV has been previously described (Chang et al., 
2003).  Characterization of DENV-2 plasmids, pVD2i, with substitutions in the E domain 
II fusion peptide (EDIIFP) and EDIII have been described previously (Crill et a ., 2009).  
pVWN, pVD2i (WT) and pVD2iG106R/L107D/K310E/E311R/P364R (RDERR) were 
manufactured by Aldevron (Fargo, ND).  pVD2i with substitutions in the transmembrane 
domain, pVD2iV474I, pVD2iV474I/A484T, pVD2iV474I/A484T/T488V, and 
pVD2iV474I/A484T/T488V/V493L (WT-TMD), were generated by using Quick change 




3’CCCCCACACGAGGACAAGAATCGCTGGTTACACG5’.     
pVD2iG106R/L107D/K310E/E311R/P364R/V474I/A484T/T488V/V493L (RDERR-
TMD)  was generated by restriction enzyme cloning by digesting 
pVD2iV474I/A484T/T488V/V493L (WT-TMD) with KpnI and StuI (New England 
Biolabs), and Quick ligation (New England Biolabs) of the transmembrane domain 
region into  the pVD2iG106R/L107D/K310E/E311R/P364R backbone.  WT-TMD and 
RDERR-TMD were grown in E. coli XL1 Blue cells and DNA purified for vaccination 
by Endofree Plasmid Maxi-prep Kit (Qiagen) as per manufacturer’s instructions.  




upon identification of the correct mutation.  Automated DNA sequencing was performed 
using a Beckman Coulter CEQ 8000 genetic analysis system (Beckman Coulter) and 
analyzed by using Beckman Coulter CEQ 8000 (Beckman Coulter) and Lasergene 
software (DNASTAR).   
Virus-like particles (VLPs) were generated by transformation of COS-1 cells as 
previously described (Chang, Hunt, and Davis, 2000) and secreted VLPs were harvested 
from serum and animal product free media [Sfm4megavir (Hyclone) supplemented with 
L-glutamine, non-essential amino acids, penicillin-streptomycin, sodium pyruvate, and 
cholesterol (Gibco)].  Tissue culture media was harvested 4 days post transformation, 
pelleted by ultracentrifugation at 19,000rpm, concentrated 100-fold in TN buffer, pelleted 
by 20% sucrose cushion, and resuspended in 1/100 of original volume in TN buffer.  
Protein concentration was determined by Bradford Assay (BioRad) as per manufacturer’s 
instructions.  Final VLP vaccines consisted of 1 µg protein in 8% Alum (Thermo 
Scientific). DENV-2 strain 16681 was propagated in C6/36 cells as described previously.  
Virion particles were similarly purified using 20% sucrose cushion, inactivated by 0.01% 
of β-propiolactone and formulated with 8% Alum.  
Mice.  C56BL/6J mice (Jackson Laboratory) were immunized im with 100µg of DNA at 
weeks 0 and 4, sacrificed on week8, splenoctomized and serum collected.  Swiss Webster
mice (Charles River) were similarly vaccinated, sacrificed on week 12, splenectomized 
and serum collected.  Swiss Webster mice (Charles River) were immunized im with 1µg 
of VLPs or 1µg of BPL inactivated purified DENV-2 virions formulated with 8% Alum 





Peptide scanning library.  A library of 15 amino acid peptides with 5 amino acid 
overlaps was designed to cover either the envelope (E) protein or the pre-membrane 
(prM) region of WNV or DENV-2. (AC Scientific, Inc.) Peptides were arranged in pools 
as described previously (Betts et al., 2001; Hoffmeister et al., 2003; Kern et al., 2000; 
Maecker et al., 2001).  Single peptides were used at a concentration of 1µg/ml with the 
total concentration of each pool being no greater than 10µg/ml (Betts et al., 2001; Kern et
al., 2000; Maecker et al., 2001).  Pool volumes were diluted in such a manner that the 
DMSO concentration is no greater than 1% of v/v (Hoffmeister et al., 2003).  Individual 
peptides were identified by pool overlap.  The selected individual peptides went through 
a second round of screening as described above.  Positive peptides were determined by ex 
vivo stimulation of vaccinated splenoctyes and demonstrated CD4+ and/or CD8+ and 
levels of IFN-γ expression. 
Epitope prediction of positive peptides was accomplished using online prediction 
engines ProPedI (http://www.imtech.res.in/raghava/propred1/) and ProPed 
(http://www.imtech.res.in/raghava/propred/) setting the threshold to the most stringent 
1%.  Helical wheel projections of peptides were generated using BioEdit 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html).    
Mixed leukocyte reactions.   Single cell suspensions were made from freshly harvested 
C57BL/6J or Swiss Webster spleens and plated in 96-well plates for extracellular surface 
antigen and intracellular cytokine staining (ICS).  Splenocytes were stimulated with 
peptides as described above or 2µg of UV inactivated DENV; PHA (Roche Diagnostcs) 
was used as a positive control, and naïve splenocytes in cell culture medium as negative 




was added to each well, incubated an additional 4 hours before extracellular and 
intracellular staining.     
Flow cytometry.  The antibodies mouse BD Fc block, phycoerythrin (PE)-conjugated 
anti-CD4, PE-conjugated anti-CD8, PE-conjugated anti-CD154, PE-Cy5-conjugated anti-
CD3, fluorescein isothiocyanate (FITC) anti-IFNγ, FITC-conjugated anti-IL-4, and 
FITC-conjugated anti-CD4 were purchased from BD Biosciences.  Stimulated 
splenocytes were centrifuged, washed with BD Stain buffer (BD Biosciences), Fc 
blocked, and labeled for CD3, CD4 and CD154, or CD8.  Spelnocytes were fixed with 
BD cytofix/cytoperm buffer (BD Biosciences) and labeled for IFNγ or IL-4.   
Fluorescence was detected with BD FACSCalibur and Cell quest software (BD 
Biosciences).  The lymphocyte population was gated on a FSC and SSC plot, and further 
gated on CD3 and CD4 or CD8 and 40,000 gated events were collected and analyzed for 
FITC and PE positive cells.  Double-positive cells from the negative control were 
subtracted from each sample before statistical analysis.  Dot plots are representative of a 
single replicate. 
Neutralization assay.  A focus reduction microneutralization (FRµNT) technique was 
utilized as previously described (Crill et al., 2009) with few modifications.  Vaccin ted 
mouse sera were diluted 1:10, heat inactivated, titrated 2-fold to the volume of 40 µL, 
and 320 virus pfu/40 µL was added to each dilution.  FRµNT titers were calculated for 
each virus relative to a back titration.  Exact FRµNT titers were modeled by the 
sigmoidal dose response with variable slope using Graph Pad Prism version 4.  Values 




Epitope-specific ELISA.  An IgG ELISA protocol described previously (Crill et al., 
2009) was used with a few modifications.  Vaccinated mouse sera (n=10) were diluted 
1:100 and serially titrated.  We utilized previously characterized epitope-specific knock-
out antigens(Crill et al., 2009).  OD values were modeled as non-linear functions of the 
log10 sera dilutions using a Gaussian non-linear regression in Graph Pad Prism version 
4.0 and endpoint dilutions determined as the titer where the OD value equaled two-times 
the OD value of the test serum reacted against normal antigen.   
EDII and EDIII epitope-specific IgG percentages were calculated as describ d 
(Crill et al., 2009) with minor modifications.  Briefly, the EDII and EDIII epito e specific 
IgG percentages for WT vaccinated mice were calculated by dividing the IgG ndpoint 
titer obtained with specific knock-out antigens by the endpoint titer obtained by WT 
antigen on the same sera, subtracting this value from 1.0 and multiplying by 100.  Since 
cross-reactivity reduced (CRR) sera contained antibodies that do not recogniz  WT 
antigen (WT antigen acts as the knock-out antigen) but recognize epitopes of the knock-
out antigens, the cognate knock-out antigen was used to determine 100% E reactivity (eg. 
RDERR sera reacted on RDERR antigen represents 100% reactivity).  CRR vaccinated 
epitope-specific percentages were calculated as 100 x [1.0-(WT antigen endpoint/ epitope 
knock-out antigen endpoint)].   
Statistical analysis.  All graphed original values are means+/-s.e.m.  Data were natural-
log transformed to achieve homogenous variances (Leven’s test) and normality 
(Kolmogrovo-Smirnov test).  Transformed data was analyzed with a Student’s t-test with 
Satterthwaite correction when necessary, or ANOVA and Tukey’s post-test as indicated.  






 The results of this dissertation confirm and expand previous observations of 
flavivirus envelope protein antigenicity.  The results also provide new insights into the 
dengue virus humoral immune response, and suggest strategies for B cell and T cell 
epitope modification to reduce the potential of vaccine-induced ADE and increase 
vaccine immunogenicity. 
 The second chapter, entitled “Humoral Immune Responses of Dengue Patients 
using Epitope-Specific Serotype-2 Virus-like Particle Antigens,” focuses on the mapping 
of cross-reactive epitopes of the DENV-2 envelope protein and the use of these VLPs to 
better understand the human humoral immune response following primary and secondary 
DENV infection.  The flavivirus E domain II (EDII) has previously been shown to 
contain multiple overlapping, broadly cross-reactive, immunodominant epitopes   (Crill 
and Chang, 2004; Crill, Trainor, and Chang, 2007; Lai et al., 2008; Oliphant et al., 2007a; 
Stiasny et al., 2006; Trainor et al., 2007) and this study confirmed that substitutions in the 
fusion peptide at G106 and L107 ablated the recognition of group cross-reactive MAbs.   
 A novel finding of chapter two is the possibility of inter-monomer epitopes.  For 
example, the reactivity of MAb D35C9-1 was only moderately reduced when tested 
against substitutions in the FP or EDIII.  However, when substitutions in FP and EDIII 
were combind into a single antigen, the reactivity of MAb D35C9-1 was greatly reduced 




eptiopes from disparate domains.  This observation heeds cautions for antigenic mapping 
studies relying on soluble E or recombinant EDIII, as the entire MAb footprint could be 
contained in multiple domains on multiple monomers.   
 Chapter two presents results from experimannts that begin to dissect the 
complexities of the human polyclonal immune response to DENV infection.  The results 
of this chapter confirm and extend previous reports on the EDII FP as an 
immunodominant region made of a series of overlapping eptiopes stimulating broadly 
cross-reactive antibodies (Lai et al., 2008; Oliphant et al., 2007a; Stiasny et al., 2006).  
The presence of these highly cross-reactive antibodies with limited neutralizing 
capabilities is presumably long-lived as many of these studies utilize convalescent sera.  
This observation has immediate implications in the theory of ADE as this 
immunodominant epitope could be exacerbating secondary DENV disease.  Interestingly, 
the total proportion of Ig recognizing EDII FP was higher in primary infections than 
secondary infections, and also higher for IgM than IgG.  In addition, IgM was also found
to target the cross-reactive EDIII epitopes in greater magnitude than IgG and also in 
greater magnitude in secondary infections.  This suggests the use of IgM in attempt to 
assign serotype to secondary DENV infections may be highly misleading.   
 The results of chapter two suggest a novel approach for DENV vaccination.  With 
the highly immunodominant nature of the EDII FP, removal of this region through 
mutagenesis could eliminate the production of highly cross-reactive antibodies an  
improve vaccine safety by limiting vaccine-induced ADE.  Moreover, the removal of 




the immune system as a small proportion of IgG recognizing EDIII was correlated with 
neutralization. 
Chapter three entitled “Dengue vaccine candidates reduce potential antibody-
dependent enhancement,” further expands on the issue of DENV vaccination safety by 
investigating the potential to engineer cross-reactivity reduced DENV vaccines by 
dampening the immune responses to these epitopes and redirect the response to less 
dominant protective epitopes.  Though antibodies targeting the EDII FP and cross-
reactive EDIII epitopes can be weakly neutralizing (Stiasny et al., 2006) and generally 
require a higher occupancy than potently type-specific neutralizing antibodies 
(Gromowski, Barrett, and Barrett, 2008), the removal of these epitopes from a DENV
DNA vaccines still elicited a high neutralizing antibody response that did not differ
significantly from vaccination with WT, unmodified, vaccine.  
In vitro enhancement of DENV infection was significantly lower when the cross-
reactive E protein epitopes were removed.  The replicative and/or immune interf rence 
associated with live attenuated vaccines, has resulted in a large proportion of non-
responders following one- and two-doses (Morrison et al., 2010; Sun et al., 2008) with 
100% tetravalent seroconversion requiring three doses spanning a year (Morrison et al., 
2010).  The time required for full seroconversion spans the epidemic season, leaving a 
significant portion of vaccinated individuals without tetravalent protective immunity at 
risk for vaccine-induced severe disease following natural infection. These results 
demonstrate the feasibility of engineering DENV vaccines with enhanced safety and 




applicable to DENV live-attenuated vaccines since many substitutions in the FP can be 
lethal (Huang et al., 2009).   
  An interesting observation in chapter three was that removal of the EDII FP 
resulted in more dramatic decreases in enhancement of DENV infection than removal of 
EDIII cross-reactive epitopes alone.  These data suggest immunodominant FP may play a 
vital role in the development of ADE and severe DENV disease seen in secondary DENV 
infection and EDIII sero-complex cross-reactive epitopes may not be as important.  This 
is intriguing due to the fact severe secondary disease is seen in DENV infection, one 
could presume the sero-complex cross-reactive antibody response would be important in 
ADE.   
The highly conserved nature of the EDII FP could suggest ADE would be a factor 
in additional flaviviruses.  The phenomenon of ADE is, indeed, not an exclusive 
mechanism of DENV.  MAbs have been demonstrated to enhance the infection of 
additional flaviviruses including WNV, TBEV and YFV in vitro (Peiris and Porterfield, 
1979; Peiris, Porterfield, and Roehrig, 1982; Phillpotts, Stephenson, and Porterfield, 
1985; Schlesinger and Brandriss, 1983).  In vivo enhancement of flaviviruses other than 
DENV has also been demonstrated in mice with enhancement of neurovirulence of YFV 
and JEV by the passive transfer of E reactive MAbs or immune sera (Gould and Buckley, 
1989).  In addition, passive transfer of JEV immune sera at subneutralizing levels 
resulted in increased viremia titers and mortality of Murray Valley encephalitis virus in 
mice (Wallace et al., 2003).  Although the possible enhanced disease of heterologous 
flaviviruses has been demonstrated with a handful of viruses in mouse models, it is 




and cocirculation of many flaviviruses, there should continued vigorous studies to 
identify the risks of exacerbated human disease in secondary flavivirus infectio s.  With 
the possible exception of a single case report of severe TBEV disease in a patient with 
previous WNV exposure (Ferenczi et al., 2008) the phenomena of severe human disease 
in secondary infection is exclusive of DENV.  
The substitution of the EDII FP at G106 and L107 was able to eliminate the cross-
reactivity of the elicited antibodies and reduce the potential of vaccine induced ADE. 
The results of the chapter two mapping study in addition to previous works (Crill and 
Chang, 2004; Crill, Trainor, and Chang, 2007; Trainor et al., 2007) have identified these 
two amino acids as key residues in MAb recognition of the EDII FP.  However, the 
substitution of G106 with arginine and L107 with aspartic acid did not eliminate the 
dominant nature of this epitope.  Instead, the substitutions elicited antibodies with a 
unique specificity that do not recognize the wild-type EDII FP.  This suggests two 
possibilities.  First, the large, charged amino acids created new binding residues for the B 
cell receptor, or second, G106 and L107 are not the essential amino acids in the 
dominance of the EDII FP.  Redirection of the immune response away from the EDII FP 
to less dominant epitopes could still be accomplished through a detailed mapping study 
of this region utilizing substitutions with glycine or alanine.  Although a large poportion 
of the antibody response to the modified vaccines were elicited against the ew amino 
acid substitutions, the fact these antibodies have a unique specificity limited their ability 
to participate in ADE.     
Interestingly, the modified vaccines were able to increase the recognition of the 




of EDIII.  This may suggest the ability of these vaccines to redirect the immune response 
away from the immunodominant EDII FP and EDIII, to epitopes that have yet to be 
classified.  Detailed mapping studies of the E protein have been described exhaustively 
for EDII FP and EDIII, however, a detailed mapping study of the antigenicity of EDI has 
yet to be accomplished.  Mapping studies have made use of murine MAbs, and although 
the results of chapter two would agree the murine type-specific MAbs can be 
characteristic of the potently type-specific human polyclonal response, recent studies 
implicate the importance of additional domains in human infection.   Characterization of 
a potently neutralizing type-specific chimpanzee MAb recognizing EDI has been recently 
described (Lai et al., 2007).  In addition, anti-EDIII depleted human sera still maintained 
high neutralizing ability, suggesting EDIII antibodies may play a smaller role in virus 
neutralization in humans (Wahala et al., 2009).  Moreover, murine MAbs recognizing 
DENV-3 EDIII were not able to effectively neutralize different genotypes of DENV-3 
(Brien et al., 2010), a phenomena yet to be demonstrated in human sera.  This suggests 
domains outside EDIII may be important in the human polyclonal response to flavivirus 
protection.  With the ability of modified CRR vaccines to increase antibody recognition 
of epitopes outside EDII FP and EDIII and yet maintain high neutralizing titers, also 
suggests a role for additional epitopes or domains in neutralization.   
Chapter four entitled, “A West Nile virus CD4 T cell epitope improves the 
immunogenicity of dengue virus serotype 2 vaccines,” investigates the ability of a 
naturally occurring flavivirus CD4 T cell epitope to act as an immunological adjuvant for 
heterologous flavivirus vaccines.  The results of chapter four reveal a dominant CD4 




between pVWN and the DENV-2/JEV chimeric pVD2i is entirely conserved with the 
exception of four amino acids; however the pVWN peptide stimulated a stronger CD4 
response than did the pVD2i peptide.  In addition, substitution of the four amino acids in 
pVD2i for the pVWN sequence resulted in a significant increase in neutralizing antibody 
titers of DENV-2 DNA and VLP vaccines.   
The use of a naturally occurring flavivirus CD4 epitope as a vaccine adjuvant is 
beneficial for several reasons.  First, the transmembrane domain of flaviviruses does not 
elicit an antibody response (Chang et al., 2003) therefore previous exposure to WNV 
would not adversely affect the efficacy of the CD4 epitope.  This is in contrast to current 
methods to increase vaccine immunogenicity through use of universal T help eptiopes 
such as tetanus toxin or hepatitis B small antigen.  Previous vaccine exposure to thes
epitopes may elicit an antibody response and therefore render the T helper epitopes inert.  
Conversely, the use of these universal epitopes could also elicit or increase the ntibody 
response against these epitopes and potentially hinder booster vaccinations against the 
parental tetanus or HBV vaccines.  In addition, the transmembrane domain does not 
affect the proper folding and antigenicity of the E protein because removal of the C 
terminal 20% of E elicits soluble E monomers with intact antigenicity (Deubel et al., 
1991; Men, Bray, and Lai, 1991).   
The transmembrane domain region of the flaviviruses though is well conserved, is 
highly variable in the alpha helices with the presence of mutational “hot spots” (Lewis et 
al., 1993).  The incorporation of the WNV CD4 epitope could enhance the 
immunogenicity of additional heterologous flavivirus vaccines.  In addition, the standard 




eliminating the road-block of replicative and/or immune interference and inducing a 
balance immune response and deserves further evaluation. 
 The goal of this dissertation research was to construct safer DENV vaccines by 
mapping the DENV-2 E protein, manipulating B cell epitopes to limit vaccine-induced 
ADE, and manipulating T cell epitopes to increase vaccine immunogenicity.  Through 
this work, we have gained a better insight into the antigenic properties of the envelope 
protein of flaviviruses and demonstrated a viable approach through B and T cell epitope 
manipulation to increase the safety and immunogenicity of DENV vaccines.  Although 
there remains much to learn about the antigenicity and immunodominance of the 
envelope protein, with the global expansion of DENV and increasing disease burden it is 
hoped these studies have contributed to the growing body of knowledge and will aid in 
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